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Abstract 
Inflammation is fundamentally a beneficial response leading to removal of the offending factor, 
and resolution, an active regulated process that is essential to maintain tissue integrity and 
function. Previous work in our department showed a role for COX-2 derived PGD2 and its 
cyclopentenone metabolite 15d-PGJ2 during resolution in a pleurisy model. I investigated mice 
lacking hPGD2S and therefore absent PGD2 and 15d-PGJ2 by inducing peritonitis with zymosan. 
The resolution of peritonitis in hPGD2S mice was delayed compared to wild type C57black VI 
mice. PGD2 via its action on the DP1 receptor controls the balance of pro- versus anti-
inflammatory cytokines that regulate leukocyte influx as well as monocyte-derived macrophage 
efflux from the inflamed peritoneal cavity to draining lymph nodes leading to resolution. 
Previous data that laid doubt to the presence of 15d-PGJ2 in in vivo models and questioned its 
role in resolution of innate inflammation.  By measurement of peritoneal exudates with LC-MS-
MS, there is definitive proof that 15d-PGJ2 is synthesised during mammalian inflammatory 
responses. When the cellular profile was examined by flow cytometry, a biphasic response of 
lymphocytes was observed with the disappearance during acute inflammation with activation of 
the DP-1 receptor. The profile of lymphocytes that reappear during resolution differed from the 
naïve state and comprised of B1, NK, gamma/delta T, CD4+/CD25+ and B2 cells. The 
lymphocytes do not appear to have a role in resolution as lymphocyte deficient RAG2-/- and wild 
types resolve uniformly. However repopulating lymphocytes are critical for modulating 
responses to superinfection as observed by the exaggerated peritonitis/death of RAG2-/- mice 
when exposed to group B streptococcus following zymosan. In gp91phox-/- mice, an 
experimental model of CGD, where the peritonitis failed to resolve, the adaptive transfer of 
resolution phase lymphocytes into the peritoneum, was protective against superinfection. 
Furthermore in wild type mice when the anti-inflammatory adenosine and downstream cAMP 
were measured in peritonitis, there was a biphasic response. In gp91phox-/- mice, both adenosine 
and cAMP were significantly lower at onset and again at resolution. Adenosine, signalling 
 15 
through its A2A receptor and therefore elevating cAMP is not only anti-inflammatory, but also 
importantly, it does not impair pro-resolution pathways as antagonism of the A2A receptor 
worsens acute inflammation and prolongs resolution.  
In summary, resolution is an active regulated process that requires the input COX-2 derived 
PGD2 as well as anti-inflammatory A2A receptor activation. To further refine this model it was 
shown that repopulating lymphocytes are essential to prevent super-infection and persistence of 
inflammation. 
  
 16 
Chapter 1 Introduction 
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1.1 Overview of Inflammation 
1.1.1 The necessity of the inflammatory response 
Inflammation is primarily a host response to an injurious stimulus such as pathogens and 
chemical irritants. The cardinal sign of inflammation heat, redness, swelling, pain and loss of 
function, was first described by Celsus more than 2000 years ago (Figure 1.1)(Gilroy, Lawrence 
et al. 2004). This is fundamentally a beneficial response leading to removal of the offending 
factor and the restoration of tissue structure and function. However, as much as an inflammatory 
response is needed to neutralise the invading pathogen, it is equally important bring about 
resolution of inflammation to maintain the integrity of the tissue that was involved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
This is mediated, in the first instance, by a host of signals that drive the inflammatory response in 
a manner well understood, which all require the up-regulation of cell adhesion molecules and 
expression of chemokines resulting in the accumulation of inflammatory leukocytes at the site of 
tissue injury. Once the inflammatory stimulus has been neutralised then inflammation can abate 
 
Figure 1.1 The cardinal signs of inflammation depicted by the 'The five 
Greeks’. Commissioned by the late Professor Derek Willoughby and drawn by 
P. Cull 
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(Nathan 2002; Serhan and Savill 2005). The whole purpose of inflammation is to remove the 
offending agent and subsequent restoration of tissue function. For example in lobar streptococcal 
pneumonia with antibiotic therapy the morphological changes caused by the infiltration of 
neutrophils and other inflammatory cells invariably resolves without any chronic tissue damage. 
This however does not happen in a passive manner as originally thought, where the 
inflammatory response was simply believed to “fizzle out”. Quite the opposite, in-as-much as 
onset is highly controlled, resolution is also an active event managed by an increasing number of 
soluble mediators and mechanisms that culminate in inflammation switching off and importantly 
resulting in the stromal tissue that hosted the response returning to is prior physiological state.  
 
1.1.2 The transition from acute inflammation to resolution 
Acute inflammation is initiated by resident cells within the affected tissue (resident 
macrophages, dendritic cells, lymphocytes) and is characterised by changes in the 
microcirculation with resultant vasodilatation leading to movement of leukocytes from the blood 
into the microenvironment termed the extracellular matrix [ECM]. This is mediated by up-
regulation of adhesion factors on the endothelial surface, which facilitate the adherence of 
inflammatory leukocytes and migration into the affected area (Lawrence, Willoughby et al. 
2002).  Table 1.1 summarises the spectrum of agents that drive the acute inflammatory process 
necessary to neutralise the offending agent. The hallmark of the acute phase is the influx of 
neutrophils within the first 24 hours in response to triggers for tissue injury such as invading 
microbes, surgical trauma that activate the release of pro-inflammatory cytokines, for example 
IL-6, IL-1β and TNFα. Arachidonate-derived prostaglandins such as PGE2 from the 
cyclooxygenase pathway and 5-lipoxygenase pathway products leukotriene B4 (LTB4) amplify 
the movement of PMNs to site of injury(Gilroy, Lawrence et al. 2004).  Once PMNs reach to site 
of injury, they remove the invading pathogen by the process of phagocytosis and neutralise by 
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the initiating an extensive intracellular armamentarium of degradative enzymes and reactive 
oxygen species (ROSs).  
 
Mediator Class Pro-inflammatory Anti-inflammatory 
Amines Histamine, bradykinin Adrenaline, noradrenaline 
Lipid Mediators PGE2, LTB4, LTC4 PGJ2, PGA2, Lipoxins 
Complement C3a, C5a C1q receptor 
Cyclic nucleotides cGMP cAMP 
Adhesion molecules E-selectin, P-selectin, 
ICAM1, VCAM1 
α2β3 integrin, TSP 
receptor, PS receptor 
Cytokines TNF-α, IL-1β, IL-6 TGF-β1, IL-10 
Chemokines IL-8, MIP-1α, MCP-1  
Steroid hormones  Glucocorticoids 
Table 1.1 Mediators of inflammation PG Prostaglandin, cGMP- cyclic guanosine 3.6 
monophosphate, cAMP-cyclic adenosine 3,5 monophosphate, I/VCAM-1- intracellular/Vascular 
adhesion molecule-1, TNF- Tumour necrosis factor, IL- interleukin, TGF-Transforming growth 
factor, MIP- Macrophage inflammatory protein, MCP-1 Monocyte chemotactic protein (adapted 
from (Lawrence, Willoughby et al. 2002) 
 
However, continued influx and persistent neutrophil activity will mean that the acute 
inflammation remains unchecked leading to oedema and permanent tissue damage. Conventional 
wisdom was that once the source for acute inflammation (invading pathogen, chemical injury) 
has been removed then the stimulus to activate pro-inflammatory mediators and cytokines is lost 
leading to reduced efflux of leukocytes allowing for the tissue to restore structure and function. It 
is now appreciated that just as the acute inflammatory process is an active response to injury, 
resolution does not occur in a passive manner and is mediated by a sequential release of 
cytokines and lipid mediators summarised in table 1.1 that is discussed in detail later in this 
 20 
chapter. The resolution involves reversing vascular permeability, the switching off of leukocyte 
migration, enabling the disposition of leukocytes and debris away from the tissue and most 
importantly to limit excessive tissue injury and prevention of the development of chronic 
inflammation. Timing here is the essence. Just as delayed triggering of resolution lead to chronic 
inflammation, premature onset of signals of resolution will mean the failure of arresting the 
offending agent leading to overwhelming inflammation (e.g. uncontrolled septicaemia) that can 
lead to permanent disability or death of the host (Hotchkiss and Nicholson 2006). The signalling 
pathways that lead to the ‘switch’ from pro-inflammatory to pro-resolution mediator release 
begin early in inflammation and often involve the share the same pathways with differing end 
products (Serhan and Savill 2005). The ‘class switch’ including COX-2 metabolite PGE2 to 
PGD2 (and its metabolite 15-PGJ2), leukotrienes (e.g. LTB4) to lipoxins (e.g. LXA4) and the 
generation of lipid mediators from omega-3 polyunsaturated fatty acids- resolvins and protectins, 
is mediated by the inflammatory leukocytes at different time periods during inflammation 
(Serhan and Savill 2005). 
 
Therefore once the offending agent is neutralised, PMNs undergo apoptosis (Savill and Haslett 
1995), which in turn is phagocytosed by tissue macrophages (Metchnikoff 1893; Savill, 
Dransfield et al. 1990), which increase in number during the resolution phase of the 
inflammation. Apoptosis of PMNs is preferred to necrosis, the latter that may promote further 
tissue injury. The onset of resolution is rapid, with PMNs falling by 50% within an interval of 8 
hours following peak inflammation as evidenced in a resolving zymosan induced peritonitis 
model (Bannenberg, Chiang et al. 2005). The phenotypes of the macrophage population that 
assist in resolution (termed resolution phase macrophages, Rm or M2) differ in phenotype to that 
of the resident or ‘inflammatory’ population (M1) as in Rm cells express TGFβ1 which 
suppresses pro-inflammatory signalling from toll like receptors, the latter a critical mediator of 
innate immunity (Zhang, McCluskey et al. 1998; Gordon 2003; Verreck, de Boer et al. 2004). 
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Finally along with the removal of the PMNs, macrophage numbers fall as the inflammatory cells 
are cleared via the draining lymphatics with restoration of normal tissue structure and 
function(Bellingan, Caldwell et al. 1996). In this milieu there also observed the disappearance of 
lymphocytes in acute inflammation and re-population during resolution whose role  (if any) is 
poorly understood. Figure 1.2 illustrates the cellular profile in both acute and resolution of 
inflammation. The principle aim as mentioned above is restoration of tissue structure and 
function. However, if the tissue injury is widespread as in a large wound infection, the tissue 
repairs itself by inward growth of surrounding tissue with vascular supply from proliferating 
capillary loops with movement of leukocytes and fibroblasts. This is termed granulation tissue 
which eventually leaves a fibrous scar (Gurtner, Werner et al. 2008) and should not be mistaken 
as failure of resolution as the resultant fibrous scar is a reflection of the insult being greater than 
the capacity of the host to restore complete function. 
 
As much as the changes in cellular profile in acute inflammation is important to restore tissue 
architecture, enhancing the ability of vertebrates to fight infection that they have previously 
encountered has been important for its evolution and survival. Therefore the antigen presenting 
cells, dendritic cells, in the site of inflammation also remove the offending agent by phagocytosis 
and then present antigenic peptides complexed with major histocompatibility molecules (MHC) 
in the lymphoid organs critical for the development immunological memory, hallmark of 
adaptive immunity. 
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Figure 1.2 The leukocyte profile during acute inflammation and resolution 
 
1.1.3 Wound Healing 
It’s important to distinguish the traditional concept of acute inflammatory resolution in response 
to an injurious agent to that of wound healing where the organ repairs itself following injury to 
the outer protective barrier (Gurtner, Werner et al. 2008; Sonnemann and Bement 2011). The 
process can be divided into three overlapping stages: inflammation, new tissue formation and 
remodelling. The epidermis and dermis of the skin act as a protective barrier and when breached, 
activated platelets form a blood clot that acts as a scaffold for infiltrating cells first being PMNs 
that release more cytokines. PMN influx is followed by macrophage infiltration that further 
exacerbates the phagocytic activity important to scavenge foreign objects, organisms and 
apoptotic PMNs. As inflammation progresses to neutralise the offending event, the process of 
new tissue formation with re-epithelialisation begins with migrating activated fibroblasts 
together with macrophages forming the granulation tissue which replaces the fibrin clot in the 
healing wound. Angiogenesis aids this process by increasing blood flow to deliver nutrients and 
oxygen in order to facilitate healing. This process gradually evolves into remodelling with 
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involution of the granulation tissue together with dermal regeneration. This involves apoptosis of 
myofibroblasts, endothelial cells and macrophages. The aim of successful wound healing process 
is to restore tissue architecture to its pre-inflamed, physiological state. 
 
1.2 Apoptosis and Phagocytosis 
1.2.1 Apoptosis 
As important as it is for PMNs to neutralise the offending agent, if they were to remain and 
function unchecked, it will lead to persistent inflammation and damage. Therefore for resolution 
to occur the inflammatory leukocytes needs to be cleared from the site of injury, one method 
being apoptosis (Savill and Haslett 1995). This is a process, by which redundant, damaged or 
infected cells are eliminated from tissues and therefore being protected from the alternative that 
is necrosis when noxious substances from the dying cells are leaked into the tissue. 
 
Morphologically this is characterised by cell shrinkage, cytoplasmic condensation, nuclear and 
chromatin fragmentation leading to the formation of an apoptotic body, which is then, engulfed 
by a phagocyte, namely monocyte derived macrophages. In innate inflammation, this is the 
principle mechanism by which inflammatory leukocytes, namely PMNs are removed from site of 
its action. 
 
The execution switch for apoptosis is a group of previously dormant proteases, the caspases that 
is activated by two distinct pathways. The extrinsic, that engage the so-called surface ‘death 
receptors’- TRAIL (TNF related apoptosis inducing ligand); TNFα, CD95L, initiate caspase-8 
mediated pathways. The second, intrinsic mitochondrial initiated caspase-9 mediated pathway is 
provoked by cell stress due to inadequate cytokine support for the cell or diffused intracellular 
damage, which is regulated by the Bcl-2 family (Roy and Nicholson 2000; Danial and 
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Korsmeyer 2004; Gupta 2005). Both caspase-8 and-9 can activate caspase-3, the critical final 
common pathway to induce apoptosis. 
 
Following the programmed death of the leukocyte during inflammation, the apoptotic body must 
be cleared from site of injury by phagocytosis by scavenging monocyte derived macrophages 
that employ two classes of adhesion molecules, integrin heterodimers of the β3 family and 
thrombospondin -1 (TSP-1) receptor (Savill, Dransfield et al. 1990; Savill, Hogg et al. 1992). 
Therefore apoptotic PMNs bind to macrophages via αvβ3 vitronectin receptor integrin and TSP-1 
receptor CD36 leading to the phagocytosis. Many other macrophage surface molecules have also 
been implicated in clearance of apoptotic leukocytes including lectin, phosphatidylserine 
receptor 61D3 and class A scavenger receptors (Savill 1997). 
 
1.2.2 Phagocytosis 
Phagocytosis is the process by which invading pathogens are taken and neutralised by the 
inflammatory cell such as PMNs, dendritic cells and macrophages. This is important for both the 
innate immune response as well as for antigen presentation and the development of adaptive 
immunity. Following uptake of the pathogen, it is trapped together with extracellular fluid in a 
vacuole termed the phagosome (Flannagan, Cosio et al. 2009). This undergoes a series of 
changes with sequential interaction with endosomes during which the vacuole lumen becomes 
increasingly acidic (Desjardins, Huber et al. 1994). Apart from the decrease in the pH, the lumen 
is enriched with degradative proteases and lysosomal associated membrane proteins (LAMP). 
This culminates with fusion with the lysosome to form the phagolysosome, which is highly 
acidic (pH 4.5) and contain an extensive repertoire to neutralise invading pathogens. The 
microbicidal activity within the phagolysosome is mediated by the acidity that inhibits pathogen 
growth and activity, degradative proteases and peptides (e.g. Latoferrin, cathelicidin, lyzozymes, 
cysteine proteases) and reactive oxygen species (ROS) (Flannagan, Cosio et al. 2009). For 
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instance during activation of neutrophils the heterodimer, gp91 phox and p22 phox (also known 
collectively as the cytochrome b558), components of the Nicotinamide Adenine Dinucleotide 
Phosphate (NADPH) Oxidase (NOX) migrate to the surface of phagosome or cellular membrane. 
This leads to the production of reactive oxygen species (ROS), superoxide with a direct 
microbicidal effect as well as the arrest of pathogen survival and growth (Quinn and Gauss 
2004). Generation of ROS leads to the consumption of oxygen termed ‘respiratory burst’. The 
importance of ROSs in elimination of microbes is highlighted by chronic granulomatous disease 
(CGD) where mutation in gp91phox subunit of NADPH oxidase, is characterized by recurrent 
infections that can result in death (Heyworth, Cross et al. 2003). The NOXs and CGD will be 
described in detail later in this chapter (1.6.2 Chronic Granulomatous Disease). 
 
1.3 Innate versus Adaptive Immunity 
Immunity, the state of protection from infectious disease, can broadly be divided into two arms: 
innate, and more specific adaptive immunity.  The innate immune response is the first line of 
defence to invading pathogens and is independent of prior exposure to the pathogen (Turvey and 
Broide 2010).  Adaptive immunity develops when the body is exposed to various antigens 
expressed by pathogens and builds a defence that is specific to those antigens which typically 
develops within five to six days of exposure.  Innate and adaptive immunity co-operate to 
generate a ‘total’ response more efficient than either alone (Turvey and Broide 2010). 
 
1.3.1 Innate Immunity 
Innate immunity plays a critical role in host defence against infection. It confers its protective 
effect by anatomic [physical barriers], physiologic [inhibition of growth and survival of 
pathogens] and by the inflammatory response as described previously. This process has remained 
conserved through evolution and is the principle mechanism by which most organisms respond 
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to infection and cellular injury. Only vertebrates have an additional adaptive immune system. 
The recognition of pathogens is through highly conserved pathogen-associated molecular 
patterns (PAMPs), such as lipopolysaccharides, mannans and bacterial CpG DNA motifs, 
common to a large group of microorganisms but absent in the host as well as damage-associated 
molecular patterns (DAMPs), endogenous products released from damaged and dying cells 
(Seong and Matzinger 2004). They are recognised by pattern recognition or germ line-encoded 
recognition receptors. There are two families of receptors that recognise the above mentioned 
integral structural components of microbes, Toll-like receptor  (TLR) family (Takeda, Kaisho et 
al. 2003; Akira and Takeda 2004) and proteins containing nucleotide-binding site and leucine-
rich repeat (NBS-LRR) domains (Chamaillard, Girardin et al. 2003). 
 
Toll-like receptors, comprise of conserved leucine-rich repeat (LRR) ectodomain, 
transmembrane and cytoplasmic tail domains. The latter contains the canonical Toll/interleukin 1 
(IL-1) receptor domain and is involved in downstream signalling process. LRR domain is 
important in ligand binding and its high specificity has led to identification of 10 and 12 
subtypes of TLRs in humans and mice respectively. TLR 1-9 is conserved in both species.  TLRs 
are expressed on macrophages, dendritic cells, B cells, specific types of T cells and also on non-
immune cells such as fibroblasts and epithelial cells. The recognition of PAMPs by TLRs occurs 
in various cellular compartments including the plasma membrane, endosomes, lysosomes and 
endolysosomes.  Therefore TLRs 1,2,4,5 and 6 are expressed on the cell surface whereas TLR 3, 
7-9 are exclusively intra-cellular. The localisation and accessibility to ligand is tightly regulated 
in order to maintain tolerance of self-antigen and downstream signal transduction (Takeda, 
Kaisho et al. 2003). 
 
However as previously mentioned, as much as inflammation is a necessary to counteract the 
injurious effects of the foreign organism, there has to be down regulation of TLR signalling to 
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limit the impact of pro-inflammatory signalling pathways. Therefore there are pathways such as 
one that involves Triad3A, a ubiquitin ligase which binds to TLR-4 and TLR-9 leading to its 
degradation and reduced TLR 4- and TLR 9 mediated NF-κB activation, one of the numerous 
natural ‘stop’ signals to prevent an exaggerated response early in the inflammatory cascade 
(Chuang and Ulevitch 2004). 
 
1.3.2 Adaptive immunity  
During vertebrate evolution, the ability to develop antigen specific immune response together 
with development of immunological memory became essential to deal with pathogens that were 
able to mutate to avoid host detection and evade the innate immune response. In contrast to 
innate immunity, which is geared for rapid sensing and elimination of pathogens, the adaptive 
immune response requires antigen presentation. The cells of the adaptive immune system include 
antigen-presenting cells i.e. dendritic cells, T lymphocytes that mature in the thymus and 
immunoglobulin secreting B-lymphocytes, which arise in the bone marrow (Bonilla and Oettgen 
2010). These facilitate antigen specific pathways, immunological memory and the ability to 
recognise self from non-self antigens. 
 
Following infection, pattern-recognition receptors expressed by antigen-presenting cells (APCs) 
such as the mannose receptor bind to PAMPs such as LPS, which mediate the uptake and 
delivery of pathogen to lysosomes. Professional APCs such as migratory dendritic cells are 
ubiquitous in regions most vulnerable to foreign insult such as the skin and mucosal surfaces. 
The pathogen is then degraded as part of the phagocytic process, and the foreign antigenic 
peptides are presented on the surface of the APCs complexed with major histocompatibility 
(MHC) molecules. These cells then home into to the lymph nodes where lymphocytes are 
activated. 
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CD4+ T helper (Th) cells activation is initiated when the T cell receptor (TCR) recognise the 
antigen peptide/MHC complex on an APC. This leads to the formation of the ‘immunologic 
synapse’ that comprise of CD3, TCR, which bind to the peptide/MHC class 2 complex, as well 
as the CD4 molecule. This interaction is further stabilised by integrins. Effector T cells then 
secrete various cytokines which in turn activate B cells, cytotoxic (Tc) cells, macrophages and 
various other cells that participate in the immune response.  
 
In order to achieve optimal lymphocyte activation a second signal is necessary to complement 
the antigen-MHC-TCR interaction in T cells and immunoglobulin- receptor in B cells and this is 
termed co-stimulation (Lafferty, Andrus et al. 1980; Brunet, Denizot et al. 1987; June, Ledbetter 
et al. 1990). For this to occur a vast array of co-stimulatory molecules exist on the surface of 
naïve T and B-lymphocytes that bind to its ligands on APCs and T helper cells respectively. 
During T cell activation, lack of co-stimulation leads to failure to sustain proliferation, the 
inability to mount a cytokine response, increased lymphocyte apoptosis and development of 
anergy i.e. unresponsive to antigenic stimuli (Schwartz 2003). The first known co-stimulatory 
molecule was CD28 on T cells that bind to B7.1 and B7.2 ligands on the APCs (Brunet, Denizot 
et al. 1987). Activated CD28 in turn up regulate CD40 ligand, which by binding to CD40 on 
APCs will in turn increase B7 expression. Furthermore, CD28 also induces T cell expression of 
ICOS (inducible co-stimulator molecule) that binds to its namesake ligand (Sharpe 2009). 
However co-stimulation needs to be kept in check to avoid uncontrolled T cell activation. The 
best studied is CTLA-4, a member of the CD28 family, whose expression is also increased with 
T cell activation which then inhibits T cell proliferation and IL-2 synthesis and therefore, co-
stimulation is a self-limiting process. 
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1.4 Cellular components in inflammation and resolution 
1.4.1 Granulocytes 
This group of cells include Polymorphonucleor Neutrophils (PMN), eosinophils/mast cells and 
basophils. The hallmark of these cells is granules that contain proteins that kill microbes and 
digest tissues. Even though the PMN is the principle cell in the acute inflammatory response, the 
important role of mast cells in both innate and adaptive immunity must be appreciated. 
 
1.4.1.1 Mast cells 
In evolutionary terms mast cells have been conserved and humans’ deficient of this group of 
inflammatory cells have never been reported (Weller, Collington et al. 2011). Even though mast 
cells have been implicated in the chronic detrimental effects due to asthma, allergy and 
anaphylaxis, they have an important role in immune homeostasis. Mast cells are strategically 
placed at the host-environment interface with the potential to be the first responders typically 
within seconds of pathogen invasion by releasing proteases [e.g.: MCP-1), IL-6, TNF following 
activation of TLRs by PAMPs leading to recruitment of PMNs and macrophages (Abraham and 
St John 2010; Weller, Collington et al. 2011). They are therefore able to communicate the 
presence of pathogens with cells in both innate and adaptive arms of inflammation- PMNs, 
macrophages, dendritic cells, B & T lymphocytes as well as endothelial, smooth muscle and 
epithelial cells.  
 
1.4.1.2 Polymorphonuclear neutrophils 
PMNs, which are generated in the bone marrow and circulate in the blood stream, are 
indispensable for the elimination of the invading pathogen. The production in the bone marrow is 
in a steady state and is increased in response to granulocyte colony stimulating factor (G-CSF) 
that occur when there is tissue injury or if microorganisms successfully overcome the physical 
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barriers (Lieschke, Grail et al. 1994). Hallmark of PMNs and other granulocytes are the presence 
of intracellular granules necessary for neutralising the pathogen. Neutrophil granules are 
classified into three distinct subsets based on the presence of characteristic granule proteins: 
primary (azurophil) granules (myeloperoxidase [MPO]), secondary (specific) granules 
(lactoferrin), and tertiary gelatinase granules (gelatinase) (Borregaard and Cowland 1997). 
Following injury or invading microorganisms, endothelial cells are activated by cytokines such 
as TNFα and IL1β that lead to capture of PMNs by selectins. This leads to a process of rolling, 
and then adhesion to the endothelium followed by trans-endothelial migration mediated by Mac-
1 and LFA-1. The neutrophils then phagocytose the invading pathogen, degranulate and then 
undergo apoptosis, with the apoptotic PMNs being scavenged by tissue macrophages 
(Borregaard 2010). 
 
Following neutralisation of the offending agent, the ‘spent’ PMN either undergoes necrosis or 
apoptosis, the latter being preferred. ChemR23 expressed on macrophages, dendritic cells and 
activated endothelial cells, mediates via phoshpinositide-3-kinase (PI3), protein kinase B (Akt) 
signalling the phagocytic capacity of macrophages for uptake of apoptotic neutrophils and 
reduce risk of necrotic PMN cell death. It also down-regulates G-CSF to limit PMN activation 
locally, a necessary ‘stop’ signal to limit acute inflammation (Kaur, Adya et al. 2010; Ohira, 
Arita et al. 2010). 
 
PMNs also neutralise the offending agent by the generation of neutrophil extracellular traps 
(NETs), a web of chromatin and serine proteases that trap and kill microbial organisms 
extending the antimicrobial activity beyond the lifespan of the neutrophil. This is distinct from 
apoptosis. The mechanism of NET formation is unclear (Brinkmann, Reichard et al. 2004). It is 
interesting to note that PMNs from newborns are partially deficient of NET production and 
demonstrate decreased microbicidal effect. Hydrogen peroxide generated by the NADPH 
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oxidase is necessary for NET formation latter being absent in PMNs of chronic granulomatous 
disease (CGD), a disease state of chronic inflammation due to absent NOX activity (Bianchi, 
Hakkim et al. 2009; Metzler, Fuchs et al. 2011). 
 
1.4.2 Mononuclear cells 
1.4.2.1 Monocytes and macrophages  
Monocytes, macrophages and dendritic cells originate from haematopoietic stem cell progenitors 
in the bone marrow. Under normal circumstances monocytes circulate for a short time before 
undergoing spontaneous apoptosis (Auffray, Sieweke et al. 2009). Monocytes may however 
escape their apoptotic fate by differentiating into macrophages with a longer life span (months to 
years) triggered by differentiating factors such as granulocyte-macrophage colony stimulating 
factor (GM-CSF), macrophage colony-stimulating factor (M-CSF) and colony-stimulating 
factor-1 (CSF-1). They are defined by the presence of the CSF-1 receptor (M-CSF, CD115). 
Monocytes differ from circulating dendritic cells (cDC) by the absence of MHC class 2 antigens 
or the integrin CD11c. Monocytes may also differentiate into inflammatory dendritic cells, the 
latter an essential component of the adaptive immune response. Activation of 
monocytes/macrophages occurs through the stimulation of TLRs leading to production of pro-
inflammatory IL-1β and TNFα. The increased production of monocyte chemoattractant protein-1 
(MCP-1/CCL2) contributes further to increase production of pro-inflammatory cytokines 
(Auffray, Sieweke et al. 2009).  
 
In human there are three subsets of monocytes based on expression of CD14 and CD16.  They 
are CD14+CD16-, which comprise 80-90% of circulating monocytes, CD14+CD16+ and 
CD14dimCD16+ (Grage-Griebenow, Flad et al. 2000; Ziegler-Heitbrock 2000). In mice, 
monocytes are identified based on the side scatter on flow cytometry, CD115, dectin-1, CD11b 
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and expression of Gr1/Ly6C antigen. Ly6C is also expressed in granulocytes, NK cells (40%) 
and subsets of dendritic cells.  Based on the expression of Gr1 and Ly6C, two subsets of 
monocytes have been identified in mice, the ‘inflammatory’ GR-1+Ly6chigh (the phenotypic 
equivalent of CD14+CD16- in humans) and ‘patrolling’ GR-1-Ly6clow monocytes (Auffray, 
Sieweke et al. 2009). Following infection, increased numbers of the inflammatory monocytes 
leave the bone marrow that express TNFα and IL-1. They are selectively recruited to inflamed 
tissue and lymph nodes where they transform to M1 type macrophages and inflammatory 
dendritic cells both that perform effector functions during acute inflammation. The patrolling 
subtype, GR-1-Ly6clow monocytes are seen on intravital microscopy to be crawling on the 
luminal surface of vascular endothelium and survey the surrounding tissues for damage and 
infection. Furthermore, GR-1-Ly6clow monocytes initiate differentiation of the ‘alternative’ or 
M2 macrophage phenotype involved in inflammatory resolution and tissue healing (see below) 
(Martinez, Gordon et al. 2006; Auffray, Sieweke et al. 2009). 
 
Macrophages are characterised by the surface expression of CD14, CD16, CD11b, and CD68 
and additionally in mice, F4/80 (Taylor, Martinez-Pomares et al. 2005). Two types of 
macrophages have been characterised, M1 and M2. M1 cells assist Th1 immune responses 
mediated by IFN-γ, IL-1β and TNFα (with low levels of anti-inflammatory IL-10) and are 
involved in antigen presentation to B cells. Furthermore these cells also demonstrate increased 
expression of COX-2, iNOS derived NO, peroxynitrite, peroxide and superoxide (Zhang, 
McCluskey et al. 1998; Mantovani, Sica et al. 2004; Verreck, de Boer et al. 2004). To 
counterbalance the effects of the pro-inflammatory M1 cells, tissue protective Th2 by cytokines 
IL-4, IL-10 and TGFβ1 production characterise an alternative macrophage population, the M2 
phenotype (Gordon 2003). There is, however, heterogeneity in this population based on the 
surface marker expression. For instance, in a resolving peritonitis model the resolution phase 
macrophages share expression of COX-2 and iNOS typical of M1 cells (Bystrom, Evans et al. 
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2008). The switch between macrophages typical of M1 versus the pro-resolution M2 is 
influenced by cAMP with the inhibition of the latter favouring the pro-inflammatory phenotype.  
 
As inflammation resolves, monocytes/macrophages numbers in sites of inflammation fall. The 
disappearance is either by apoptosis, which is caspase-3 dependent (Parihar, Eubank et al. 2010), 
or via draining lymphatics (Bellingan, Caldwell et al. 1996; Bellingan, Xu et al. 2002). More 
recent work done in a peritoneal model of inflammation [sterile zymosan induced peritonitis], 
macrophages with the M1 phenotype is thought to be pro-inflammatory and aiding the acute 
inflammatory response, whereas the M2 macrophages is actively involved in promoting 
resolution (Bystrom, Evans et al. 2008). 
 
1.4.2.2 Dendritic cells 
Dendritic cells (DC) are professional antigen presenting cells critical for adaptive immunity. 
Monocytes, macrophages and dendritic cells share a common macrophage-dendritic cell 
progenitor (MDP) (Fogg, Sibon et al. 2006) but there is a DC progenitor (CDP) that exclusively 
produces dendritic cells (Liu, Victora et al. 2009). 
 
Dendritic cells can further be classified as conventional DCs and non-conventional DCs. The 
latter is not seen in a steady stage and develops in the presence of inflammatory stimuli. 
Conventional DCs are further sub-classified to migratory, which are able to carry antigen-MHC 
class 2 complexes from periphery (e.g. skin, lung) and migrate to draining lymph nodes where 
interaction with lymphocytes occurs. In contrast, lymphoid DCs are resident in lymphoid tissue 
and lack the migratory capacity. Non-conventional DCs differ by their capacity to express δIFN 
and can further be sub-classified into plasmacytoid and monocyte derived DCs, further 
illustrated by Figure 1.3 (Kushwah and Hu 2011). 
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Figure 1.3 Dendritic cell sub-types 
 
1.4.2.3 Lymphocytes 
Predominant subsets of lymphocytes are T and B cells.  Natural Killer cells (NK cells) are 
classified separately as a lymphocyte subclass and play a role in the innate immune system that 
kill cells by release of small cytoplasmic granules called granzyme and perforin (Cooper, 
Fehniger et al. 2001; Lanier 2005). At an evolutionary level they are more primitive and play an 
important role in defence against pathogens, virally infected cells and tumour cells. In humans 
they express CD16 and CD56 and in a majority CD8. 
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1.4.2.3.1 T cells 
T cells that undergo maturation in the thymus are distinguished from B cells and NK cells by the 
expression of the CD3+ T cell receptor (TCR) (Takahama 2006; Hedrick 2008). They play a 
central role in cell-mediated immunity and are responsible for immunological memory. 
 
T helper cells  (Th), characterised by the expression of CD4 on its surface, is essential for 
maturation of B cells into immunoglobulin producing plasma cells and the activation of 
cytotoxic T cells. Therefore their effect against foreign organisms or autoimmunity is indirect.  
Th cells can further be subdivided based on the cytokine profile (Table 1.2). Th1 cells produce 
IFN-γ whereas Th2 cells produce IL-4, IL-5, IL-6 and IL-13. Th1 cell production is IFN-γ 
dependent, inhibited by IL-4 whereas the converse is true for Th2 cells (Bonilla and Oettgen 
2010). In response to an antigen, critical determinant to activation of the Th cell is the cytokine 
profile by which naïve T helper cell is activated. IL-12 interacts with naive Th lymphocytes to 
activate Signal Transducer and Activator of Transcription 4 (STAT4) leading to expression of 
the transcription factor T-box expressed in T cells (T-bet) that is responsible for differentiation to 
Th1 phenotype, the essential component of cell mediated immunity. It simultaneously blocks the 
expression of Th2 cytokines and negatively regulates Th17 differentiation. IL-4 is the principle 
determinant of Th2 differentiation. IL-4 activates STAT6 that in turn promotes expression of 
GATA-3 and suppresses expression of T-bet. Th2 cells are essential for host humoral immunity 
to various infections including extracellular parasites such as helminths and are responsible for 
the development of allergic inflammatory disease such as asthma. Th 17 cells are a more recently 
discovered subset that produces IL-17, thought to play a role in autoimmunity (Fouser, Wright et 
al. 2008). 
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Family Cytokine repertoire 
Th1 IFN-γ, TNF-α, IL-2, IL-3 
Th2 IL-2, IL-4, IL9, IL-13 
Th17 IL-17, IL-21 
Treg IL-10 
(CD25+Foxp3+)   
 Table 1.2 Subtypes of CD4+ Th cells 
 
In addition to subsets of Th cells, several families of CD4 positive regulatory T cells [T-reg] have 
been identified that include IL-10 producing peripherally differentiated (induced) Treg (iTreg) 
cells, thymic derived CD25+ natural T reg cells. Thymic derived T reg cells are characterised by 
the constitutive expression of the transcription factor Forkhead box P3 (FOXP3) (Shevach, 
DiPaolo et al. 2006; Vignali, Collison et al. 2008). 
 
1.4.2.3.2 B-lymphocytes 
B-lymphocytes are generated by haematopoietic stem cell progenitors. The classic role of B 
lymphocytes is in the adaptive immune response with antigen presentation, production of high 
affinity protective immunoglobulins, up-regulation of co-stimulatory molecules, production of 
cytokines and regulation of T cell repertoire and response (Roosnek and Lanzavecchia 1991; Yi, 
Klinman et al. 1996; Lee and Koretzky 1998). This is mediated by the predominant B-2 cell 
subset, accounting for 85% of splenic and over 99% of circulating B cells (von Boehmer and 
Melchers 2010). However with the discovery of expression of TLRs on murine B cells, another 
subset (named B-1), characterised by the surface expression of CD5+ was discovered with an 
important role in innate immunity (Hayakawa, Hardy et al. 1983; Wortis and Berland 2001; 
Dorshkind and Montecino-Rodriguez 2007). B-1 cells are relatively sparse in the spleen (2%) 
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but are the predominant resident B cell subset in peritoneal and pleural cavities occur earlier than 
B-2 during lymphocyte development (Godin, Garcia-Porrero et al. 1993). B-1 cells traffic 
continuously through the omentum that is mediated by peritoneal macrophage derived CXCL13 
(Ansel, Harris et al. 2002).  
 
With the discovery of the innate arm of lymphocyte biology, it is widely appreciated that B cells, 
in particular B-1 act as a bridge between innate and adaptive immune responses (Viau and Zouali 
2005). The resident B-1 cells in pleural and peritoneal cavities are not continuously replenished 
unlike B-2 cells, which have a half-life of 5 months (Hao and Rajewsky 2001). T lymphocytes 
and B-2 cells that emerge are ‘negatively selected’ in order to remove self-reactive cell 
population in order to prevent auto-immunity but B-1 are ‘positively selected’ that produce self-
reactive antibodies which also cross react with many pathogens and important for innate 
immunity. 
 
B-1 cells, by producing a steady state of IgM, are able to neutralise invading pathogens early 
during infection by inhibiting replication and through complement binding (Baumgarth 2011). 
They are activated by TLR agonist such as lipopolysaccharide [LPS] and are unresponsive to B 
cell receptor activation as opposed to B-2 cells (Ansel, Harris et al. 2002; Baumgarth 2011). 
Following activation, B-1 cells migrate from the peritoneal cavity to the spleen or mucosal 
tissues where they differentiate to IgM or IgA secreting cell.  Furthermore in the gut mucosa and 
respiratory tract, it acts as the first line of defence by polyspecific production of IgA. In tissue 
homeostasis, IgM bind and neutralise altered self antigens on apoptotic cells preventing 
autoantibody production, decrease development of atherosclerosis by binding to lipoproteins and 
enhance phagocytosis by dendritic cells. In IgM deficient mice B-1 cells are increased by almost 
three fold demonstrating this immunoglobulins’ negative regulatory effect on this subset of B 
lymphocytes. However the local tissue homeostasis of these mice are unaffected. This may be 
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due to uptake of apoptotic bodies by the increased numbers of B-1 cells. In summary, the 
emerging role of B-1 cells and also perhaps the recently discovered IL-10 producing B-
regulatory cells has potentially important implications in the regulating of both acute 
inflammation as well as promoting inflammatory resolution (Yang, Sun et al. 2010). 
 
1.5 Mediators of resolution 
Acute inflammation that is characterised by the movement of leukocytes from the blood into the 
microenvironment is facilitated by the release of pro-inflammatory cytokines and chemotactic 
mediators (Table 1.1). The focus of this thesis is the resolution potential of lipid mediators and 
adenosine which will be discussed in depth below: 
1.5.1 Arachidonic acid metabolism by cyclo-oxygenase 
Arachidonic acid [AA], released from the plasma membrane phospholipids via the action of 
calcium dependent phospholipase A2 (Figure 1.4). It is then converted to prostaglandin D2 and 
H2 sequentially by prostaglandin synthase also known as cyclooxygenase [COX]. PGH2 formed 
from by the action of COX is then converted to prostaglandins [PGD2, PGE2 and PGF2α], 
thromboxane and prostacyclin by specific synthases.  
 
There are three isoforms of Cyclooxygenase [COX], formerly known as prostaglandin G/H 
synthase [PGHS]. The first, COX-1 is constitutively expressed in most tissues and synthesises 
prostaglandins at low levels to maintain physiological function (Smith, Garavito et al. 1996). 
COX-2 is inducible in response to inflammatory and mitogenic stimuli (Hla and Neilson 1992; 
Sirois and Richards 1992) but is constitutively expressed in the forebrain (Kaufmann, Worley et 
al. 1996), macula densa of kidneys (Harris, McKanna et al. 1994) and in un-stimulated 
endothelial cells ex vivo (Grosser, Fries et al. 2006) and adjacent epithelial cells of the cortical 
thick ascending limb of the kidney (Harris, McKanna et al. 1994; Kaufmann, Worley et al. 
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1996). Both COX-1 and 2 share similar structural properties including a hydrophobic substrate 
specific tunnel. The COX-2 tunnel is more accommodating as it has a side pocket and therefore 
broader substrate recognition (Rajakariar, Yaqoob et al. 2006). It was observed that there was a 
rapid induction of COX-2 during inflammation accounting for the prostaglandin production, and 
the structural difference from COX-1 led to the discovery of drugs that selectively inhibit COX-
2, which were marketed as being anti-inflammatory but without the gastric toxicity, latter 
implicated to the inhibition of COX-1. These selective COX-2 inhibitors (coxibs), celecoxib, 
rofecoxib and valdecoxib were approved by the US Food and Drug Administration (FDA) on the 
basis of small clinical studies in a period during which there were increasing evidence of the role 
of COX-2 in mediating inflammatory resolution. Furthermore, even though relatively small 
studies supported the gastro protective properties of selective COX-2 inhibitors, there were five 
large randomised controlled trials that demonstrated an increased risk of death from myocardial 
infarction and stroke in patients treated with coxibs leading to withdrawal of many compounds in 
this class. (Grosser, Fries et al. 2006). This may be explained by the observation that prostacyclin 
(PGI2) production is mediated by increased expression of COX-2 in endothelial cells, its role of 
limiting platelet aggregation, as well as the lack of inhibition of pro-platelet aggregator TXA2 
production. Therefore, compared to traditional non selective non steroidal anti inflammatory 
drugs (NSAIDs), there is an imbalance between PGI2 and TXA2 in favour of increased 
expression of the latter leading to enhanced platelet aggregation (Grosser, Fries et al. 2006). 
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Figure 1.4 The Prostaglandin pathway-Synthesis of prostanoids by cyclo-oxygenase (COX) 
following the catalytic release of arachidonic acid from membrane phopholipids by by calcium 
dependent phospholipase A2. PGH2 is metabolised to PGD2, E2, F2α, Thromobxane [TxA2] and 
prostacylin [PGI.2] by specific synthases. Alternatively, arachidonic acid can be metabolized by 
lipoxygenase [5-, 12- & 15-] or cytochrome p450 to leukotrienes, lipoxins and 
hyroxyl/epoxyeicosatetraenoic fatty acids. 
 
 COX-3, a splice variant of COX-1 whose inhibition by acetaminophen is thought to promote the 
latter’s anti-pyretic and analgesic effects (Ayoub, Botting et al. 2004). However the expression 
of acetaminophen sensitive COX-3 at a protein level in humans has been questioned (Schwab, 
Schluesener et al. 2003). 
 
Even though the focus of this thesis is the resolution friendly mediators of the cyclo-oxygenase 
pathway, there are alternative ways in which arachidonic acid can be metabolized which include 
lipoxygenase [5-, 12- & 15-], cytochrome p450, leukotrienes, lipoxins and 
hyroxyl/epoxyeicosatetraenoic fatty acid (Figure 1.5) (Samuelsson, Dahlen et al. 1987). 
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As mentioned previously with the onset of resolution, there is a ‘class switch’ in the 
lipoxygenase pathway from pro-inflammatory leukotrienes that mediate increased vascular 
permeability and influx of leukocytes to site of injury to that of lipoxins (Serhan and Savill 
2005). One of the molecules extensively studied is LXA4 that has been shown to inhibit PMN 
chemotaxis, endothelial transmigration of granulocytes and reduce PMN mediated vascular 
permeability (Serhan, Hamberg et al. 1984). Lipoxins also enhance movement of monocytes to 
sites of inflammation and mediate monocyte-derived macrophage phagocytosis of apoptotic 
PMNs necessary to promote resolution (Maddox and Serhan 1996). 
 
Following liquid chromatography tandem mas spectrophotometric assessment of exudates from 
inflamed dorsal air pouch model, another group of resolution mediators that is influenced by 
COX were discovered. They are resolvins and protectins, that are converted from omega-3 
polyunsaturated fatty acids; eicosapentaenoic acid (EPA) and docasahexanenoic (DHA) 
respectively (Serhan, Hong et al. 2002). Endothelial cells in the presence of non-selective COX 
inhibitor aspirin, EPA is converted to resolvins that inhibit PMN migration enabling resolution 
(Bannenberg, Chiang et al. 2005). 
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Figure 1.5 Lipoxigenase pathway- Leukotriene and lipoxin metabolism. LOX- Lipoxygenase. 
FLAP- 5-LOX Activating Protein. LT- Leukotriene. HPETE- hydroperoxyeicostetraenoic acid. 
HETE- hydroxyeicosatetraenoic acid. The red box is the leukotriene arm of the lipoxygenase 
pathway. 
 
1.5.1.1 COX and inflammation 
1.5.1.1.1 COX-1 
As mentioned previously, COX-1 is constitutively expressed in most tissues and generates 
prostaglandins to maintain normal physiological functions. In cultured 3T3 cells, a fibroblast cell 
line, COX-1 was expressed at constant but low levels throughout the cell cycle. However to term 
COX-1 as constitutive whereas COX-2 being inducible is an oversimplification as COX-1 levels 
can be down-regulated in endothelial cells by acidic fibroblast growth factor and up-regulated in 
mast cells following response to stem cell factor and dexamethasone (Smith, Morrow et al. 1993; 
Kaufmann, Worley et al. 1996).  
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In the rat carrageenin-induced pleurisy model, with the use of more selective COX-1 inhibitors 
piroxicam and aspirin were shown to have greater and more prolonged anti-inflammatory effects 
than selective COX-2 inhibitors NS-398 and nimesulfide in the early stage [2 and 6 hours] of 
inflammation (Gilroy, Tomlinson et al. 1998). Also inflammatory models in COX-1 deficient 
mice provided further evidence to support its pro-inflammatory role. For instance, oedema 
induced by arachidonic acid was inhibited by 70% in knockout mice compared with wild-type 
mice (Langenbach, Morham et al. 1995). Further support for the pro-inflammatory role of COX-
1 induced prostaglandin synthesis is based on the differential inflammatory response of both 
COX-1 and COX-2 deficient mice.  Triphorbol myristate acetate response in ear swelling and 
carrageenin-induced paw oedema was similar in both COX-2 knockout mice and wild type mice 
suggesting that the constitutively expressed COX-1 isoform that is still present in both groups is 
synthesizing sufficient amount of prostaglandins for inflammation to proceed.  
 
1.5.1.1.2 COX-2 
In the seminal paper on the phenotype of COX-2, mice lacking this enzyme (COX-2-/-) 
spontaneously developed suppurative peritonitis with multiple adhesions amongst the abdominal 
organs consistent with chronic inflammation (Morham, Langenbach et al. 1995). Therefore, it 
became apparent that perhaps some of the COX-2 metabolites were also responsible for the stop 
signals necessary for switching off inflammation.  In a resolving acute lung injury model, 
selective COX-2 inhibition led to a rise in leukocyte counts in the broncho-alveolar lavage.  In 
the gastro-intestinal system, COX-2 expression was up regulated in a rat ischaemia-reperfusion 
model and also following induction of colitis (Maricic, Ehrlich et al. 1999). Furthermore, 
haemorrhagic gastric injury significantly worsened with a selective COX-2 inhibition. During 
colitis, inhibition of COX-2 lead to worsening of colitis with intestinal perforation. This may 
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partly explain why the COXibs only reduced the rate of gastric ulceration by only 50% as it 
plays a protective role against luminal irritants (Wallace and Devchand 2005).  
 
Consistent with the above findings, the anti-inflammatory role of COX-2 was further elucidated 
in a carrageenin induced pleurisy model in rats (Gilroy, Colville-Nash et al. 1999). In this model 
there were two peaks of COX-2. First in the early phase the rise in COX-2 was associated with 
production of the pro-inflammatory prostaglandin PGE2. In the later phase of mononuclear cell 
dominated inflammation there was a 3-fold greater second peak of COX-2 coincident with the 
resolution phase latter mediated by another PGH2 metabolite PGD2 and its dehydration product 
15deoxyΔ12-14PGJ2 (15d-PGJ2) (Gilroy, Colville-Nash et al. 1999). Both the non-selective COX-
1/COX-2 inhibitor and the selective COX-2 inhibitor, NS-398, inhibited the acute inflammatory 
response, but impaired resolution with worsening inflammation 48 hours following induction of 
inflammation with reduced PGD2 and 15-d-PGJ2. The role of this cyclopentenone prostaglandin 
and its product 15-d-PGJ2 will be discussed in detail in the following section (1.5.1.2.2 PGD2 and 
1.5.1.2.3 15deoxyΔ12-14PGJ2 ).  
 
1.5.1.2 COX derived mediators of inflammation and resolution 
1.5.1.2.1 PGE2 
In the acute phase of carrageenin-induced pleurisy, there is an exaggerated release of PGE2 
formed from PGH2 mediated by PGE synthase (PGES) (Gilroy, Colville-Nash et al. 1999). There 
are three isoforms- cytosolic PGES, membrane PGES 1&2 [mPGES-1 & 2]. The expression of 
these enzymes is up regulated by many pro-inflammatory cytokines including IL-1β and TNF-α. 
In the study of Astiz et al, levels of prostaglandin E2 when measured in patients with sepsis or 
septic shock was significantly elevated compared to normal controls (Astiz, Saha et al. 1996). In 
mice deficient of mPGES-1, there is no PGE2 production from peritoneal macrophages 
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stimulated with LPS and pain as assessed by ascetic acid writhing is significantly reduced 
(Kamei, Yamakawa et al. 2004).  PGE2 acts via the EP receptor, which has four subtypes [EP 1-
4] (Andreasson 2010). The EP-2 and EP-4 receptors increase cAMP levels via activation of 
adenylate cyclase that further increases mPGES-1 expression in a positive feedback manner 
(Inoue, Takamori et al. 2002; Kojima, Kato et al. 2005). In a rat acute lung injury model caused 
by LPS, PGE2 levels in brocho-aleveolar lavage was increased together with enhanced ICAM-1 
expression on the vascular endothelium (Alba-Loureiro, Martins et al. 2004). In IL-1β stimulated 
human synovial fibroblast cultures, PGE2 was shown to regulate the production of pro-
inflammatory IL-6 and pro-angiogenic VEGF, as well as increasing EP 2 & 4 receptor mRNA 
expression (Inoue, Takamori et al. 2002). In the absence of IL-1β however, the ability of PGE2 to 
produce IL-6 and VEGF was low suggesting the role of PGE2 to be a promoter rather than a 
mediator of inflammation. In response to TNF-alpha, PGE2 levels rose acutely followed by the 
anti-inflammatory lipoxin A4 [LXA4] formed by the conversion of AA by 15-lipoxigenase [15-
LO] in a mouse air pouch model (Levy, Clish et al. 2001). PGE2 has also been shown to mediate 
the expression of 15-lipoxigenase and inhibit the production of the pro-inflammatory LTB4 
(Levy, Clish et al. 2001). Therefore, COX-2 derived PGE2 not only promotes acute 
inflammation, but also modulates it by switching on pro-resolution factors. In an allergic 
pleuritis model in which both PGE2 and LXA4 levels were raised in the pleural exudates, pre-
treatment with a PGE2 analogue, misoprostol, significantly reduced the duration of inflammation 
with no effect on the magnitude of the response (Bandeira-Melo, Serra et al. 2000). 
 
1.5.1.2.2 PGD2 
In pursuit of the COX-2 derived pro-resolution factors, as mentioned previously, in the rat 
carragenin-induced pleurisy model, second peak of COX-2 activity during inflammatory 
resolution was not associated with a rise in PGE2 but another PGH2 metabolite, PGD2 and its 
dehydration product 15deoxyΔ12-14PGJ2 (15d-PGJ2) (Gilroy, Colville-Nash et al. 1999).  
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There are two forms of PGD2 synthase [PGD2S]. The Lipocalin PGD2S [L-PGD2S], a 26 kDa 
protein is expressed in the central nervous system, testes, vascular endothelial cells, intimal 
smooth muscle cells and cardiomyocytes (Urade and Eguchi 2002). L-PGD2S has been linked to 
diabetes, renal injury associated with hypertension and in patients with coronary artery disease 
(Hirawa, Uehara et al. 2002; Miwa, Takiuchi et al. 2004; Ragolia, Palaia et al. 2005). The 
haematopoietic PGD2S [h-PGD2S], also a 26 kDa cytosolic protein is responsible for conversion 
of PGH2 to PGD2 at sites of inflammation, within the central nervous system and in the testes. H-
PGD2S is expressed in mast cells, antigen presenting cells and Th2 cells (Kanaoka and Urade 
2003). In the pleurisy model, selective COX-2 inhibition during the resolution phase led to 
suppression of PGD2 levels and the concomitant rise in exudates volumes and leukocyte numbers 
which was reversed with the addition of PGD2 or 15d-PGJ2 (Gilroy, Colville-Nash et al. 1999). 
The latter, a metabolite of PGJ2 itself a formed by spontaneous dehydration of the cyclopentane 
ring of PGD2 (Fitzpatrick and Wynalda 1983). 
 
PGD2 binds to and activates two G-protein coupled receptors DP1 (Narumiya, Sugimoto et al. 
1999) and CRTH2 (Chemoattractant Receptor-homologous molecule expressed on Th type 2 
cells) (Hirai, Tanaka et al. 2001), which is also known as DP2, has emerged as an important 
factor released by mast cells during an acute asthmatic attack (Kabashima and Narumiya 2003). 
In adaptive immunity, dendritic cells that are antigen presenting cells can initiate immune 
responses with captured antigen when they have migrated to draining lymph nodes. PGD2 has 
been shown to prevent the movement of epidermal Langerhans cells to the draining lymph 
nodes, when FITC labelled OVA were administered intra-tracheally to BALB/c mice. This 
inhibition of APC migration, were by the agonism of the DP1 and not the CRTH2 receptor 
(Angeli, Staumont et al. 2004). Whereas PGD2 has an anti-inflammatory phenotype by the 
activation of the DP1 receptor, the opposite is true in its action on the CRTH2 receptor. The 
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activation CRTH2 receptor in the airways of rats resulted in eosinophilic inflammation (Hirai, 
Tanaka et al. 2001). PGD2 has also been shown to induce pro-inflammatory Th2 type cytokines 
IL-4, IL-5 and IL-13 via its action on CRTH2 receptor but with no rise of the anti-inflammatory 
IL-10 (Xue, Gyles et al. 2005). However, it has been shown in our laboratory that in a delayed 
type hypersensitivity model, though lymphocytes isolated from hPGD2S knockout mice showed 
hyper proliferation and increased IL-2 levels these pro-inflammatory effects were not rescued by 
either selective DP1 or CRTH2 agonists (Trivedi, Newson et al. 2006).  
 
A direct role of PGD2 in innate inflammatory resolution via its G-coupled receptors requires 
further investigation. In a study using a murine air pouch model that mimics monosodium urate 
monohydrate crystal induced gouty arthritis, transfection of hPGD2S into C57/BL/6 fibroblasts 
led to persistent increased levels of PGD2 and reduced PGE2 levels with concomitant reduction 
of cellular infiltration with crystal induced acute inflammation being inhibited (Murakami, 
Akahoshi et al. 2003). As in the air pouch model, PGD2 is also elevated at the early stages of 
chemically induced rat colitis, and similar to the pleurisy model there is a substantial increase in 
PGD2 in the absence of a rise in PGE2 during the resolution phase (Zamuner, Warrier et al. 
2003). In humans this is supported further by the up regulation of PGD2 in patients in long term 
remission from ulcerative colitis (Vong, Ferraz et al. 2010). 
 
1.5.1.2.3 15deoxyΔ12-14PGJ2 (15d-PGJ2 ) 
In a carrageenin-induced pleurisy at 48 h after irritant injection, the second peak of COX-2 
protein expression coincident with resolution of the inflammation, late influx of mononuclear 
cells was also associated with a rise of 15d-PGJ2. Treatment with COX-2 selective inhibitors 
from 24 h to 48 h post-injection of irritant, i.e. during the resolving phase, resulted in a 
prolongation of the inflammatory response while concomitant administration of COX-2 
inhibitors orally and therefore rescuing the depleted PGD2 and cyclopentenone prostaglandins 
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locally, restored resolution (Gilroy, Colville-Nash et al. 1999). As mentioned above, PGD2 
undergoes spontaneous dehydration within its cyclopentane ring to ∆12PGJ2 and then 15d-PGJ2 
which is characterized by the presence of a reactive α,β-unsaturated ketone in the 
cyclopentenone ring (Straus and Glass 2001). The reactive ketones contain an electrophilic 
centre which makes prostaglandins to undergo addition reactions termed ‘Michael addition’ with 
nucleophiles such as free sulfhydryl group of cysteine residues located in reduced glutathione or 
cellular proteins (Fukushima 1992), for example the high affinity binding of 15d-PGJ2 to 
intracellular PPARγ (Ide, Egan et al. 2003).  
 
Peroxisome proliferator-activated receptor [PPAR], a family of transcription factors that regulate 
gene expression of enzymes associated with lipid homeostasis, inflammation cell proliferation 
and malignancy. PPAR family consist of three isoforms- PPAR-α, PPAR-β/δ and PPAR-γ (Zhu, 
Qi et al. 1995; Fajas, Debril et al. 2001). All three contain a central DNA binding domain that 
recognizes DNA sequences known as PPAR response elements. PPAR-γ was originally thought 
to be expressed only in adipocytes and hepatocytes, but was later found in many other cell types 
including macrophages/monocytes, myocytes, fibroblasts and human bone marrow precursors 
(Greene, Blumberg et al. 1995; Braissant, Foufelle et al. 1996). Though resident peritoneal 
macrophages express low levels of PPARγ, its expression is induced to high levels in activated 
macrophages. Binding of 15d-PGJ2 leads to its translocation from the cytoplasm to the nucleus 
and inhibition of pro-inflammatory AP-1, NF-κB and STAT1 transcription (Ricote, Li et al. 
1998).  
 
15d-PGJ2 has also been shown to induce responses by inhibiting multiple steps of the pro-
inflammatory NF-κB pathway independent of PPARγ (Straus, Pascual et al. 2000). NF-κB is an 
important mediator of innate immune responses, which is responsible for induction of pro-
inflammatory genes such as cytokines, chemokines and adhesion molecules. NF-κB is usually in 
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its inactive state by being bound to the inhibitory protein IκB in the cytoplasm. On activation, 
IκB is phosphorylated by IκB kinase [IKK] leading to proteasomal degradation. This allows the 
active components of NF-κB, p50 and p65 to translocate to the nucleus to regulate gene 
expression. 15d-PGJ2 has been shown independent of PPARγ to impact on the NF-κB pathway, 
including inhibition of IKK and direct inhibition of NF-κB binding by alkylation of the cysteine 
residue located in NF-κB binding domain (Straus, Pascual et al. 2000).  
 
In a carrageenin induced pleurisy model in rats, 15d-PGJ2 brings about inflammatory resolution 
by leukocyte apoptosis (PMNs and macrophages) as determined by Annexin/PI staining and 
TUNEL methods (Gilroy, Colville-Nash et al. 2003). It is likely 15d-PGJ2 brings about its pro-
apoptotic effects and therefore aiding resolution via the inhibition of the NF-κB pathway 
(Gilroy, Lawrence et al. 2004). Inhibition of NF-κB has been shown to significantly increase 
granulocyte apoptosis in response to TNF-α and then allowing the clearance of apoptotic cells by 
phagocytic macrophages and for resolution to occur (Hallett, Leitch et al. 2008). 15d-PGJ2 has 
similar effects on eosinophil survival and may play a role in the resolution of allergic 
inflammation. Apart from inducing leukocyte apoptosis, 15d-PGJ2 can also inhibit monocyte 
trafficking, regulate macrophage activation and pro-inflammatory gene expression (Jackson, 
Parhami et al. 1999; Pasceri, Wu et al. 2000; Zhang, Wang et al. 2001; Lawrence 2002). 
 
Central to the role of COX-2 derived cyclopentenone prostaglandins in the resolution of 
inflammation is whether it plays a role in normal physiological conditions. PGD2 and 15d-PGJ2 
have been demonstrated in biological samples using EIA kits developed by Cayman Chemical 
Company Ltd. However the 15d-PGJ2 assay has been criticized for having high background 
levels and a more recent kit by R&D systems has become more popular. However the best 
method for the measurement of 15dPGJ2 is liquid chromatography–mass spectrometry–mass 
spectrometry [LC-MS-MS]. Using this technique Bell-Parikh et al have failed to demonstrate 
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significant levels of 15d-PGJ2 in sites of inflammation in humans (Bell-Parikh, Ide et al. 2003). 
However it was measured in the synovium of patients with rheumatoid arthritis a chronic 
autoimmune inflammatory model. It is conceivable that the absence or depressed levels of 15d-
PGJ2 may be a reflection of the ‘non-resolving’ nature of the inflammatory response and its 
profile in an in vivo resolving model of inflammation require investigation. 
 
1.5.2 Adenosine 
Adenosine is a purine nucleoside, a product of ATP degradation that rises by up to 200 fold in 
response to inflammation and hypoxia. It acts via A1, A2A, A2B and A3 receptors (Fredholm, 
AP et al. 2001; Eltzschig, Sitkovsky et al. 2012). With respect to inflammation most attention 
has been addressed to the A2A receptor, which has potent anti-inflammatory properties. 
 
Adenosine is produced by the breakdown of ATP as well as AMP via the action of membrane 
bound ecto-apyrases such as CD39 and CD73, the latter being the rate limiting step. These 
enzymes are abundant in lymphocytes and endothelial cells and strategically located in the 
inflammatory cascade to modulate the acute inflammatory response. Adenosine has a short half-
life and is broken down to inosine by adenosine deaminase (ADA), which is both cytosolic and 
membrane bound (Figure 1.6). Inosine, when finally broken down to uric acid which is excreted 
in the urine (Kumar and Sharma 2009). The breakdown of the ‘active’ adenosine to inosine is a 
necessary event, as persistence of this powerful anti-inflammatory mediator will limit the ability 
of the host to fight the offending agent leading to persistent and on going tissue damage. 
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Figure 1.6 Adenosine metabolism- Adenosine production by the breakdown of ATP/ AMP by ecto-
apyrases such as CD39 and CD73. Adenosine is then broken down to inosine by adenosine 
deaminase (ADA).  
 
1.5.2.1 A2A receptor 
Adenosine binding to A2A receptor leads to stimulation of the G protein coupled adenylyl 
cyclase (AC) leading to rise in intra-cellular cyclic AMP (cAMP) with activation of down-stream 
protein kinase A (PKA), cyclic nucleotide gated ion channels and exchange proteins directly 
activated by cAMP (EPAC) that in turn mediate its anti-inflammatory effects (Thiel, Caldwell et 
al. 2003).  It exerts its action by inhibiting pro-inflammatory signalling pathways e.g. the NF-κB 
and Janus kinase/signalling transducer and activator of transcription (JAK/STAT) pathways 
respectively. A family of cAMP phosphodiesterases opposes this by hydrolysing cAMP to 
5’AMP, leading to signal termination (Milne and Palmer 2011). 
 
The A2A receptor is expressed on PMNs, Monocytes, T lymphocytes and NK cells.  In innate 
immunity the effect of adenosine via the A2A receptor leads to decreased recruitment to sites of 
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inflammation due to decreased endothelial cell adherence (Hasko, Linden et al. 2008).  This is 
due to cAMP and PKA-dependent down regulation of VLA-4 (‘Very Late Angtigen-4) that 
interacts with VCAM-1. Also A2A activation leads to inhibition of phagocytosis and decreased 
production of ROS. A2A receptor activation in macrophages leads to direct reduction of pro-
inflammatory mediators such as TNFα, IL-12 or increased anti-inflammatory cytokine IL-10 
(Mosser and Edwards 2008). The latter further blocks pro-inflammatory IL-6 as well as the 
chemokine MCP-1. These actions can occur by both cAMP and PKA dependent and PKA 
independent EPAC dependent mechanisms (Milne and Palmer 2011). Adenosine also plays an 
anti-inflammatory role in the adaptive arm of immunity via its action on various subsets of T 
lymphocytes that have been summarised in Table 1.2 shown below (Ernst, Garrison et al. 2010; 
Milne and Palmer 2011). 
 
             
CD4 Th1 and Th2 
Suppression of proliferation and 
maturation  
  
Inhibition of pro-inflammatory cytokine 
production 
       
 Tregs Up regulation of FOXP3 expression  
       
       
       
CD8  
Suppression of cytolytic 
activity   
    
Inhibition of pro inflammatory cytokine 
production 
Table 1.2 Effect of adenosine on T cell subsets 
 
In contrast to the A2A receptor, the A2B receptor is of low affinity to adenosine and therefore 
requiring greater tissue concentrations of adenosine for activation. Like A2A, it is also coupled 
to the Gsα subunit of adenylyl cyclase leading to increased cAMP levels on activation. In spite of 
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A2B being of low affinity, adenosine levels rise to sufficient levels during hypoxia and 
inflammation to activate this receptor, which also has anti-inflammatory properties that has been 
shown to modulate inflammation [e.g.: colitis] and renal ischaemia-reperfusion injury (Aherne, 
Kewley et al. 2011).  
 
Both the A1 and A3 receptors similar to A2AR, have a high affinity to adenosine. Activation of 
the A1 receptor leads to inhibition of cAMP production. Its activation has a depressant effect on 
the conduction system in the heart and therefore explains the anti-arrhythmic properties of 
adenosine. A3 receptor however also has potent anti-inflammatory properties and a selective 
agonist CF-101 is being investigated as a disease-modifying agent in rheumatoid arthritis 
(Varani, Padovan et al. 2010). 
 
1.6 Models of Chronic inflammation 
Resolution of inflammation occur when the acute pro-inflammatory signals are balanced by 
‘stop’ signals such as COX-2 derived PGD2, its cyclopentenone metabolites, lipoxins, resolvins 
which lead to removal of dead cells and facilitate the exit of inflammatory cells. The failure of 
the ‘stop’ signals to counterbalance the triggers for acute inflammation, lead to persistent 
oedema, abscess formation tissue scarring and deformity for example, chronic deforming 
arthropathy in rheumatoid arthritis. This is further illustrated by two clinical examples, 
encapsulating peritoneal sclerosis (EPS), a potentially fatal complication in patients with End 
Stage Renal Disease (ESRD) undergoing peritoneal dialysis (PD), and Chronic Granulomatous 
Disease (CGD), an inherited condition due to impaired phagocytosis. 
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1.6.1 Peritoneal Dialysis (PD) and encapsulating peritoneal sclerosis (EPS) 
Peritoneal dialysis is a widely practiced form of renal replacement therapy in patients with end 
stage renal failure. In an audit in London the prevalence is 28% (Davenport 2009) though the 
number of patients on this modality is falling (Castledine, Casula et al. 2012). For a patient 
requiring dialysis, it is often the first line modality, which affords many advantages, principally 
because it is a home-based treatment. Also worldwide, it has provided the means of managing 
patients who would otherwise have been denied treatment due to resource limitations. This 
method involves the surgical placement of intra-abdominal catheter and the use of the peritoneal 
lining as a dialysis membrane. Dialysis consist of infusion of fluid rich in either glucose or 
glucose-based polymers and the movement of uraemic toxins and water down an osmotic 
gradient. Once steady state has been achieved the peritoneal fluid is removed and fresh dialysate 
is infused. There are two predominant forms of peritoneal dialysis. Continuous Ambulatory PD 
[CAPD], this involves multiple exchanges during the day (usually three) followed by an 
overnight dwell. Automated PD (APD) is an automated form of therapy in which a machine 
cycler delivers up to 6 exchanges while the patient is asleep. There may be an additional 12 to 15 
h daytime dwell depending upon the adequacy of dialysis and volume status of the patient. 
 
1.6.1.1 Peritonitis 
Peritonitis is the most common and significant complication of peritoneal dialysis (Mactier 
2009). It accounts for up to 35% of hospital admissions of patients on PD and remains the main 
reason for the switch to hospital based haemodialysis and mortality(Boudville, Kemp et al. 
2012).  
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Peritonitis is defined as a patient presenting with two or more of the following: 
• Clinical symptoms and signs- Abdominal pain, nausea and vomiting, tender 
abdomen on palpation 
• Cloudy dialysate 
• >100 leukocytes per mm3 on microscopy 
In most cases the causative organism is identified, the majority of which is due to pathogenic 
bacteria (Table 1.3). 
 
In up to 25% of cases the culture may be negative (Davenport 2009), which may be due to the 
culturing of the effluent very early in the course of peritonitis when the colony numbers are low, 
antibiotic contamination or inappropriate culture technique. 
 
Treatment of peritonitis involves empirical antibiotic therapy based on the known incidence of 
different pathogens followed by treatment based on the cultured organism and antibiotic 
sensitivities. Resolution of the inflammation occurs in 90% of the episodes with appropriate 
antibiotic therapy. In the remainder the catheter is removed and patients transferred to 
haemodialysis. Catheter removal rates are higher with S. aureus and gram-negative infections. In 
addition, the removal of the PD catheter is mandatory if the infection is due to Pseudomonas or 
fungi. Failure of resolution is greater in patients with culture negative peritonitis and those who 
relapse soon after a previous treated episode.  
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 Episodes/patient-year 
Gram-positive  
   Staphylococcus epidermidis 0.17-1.04 
   Staphylococcus aureus 0.09-0.15 
   Streptococcus 0.04-0.14 
   Enterococcus 0.01-0.04 
   Other Gram-positive <0.01-0.02 
Gram-negative 0.09-0.24 
Fungal <0.01-0.07 
Mycobacterial <0.01 
Sterile 0.10-0.20 
Table 1.3 Organisms responsible for peritoneal dialysis peritonitis. Adapted from Gokal et 
al Textbook of peritoneal dialysis 2nd Edition Kluwer academic publishers 2000 
 
Peritonitis in patients on peritoneal dialysis affords an imperfect but the closest human 
equivalent to study the changes in cytokines in both acute resolving and non-resolving 
inflammation as inflammatory exudate samples can be obtained during the course of 
inflammation. The diversity of patients, varied time of presentation and collection of PD effluent 
mean obtaining samples for analysis is practically difficult. Therefore the available information 
in the literature is limited. In a study by Lai et al, serial changes in cell and cytokine profiles was 
assessed in 35 patients with acute bacterial peritonitis and compared with the PD effluent of 76 
patients with no infection (Lai, Lai et al. 2000). Even though clinically resolved the total 
leukocyte counts were significantly greater. Cytokine levels were measure at day 1, 3, 5, 10, 21 
and 42. Peak levels of pro-inflammatory IL-1β, IL-6 and anti-inflammatory TGF-beta was found 
at day 1 with progressive decrease with resolution. However even at 6 weeks, the effluent of 
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infected PD patients the levels were significantly greater than in non-infected controls (Lai, Lai 
et al. 2000). In another study, the investigators recognized two groups of patients with 
peritonitis, one with a rapid response to treatment with a progressive increase in T cell CD4/CD8 
ratio and another group with delayed response to therapy with a decrease in CD4/CD8 ratio 
(Wang, Lin et al. 2003). The authors suggested the pattern of T cell may influence both treatment 
and future sequelae (Wang, Lin et al. 2003; Griveas, Fleva et al. 2009).   
 
1.6.1.2 Encapsulating peritoneal sclerosis 
EPS is by far the most serious and devastating consequence of peritoneal dialysis (Chin and 
Yeun 2006). The affected patient may present with abdominal pain, vomiting and intermittent 
bowel obstruction leading to progressive malnutrition. The small intestine is bound or 
encapsulated by a thick fibrous layer. The prevalence varies amongst different clinical units, 
from 0.7% to 3.7%. Risk factors include duration on peritoneal dialysis treatment, recurrent and 
‘non-resolving’ grumbling and severe peritonitis, poor biocompatibility of the dialysate and 
duration on peritoneal dialysis. EPS is not exclusively related to PD and can occur with 
autoimmune disease, beta-blocker therapy, intra-abdominal malignancy and exposure to talc. 
Research in this area has been hampered by the lack of reproducible animal models. A ‘two hit’ 
hypothesis has been proposed with the initial insult being peritoneal exposure to dialysate fluid 
(glucose, glucose degradation products, pH) in the context of uraemic state (Honda and Oda 
2005). This leads to increased TGFβ and VEGF activity and peritoneal fibrosis that can occur 
over years. A ‘second hit’, i.e. peritonitis, withdrawal of peritoneal dialysis, transplantation can 
accelerate the pro-fibrotic process leading to adhesions, the hallmark of EPS. The progression of 
peritoneal sclerosis and EPS may be a consequence of the imbalance between pro and anti-
inflammatory cytokines leading to accumulation macrophages and fibroblasts leading to a pro-
fibrogenic state. 
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There is scant evidence for the role of resident lymphocytes in modulating both peritonitis and 
EPS. A recent study identified a population of effector memory T cells (TEM) that were 
potentially protective against invading pathogens (Roberts, Baird et al. 2009). Furthermore in an 
animal model of peritoneal sclerosis, rosiglitazone, a PPARγ agonist, was able to ameliorate the 
degree of fibrosis (Sandoval, Loureiro et al. 2010). This was associated with increased CD3+ T 
lymphocytes in particular CD4+ CD25+ FoxP3+ cells as well as increased IL-10 levels. Another 
study of PD effluents from patients who previously had peritonitis showed a progressive 
decrease in the CD4/CD8 lymphocyte ratio that was associated with increased TGF-β1 
expression and change in transporter status to a rapid equilibration with plasma for glucose, a 
risk factor for developing EPS (Wang, Lin et al. 2003). 
 
1.6.2 Chronic granulomatous disease 
Chronic granulomatous disease (CGD) is disease affecting the innate immune system 
characterised by impaired phagocytosis due to absence of superoxide generating NADPH 
oxidase (NOX). This makes patients with CGD susceptible to serious bacterial and fungal 
infections with an incidence of 1 in 200,000 births (Segal, Leto et al. 2000; Winkelstein, Marino 
et al. 2000). Over two thirds of CGD is X-linked recessive and therefore predominantly affects 
males. There are no known autosomal dominant cases. 
 
NADPH is an enzyme complex which comprise of membrane bound b558 (consisting 
gp91 phox and p22 phox) and cytosolic p47phox and p67phox components (Holland 2010). CGD can 
manifest due to mutations in any of the four structural genes. Mutations in gp91 phox account for 
65% of clinical presentations (Holland 2010). The critical regulatory component for activation of 
NOX is p40phox and Rac. On cellular activation, the phosphorylated cytosolic components 
associate with p40phox and Rac, which then combine with gp91 phox and p22 phox that result in the 
activation of the NADPH complex. This leads to production of superoxide, a ROS, which in the 
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presence of superoxide dismutase is converted to hydrogen peroxide that is critical for microbial 
killing (Segal, Leto et al. 2000). The main sources of ROSs are phagocytic cells, namely PMNs 
and macrophages. In addition to direct microbicidal activity via superoxide and its metabolites, 
hydrogen peroxide, peroxinitrite, hypochloric acid, ROS also arrest pathogen survival and 
growth and activate the formation of neutrophil extracellular traps (NETs) (Kirchner, Moller et 
al. 2012). 
 
The commonest infections in CGD patients are Staphylococcus aureus, Burkholderia cepacia, 
Serratia marcescents, Nocardia and Aspergillus (Segal 1996; Segal, Leto et al. 2000; Martire, 
Rondelli et al. 2008). Other infectious organisms associated with CGD being Salmonella and 
Tuberculosis. The overall survival from CGD has improved over time with the advent of co-
trimaxazole prophylaxis and anti-fungal agents. 
 
1.7 Objectives of this thesis 
1.7.1 Hypothesis 
1. PGD2 and its cyclopentenone metabolite 15d-PGJ2 are essential for resolution of 
inflammation in mammalian model of acute resolving inflammation (Chapter 3) 
 
As has been the theme of this introduction to the thesis, resolution of inflammation is an active 
process. The work in our laboratory has been in dissecting the role of lipid mediators of the 
cyclo-oxygenase pathway in inflammatory resolution. I therefore investigated the role of PGD2 
and its downstream metabolite 15d-PGJ2 in inflammatory resolution. To this end, a sterile 
resolving model of chemical peritonitis induced by a fungal product zymosan was used with 
inflammation induced in genetically modified mice lacking the hPGD2S and wild type controls. 
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As doubts were cast on the physiological significance of 15d-PGJ2 in mammalian systems, this 
was measured by LC-MS-MS in selected time points of acute peritoneal inflammation. 
 
2. Resolving phase lymphocytes promote resolution of peritoneal inflammation by a 
PGD2 dependent manner (Chapter 4) 
 
During the course of the study, changes in lymphocyte numbers were observed, to be reduced in 
numbers during the acute phase followed by re-population during the resolution phase. Therefore 
lymphocytes during the course of peritonitis were characterised and the role of PGD2 in 
modulating the cellular profile was also investigated  
 
3. Reduced production of adenosine is responsible for the hyper-inflammatory 
phenotype in mice lacking the gp91 phox  subunit of NADPH oxidase, a model of chronic 
granulomatous disease, during zymosan peritonitis and is due to decreased activation of  
the A2A receptor (Chapter 5) 
 
In order to elucidate what happens in a non-resolving chronic innate model of inflammation with 
respect to both cellular components as well as mediators of resolution, mice lacking the 
gp91 phox  subunit of NADPH oxidase, a model of chronic granulomatous disease was 
investigated. There was no difference in  PGE2 and PGD2 levels in knock out mice compared to 
wild types. Therefore, reduced expression of xanthines- adenosine and its metabolites were 
thought to play a role in the failure of resolution in  CGD mice. 
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Chapter 2 Materials and methods 
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This chapter will describe all of the general methods used in this thesis as a whole. The design of 
individual experiments will be described in the results chapters.  All materials unless mentioned 
otherwise were purchased by Sigma-Aldrich Chemical Co., UK. 
 
2.1 Animal Husbandry 
C57 black VI male mice [8 weeks old] were purchased from Charles River, Margate, Kent, UK. 
Three different genetically modified mice of C57BL/6 mouse strain were used for in vivo 
experimentation, hPGD2 synthase knock out (hPGD2S-/-), RAG2 knockout (RAG2-/-) and 
NADPH oxidase gp91phox-/- mice. Animal work was performed according to Home Office 
regulations [Scientific Procedures Act 1986]. 
 
2.2 hPGD2 synthase knockout mice (hPGD2S -/-) 
A breeding program for hPGD2 synthase knockout mice was undertaken in the Biological 
Services Unit at the William Harvey Research Institute, Charterhouse Square, London. The 
mouse colonies were housed under standard conditions in a room with controlled lighting [lights 
on 08:00-22:00] in which the temperature was maintained at 21-23ºC and on a standard chow 
pellet diet with tap water ad libitum. The litters from the hPGD2 synthase knockout colonies 
were genotyped as below and male knockout mice and littermate controls were used for the 
experiments. However when there was an excess of knockout and heterozygotes commercially 
purchased age matched C57BL/6 wild type mice were used. 
 
2.2.1 Generation of H-PGD2S gene-disrupted mice 
hPGD2S gene-disrupted mice were generated through the standard gene targeting technology 
with mouse embryonic stem cells derived from the 129 strain and backcrossed to the inbred 
C57BL/6J strain 15 times.  The strain was created at Osaka Bioscience Institute and Japan 
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Tobacco Inc. Pharmaceutical Frontier Research Laboratories. Figure 2.1 summarizes the 
development of the hPGD2S knockout mice. 
 
Figure 2.1 Structure of the wild-type H-PGDS allele (Top), the targeting vector (Middle), and the 
targeted allele (Bottom).  The probe used for Southern blot analysis is shown as a thick line.  
Restriction sites: N, NcoI; E, Eco47III; B, BstXI. TK, Herpes simplex virus thymidine kinase gene; 
neo, neomycin resistance gene.  (B) Southern blot analysis of NcoI-digested tail DNA (10 µg/lane) 
from heterozygous offspring with the 32P-labeled probe as shown in (A).  (C) Genotyping of wild-
type and H-PGDS knockout mice by PCR analysis.  For genotyping for H-PGDS, primer F1 (5’-
GAGTTGCTGCATCTGACCTTTC-3’) and R1 (5’-TAGCGAATAATTTCGGCTCTTCC-3’) were 
used for the detection of wild-type allele, and F2 (5’-AAGATCTGTCTTGTTGCGTACGCT-3’) 
and Neo (5’-GTCCAGATCATCCTGATCGAC-5’), for that of the targeted allele. 
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2.2.2 Genotyping of mice 
Genotyping was necessary to identify the knockout mice from heterozygote and wildtype mice. 
To this end mouse tissue (ear notch) was first digested and polymerase chain reaction (PCR) 
with the appropriate primers were undertaken. 
 
2.2.2.1 Tissue Digestion 
The mice were ear notched for identification and the ear tissue was used for genotyping. It was 
digested with 50 µL of digestion buffer overnight at 55ºC. Digestion buffer comprised of 0.1 
mg/mL Gelatin, 100mM Tris pH 8, 500 mM KCl, 0.45% NP-40, 0.45% Tween-20, 500 µg/mL 
Proteinase K. The samples were spun briefly and then incubated at 94ºC for 10 min to inactivate 
the proteinase K followed by centrifugation at 958g for 5 min. 2 µL of supernatant was used for 
the PCR reaction. 
 
2.2.2.2 Polymerase Chain reaction 
PuReTaqTMReady-To-GoTMPCR beads [Amersham] were used.  
The primers were as follows: 
Wild type allele F1  5’-GAGTTGCTGCATCTGACCTTTC-3’ 
R1  5’-TAGCGAATAATTTCGGCTCTTCC-3’  
Knockout allele F2  5’-AAGATCTGTCTTGTTGCGTACGCT-3’ 
Neo  5’-GTCCAGATCATCCTGATCGAC-5’ 
 
The primers were diluted to 1 µM and 5 µL of the wild type and knockout primers were 
multiplexed with 13 µL of molecular grade water and added to the PCR beads. 2 µL of the 
digestion was then added. In the final volume of 25 µL each bead contained 2.5 units of puRe 
Taq DNA polymerase (GE healthcare, Buckinghamshire, UK), 10 mM Tris-HCl (pH 9), 200 µM 
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dNTPs, 50 mM potassium chloride and 1.5 mM magnesium chloride. The reaction conditions: 
initial denaturation at 94ºC for 5 min followed by 94 ºC 30 s/ 55 ºC 30 s/ 72 ºC 50 s for 35 
cycles. Following the PCR reaction, the loading buffer [40% sucrose and methylene blue] was 
added [3 parts reaction mixture 1 part loading buffer]. Reaction was run on a 1% agarose gel 
with 0.001% Ethidium Bromide. A positive control from a previous batch of reaction and a 
negative control [no DNA sample] were included in each gel. Bands for wild type (WT) and 
knockout (KO) alleles were visualized with a UV transilluminator. Figure 2.2 shows the relative 
positions of wild type and knockout alleles. 
 
 
Figure 2.2 Bands of WT and KO alleles visulaised by UV transilluminator with the upper band 
corresponding to the WT allele and lower being the knockout allele. 
  
2.3 Study of Peritonitis 
Peritoneal inflammation was used as a model of innate inflammation to test the hypothesis 
generated in this thesis. Both a murine and human model of peritonitis was investigated. 
 
2.3.1 Murine Peritonitis 
Murine peritonitis was induced with the intraperitoneal administration of two different agents in 
the course of experiments. All experiments however were carried out with the i.p. administration 
of Zymosan Type A Saccharomyces cerevisiae   [Sigma catalogue number Z4250] to induce an 
experimental sterile inflammation. However in the study assessing the role of re-populating 
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lymphocytes during resolution following zymosan peritonitis (detailed in chapter 4), group B 
streptococcus (GBS) was administered i.p. to induce peritonitis. 
 
2.3.1.1 Preparation of Zymosan Type A for experimentation 
Zymosan A is activated in order to induce an inflammatory response and this form is stored at -
20ºC until use. One gram was placed in a conical flask with 200 mL of sterile PBS. The mixture 
is heated for 30 minutes with constant stirring until boiling point is reached. Once the suspension 
has cooled, it is then aliquoted into 20 tubes [10mL each] and centrifuged at 310g for 10 min at 
4ºC. The supernatants were washed three times with sterile PBS. Pellets are then pooled 
sequentially until a single pellet of zymosan is left. The pellet is resuspended in 20 mL [ie: 1000 
mg in 20 mL] and then aliquoted.  The aliquots are centrifuged at 3000 rpm for 5 min and the 
pellets are frozen at -20ºC until use. On day of use the aliquot is allowed to defrost at room 
temperature for 30 min and then suspended in sterile PBS [pH 7.2] at a concentration of 2 
mg/mL for use. 
 
2.3.1.2 Preparation of Group B streptococcus (GBS) for experimental peritonitis\ 
The clinical GBS isolate, NCTC10/84 (serotype V) was grown in Todd Hewitt Broth (THB) 
without agitation at 37oC to an OD600 of 0.4; equivalent to 1x108 CFU/mL. Bacteria collected by 
centrifugation were washed with sterile PBS.  
 
2.3.1.3 Induction of murine Peritonitis 
Peritonitis was induced by a single injection of Zymosan A 1 mg in 0.5 mL of sterile PBS, pH 
7.2. At selected time points the mice were killed by CO2. The peritoneal cavity is then injected 
with 3 mL of sterile PBS followed by gentle massage to circulate the buffer within the peritoneal 
cavity. The peritoneum is then exposed and the lavage is transferred to 2mL eppendorf tubes 
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using a 3 mL Pasteur pipette. In the survival experiments described in chapter 4 during the 
resolution phase of zymosan peritonitis, mice were inoculated by i.p. injection with 5x107 CFU 
in 0.3 mL of PBS. 
 
2.3.1.4 Measurement of cell numbers 
Cell number in the lavage was determined by staining of nuclei with Turks’ solution (0.01% 
Crystal Violet, 3% Ascetic Acid). 900 µL of Turks’solution is added to 100 µL of cells from 
lavage. Cell number is then counted using a haemocytometer. 
 
2.3.1.5 Trypsinization of peritoneal cavity 
During the acute phase of peritonitis, as PMN numbers peak, lymphocyte numbers fall only to 
repopulate during the resolution phase. One hypothesis was that the peritoneal lymphocytes 
become adherent to visceral peritoneal lining. Therefore to determine the fate of peritoneal T and 
B cells, 4 h after zymosan injection, peritoneal cavities of mice were lavaged with sterile PBS to 
remove accumulated inflammatory cells. Then, 5 mL of pre-warmed 5% trypsin was then added 
to the peritoneal cavity of these for 10 min followed by an equal volume complete medium to 
acquire cells adhered to the peritoneal lining/greater omental lymphoid organ. Cells were then 
analysed for composition by flow cytometry. 
 
2.3.2 Human Peritonitis 
We considered peritonitis a complication of patients undergoing peritoneal dialysis, to be an 
ideal human model to investigate innate inflammation and resolution as effluent samples can be 
obtained at selected time points. Ethical approval [P/03/136A] for collection of human peritonitis 
samples was obtained from St. Bartholomew’s & the Royal London Hospitals from end stage 
renal failure patients undergoing peritoneal dialysis. When patients develop peritonitis usually at 
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home, the effluent is brought in to hospital when they arrive to commence treatment. A sample is 
sent for microscopy, culture and the remainder is collected for experimentation. Less commonly 
the patient may have already been admitted to hospital for another reason when he or she 
develops peritonitis. The patient then commenced on antibiotic treatment and either sent home or 
admitted depending on the severity of symptoms. If the patient is sent home, they then return on 
day 3, 5, 10 and 15 when the overnight effluent is drained out and collected for experimentation.  
If admitted, the overnight dwell when drained out the following morning is used for 
experimentation.  
 
Once the sample is collected, the cell numbers were counted as described above (2.3.1.4 
Measurement of cell numbers). The cellular profile was assessed by specific fluorescent 
antibodies using flow cytometry as described below (2.4.1 Flow cytometry). The cell rich 
effluent was then centrifuged at 1500 rpm for 5 min and cell free supernatant was stored at -80°C 
until further use. 
 
2.4 Analysis of leukocyte profile and function 
2.4.1 Flow cytometry 
The differential cell profile is analysed by flow cytometry using FACSCalibur and CellQuest 
software [BD Biosciences]. Following the cell count the appropriate volume of exudates 
containing 250,000 cells was centrifuged at 239g for 5 min, then washed with sterile PBS and re-
suspended with 50 µL of PBS pH 7.2/1%BSA/20 mM glucose and incubated with 2.5µL of the 
antibody as recommended by the manufacturer for 30 min at room temperature. Then the 
samples were centrifuged at 214g for 5 min, washed with PBS pH 7.2/1%BSA/20mM glucose 
and re-suspended in 250µL of PBS for FACS. The lavage was also incubated with the relevant 
isotype control antibodies. The following table 2.1 summarises the antibodies by AbD Serotec 
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Ltd., Kidlington, UK unless otherwise mentioned. FACS plot for leukcocyte sub-populations is 
demonstrated in figure 2.3 and in figure 2.4 the staining for GR-1 (PMNs) and F4/80 
(macrophages) during the first 24 hours of zymosan induced murine peritonitis is summarised. 
 
Table 2.1 Antibodies used for FACS analysis of murine peritoneal leukocyte exudate 
Cell Type Antibody Isotype 
Polymorphs 
 
Rat anti-Mouse Ly-6G & 
Ly-6C (Gr-1) Monoclonal 
antibody-PE (BD 
Biosciences, UK) 
IgG2b 
Macrophages Rat anti Mouse F4/80 FITC 
(Caltag MedSystems 
Towcester, UK) 
IgG2A 
T Lymphocytes Rat anti Mouse CD3 FITC  IgG2A 
B Lymphocytes Rat anti Mouse CD45 FITC IgG2A 
CD4+ lymphocytes Rat anti Mouse CD4 FITC IgG2A 
CD8+ lymphocytes Rat anti Mouse CD8 Alpha 
FITC 
IgG2A 
 
 
 
Figure 2.3 FACS plots for different leukocyte sub-populations 
  
Lymphocytes+
macrophages+
PMNs+
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Figure 2.4 GR-1 and F/80 profile in the first 24 hours following zymosan Upper two panels are the 
GR-1 positive cell profile mice with the final plot of the isotype control at 4 and 8 hours following 
zymosan peritonitis. The lower two panels demonstrate dual staining with GR-1 and F4/80 together 
with isotype control (5th plot) with reduction in GR-1 numbers and rise in F4/80 positive cells as 
resolution ensues at 12-24 hours following zymosan. 
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2.4.2 Leukocyte separation  
2.4.2.1 Isolation of lymphocytes from peritoneal lavage 
At selected time points the mouse peritoneal cavity was lavaged as described above, cell 
numbers counted and then cells were centrifuged and resuspended in RPMI 1640 (RPMI) with 
2% foetal calf serum (FCS) at a concentration of 1 x 106 cells/mL.  The macrophages were 
separated from remaining lymphocytes by adherence to the bottom of 6-well tissue culture plates 
following incubation in a humidified incubator with 5% CO2 for 90 min.  Unbound cells were 
removed using a sterile pipette and cells numbers were estimated. The cell rich medium was then 
centrifuged at 484g for 7 min and suspended in the RPMI/ 2% FCS medium at a concentration of 
2.5 x 106 cells/mL. T and B-lymphocytes were isolated using the Dynal mouse B cell and T cell 
negative isolation kit according to the manufacturer’s instructions (Dynal Biotech Ltd).  
 
2.4.2.2 Negative isolation of T cells 
A mixture of rat monoclonal antibodies with specificity to all mouse non-T cells cells was added 
to cell suspensions. The antibody mix contains a mixture of rat monoclonal antibodies against 
mouse CD45R (B220), CD11b (Mac1), Ter-119 and CD16/32. Cells coated with the added 
monoclonal antibodies were then removed with magnetic beads coated with sheep polyclonal 
antibody to rat Ig. The cells suspension is incubated at 4°C with tilting and rotation for 45 min. 
Then the test tube is placed on a cold dynal magnet for 3 min and supernatant is pipetted out. 
This is centrifuged at 484g and re-suspended in RPMI/FCS and centrifuged again to remove any 
residual beads. The T cells are then resuspended in RPMI/2% FCS. Purity of the cells were 
regularly >95% 
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2.4.2.3 Negative isolation of B cells 
As mentioned supernatant from the initial separation phase contained both B cells and T cells. 
The latter were removed by the use of a pan T-cell magnetic beads. The supernatant was first 
centrifuged 484g for 7 min and suspended in the RPMI/FCS medium at a concentration of 2.5 x 
106 cells/mL and then 10 µL of the pan T cell beads were added per 106 target cells. The cell 
suspension is incubated and placed on a cold dynal magnet as described in section 2.4.2.2. The B 
cells are then resuspended in RPMI/FCS at the desired cell density. 
 
2.4.3 Adoptive transfer of lymphocytes into gp91phox knockout mice 
Contents of resolving phase peritoneal cavities of wild type animals were isolated and 
macrophages separated from remaining lymphocytes by adherence to the bottom of 6-well tissue 
culture plates. Non-adherent cells were removed and used to isolate T and B cells as well as NK 
and gamma/delta T cells for adoptive transfer to gp91phox knockouts using FACS and relevant 
antibodies to confirm that their composition and ratios reflects that present in situ at resolution. 
Resolving phase lymphocytes were enriched at a concentration of 1.0x106/mL and 0.5 mL 
injected in to gp91phox knockouts. In addition, one of the problems with identifying discrete 
populations of cells such as that found at sites of inflammation by FACS from a larger mixed cell 
population is that the fluorescence of one cell type after labelling with a fluorescent antibody 
may be masked by the natural fluorescence of others. In order to confirm the cell types identified 
using cell surface antigen markers, peritoneal lymphocytes and macrophages were also isolated 
and put back into the FACS with their forward and side scatter signatures compared against 
specifically labelled cells. Thus, after lymphocytes were removed from 6-well plates above, 
adherent cells, mainly macrophages, were eluted with Versene, washed with 2% FCS in HBSS 
and re-suspended in DMEM. These cells were further depleted of contaminant T and B cells 
using magnetic beads coated with rat monoclonal antibodies to mouse CD3 or B220 (Dynal 
Biotech Ltd; Paisley, UK).  T and B lymphocytes were isolated using the Dynal mouse B cell (or 
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T cell) negative isolation kit according to the manufacturer’s instructions (Dynal Biotech Ltd) as 
described above.  
 
2.4.4 Macrophage isolation and culture  
2.4.4.1 Isolation of macrophages from peripheral blood sample 
Peripheral venous blood samples were collected from both healthy volunteers and patients with 
CGD, into heparin containing syringes (5U/mL). Mononuclear cells were isolated by differential 
centrifugation (860g, 30 min, 20oC) over Lymphoprep® (Axis-Shield, Oslo, Norway) and washed 
twice with sterile phosphate-buffered saline (PBS) (GIBCO, Paisley, UK) at 310g (5 min, 20oC). 
Cells were re-suspended in 10 mL RPMI-1640 medium (Invitrogen, Paisley, UK) supplemented 
with 100 U/mL of penicillin (GIBCO) and 100 µg/mL streptomycin (GIBCO) and 20 mM 
HEPES buffer and plated at a density of approximately 5x106 cells/mL in 8cm2 NunclonTM 
Surface tissue culture dishes (Fisher Scientific, Loughborough, UK). After an initial culture 
period of 2 h in a humidified environment at 37oC, 5% CO2, the non-adherent cells were 
discarded and 10 mL of fresh RPMI supplemented with 10% foetal bovine serum (10% 
FBS/RPMI) added to each tissue culture dish. Cells were then cultured for 5 days at in a 
humidified enviroment at 37oC, 5% CO2, with the addition of a further 10 mL fresh 10% 
FBS/RPMI after 24 h. Adherent cells were were lifted with a plastic cell lifter on day 5 and re-
plated in 96-well culture plates at equal densities (105/well) in X-Vivo-15 medium (Cambrex 
Bioscience, Wokingham, UK). These primary monocyte-derived macrophages were incubated 
overnight at 37oC, 5% CO2 to adhere, and then stimulated for 24 h with 200 ng/mL 
Lipopolysaccharide (LPS) (Alexis, Enzo Life Science UK Ltd). These studies were approved by 
the Joint UCL/UCLH Committees on the Ethics of Human Research (02/0324). Written 
informed consent was obtained from all volunteers. No patient was studied more than once in 
each of the different sets of experiments. 
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2.4.4.2 Culture of bone marrow derived macrophages 
Macrophages were obtained from the distal limb bone marrow of male mice that were 4-6 weeks 
old. Once the mice were sacrificed, femur and tibia were freed from all flesh and then placed in 
RPMI1640 with 10% FCS. In a tissue culture hood the bones were placed on a petri dish and 
washed for 1 minute in 70% ethanol and then transferred to RPMI/10% FCS. With the use of a 
10 mL syringe the bone marrow is removed into the media and then transferred to a 50 mL tube 
and centrifuged at 215g for 5 min. The pellet is then re-suspended in conditioned medium which 
is RPMI1640, 10% FCS, 10 mM HEPES, and 15% L-conditioned media (L929 supernatant-the 
source of macrophage colony stimulating factor, M-CSF). The cell suspension is plated onto 10 
mL per 10 cm diameter plate and incubated at humidified 37oC, 5% CO2. At day 3 further fresh 
RPMI/10% FCS and on day 7, RPMI/10% FCS/10 mM HEPES/15% L-conditioned media is 
added. On the day before stimulation media was removed and cells made less adherent with 10 
mM EDTA and 4 mg/mL Lignocaine-HCL for 10 min prior to harvesting. The cell suspension is 
then aspirated and centrifuged at 215g for 5 min. Cells are then suspended in RPMI 1640/10% 
FCS and counted. 
 
2.4.4.2.1 L929 supernatant 
In order to stimulate bone marrow derived macrophages, M-CSF is needed. The source is L929 
cells, which is initially plated in a T75 flask with 25 mL DMEM/10% FCS. Once confluent, the 
cells are washed with PBS and 100 mL of DMEM/10%FCS are added. On day 3 the medium is 
collected, centrifuged at 1935g for 5 min and the supernatant is then aliquoted and stored at 20% 
until use. 
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2.4.4.3 Culture of peritoneal macrophages 
Peritoneum is lavaged as before, cells stained with Turks’ solution and counted and re-suspended 
in RPMI/10% FCS at a concentration of 1x 106 cells/mL. Cells are then plated onto a petri dish 
at incubated at humidified 37oC, 5% CO2 for 1 h. Then the media is aspirated and adherent cells 
(peritoneal macrophages) are washed with PBS followed by incubation with Trypsin/EDTA to 
remove the adherent cells. Adherent cells are aspirated with repeated pipetting and with the 
syringe. Cells are counted; centrifuged at 215g for 5 min and re-suspended at 1x 106 cells/mL in 
RPMI/10% FCS. 
 
2.4.5 Stimulation of leukocytes 
B lymphocytes as well as macrophages (BM derived and peritoneal) from hPGD2S-/- and C57 
black 6 wild type mice were incubated with the selective DP1 agonist (BWC245, Cayman 
chemicals distributed by Cambridge Bioscience Ltd, Cambridge, UK) DP2 agonist (15-R- 15 
Methyl PGD2, Cayman) or 15d-J2 (Cayman) with media as control and then stimulated with 100 
µg/mL Zymosan Type A, LPS (1µg/mL) or vehicle. Experiment was terminated 24 h later and 
supernatant stored at -80°C until further use. The protocol for T cells was similar apart from 
stimulation with anti-CD3 antibody. 
 
2.4.6 Macrophage clearance assays 
The macrophage specific stain, PKH26-PCL (Sigma, 2 mL of 500 nM) was injected into the 
inflamed peritoneal cavity during the resolution phase (48 h). The PKH26-PCL dye is diluted at 
a ratio of 1:10 in absolute ethanol and 100 µL of the diluted dye is added to 10 mL of the diluent 
provided with the kit. The resulting solution is mixed vigorously on vortex mixer for 15 min and 
then allowed to stand for further 15 min. 1 mL of the diluted dye solution is then injected to the 
mice intra-peritoneally. At 72 h the peritoneal cavity was lavaged, cells numbers counted and re-
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suspended at 1x106 cells/mL in PBS and examined by flow cytometry. Cells staining positive for 
PKH26-PCL (FL2 channel) were identified with FITC-labelled F4/80 (FL1 channel). Staining 
was found almost exclusively within macrophages (Figure 2.5). At the same time points as the 
peritoneal lavage, parathymic lymph nodes isolated, extracted and snap frozen in OCT1. Serial 
sections (minimum 15 sections per node) examined for the presence of fluorescent PKH26-PCL 
labelled macrophages. Two independent observers scored all sections blindly based on a 
previously validated analogue scale using an Olympus Axioscop microscope.  
 
 
 
Figure 2.5 Dual labelling for PKH26-PCL and F4/80. When the leukocytes from peritoneal lavage 
48 hours following zymosan were stained with PKH26-PCL (FL-2 channel), were F4/80 positive 
macrophages (FL-1 channel) 
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2.5 Measurement of apoptosis 
Apoptosis was measured in the peritoneal cell rich effluents using two methods, Annexin V and 
Propidium iodide (PI) staining of leukocytes assessed by flow cytometry as well as Caspase-3 
activity. 
 
2.5.1 Flow Cytometry 
Annexin V is a 35 kDa calcium dependent protein with high affinity for phophatidylserine [PS], 
which in apoptosis is translocated from the inner to the outer leaflet of the plasma membrane. 
Annexin V is a sensitive marker of apoptosis as PS translocation occurs early in the apoptotic 
process. It is conjugated with fluorescein isothiocyanate [FITC] for identification by flow 
cytometry. As apoptosis leads to cell death, they eventually lose their cell wall integrity and 
become propidium iodide (PI) positive. By dual labelling apoptotic cells with Annexin V-FITC 
and PI the percentage of apoptotic cells are analysed by flow cytometry. Briefly, at selected time 
points 500,000 inflammatory leukocytes of the peritoneal lavage was suspended in binding 
buffer [10mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5mM CaCl2] were incubated with 2.5 
µL annexin V- FITC [BD Biosciences] and 5µL PI [BD Biosciences] for 10 min at room 
temperature in the dark. The samples were then using FACSCalibur and CellQuest software [BD 
Biosciences]. Cells staining for both annexin V and PI were defined as being apoptotic. 
 
2.5.2 Caspase-3 
The activity of caspase-3 was measured using the fluorimetric substrate Ac-DEVD-AMC. For in 
vivo experiments, frozen cell pellets were lysed in in ice-cold RIPA [20 nM Tris (pH 7.4) 150 
mM NaCl, 1% NP-40, 0.5 % w/v Na deoxycholate, 0.1 % SDS (Promega)] for 10 min. After 
centrifugation at 16000 g for 15 min at 4˚C, the supernatant was aspirated and protein quantified 
as described below (section 2.5.2.1). The cellular protein was incubated with 50 µM substrate in 
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caspase assay buffer (213.5 mM HEPES, pH 7.5, 31.25% sucrose, and 0.3125% CHAPS) for 1 
h, and fluorescence was measured on a microplate reader (Fluostar Galaxy, BMG Laboratory 
Technologies, Aylesbury, UK), with excitation at 380 nm and emission set at 460 nm. For each 
sample, four replicates were assayed with two replicates containing 50 µM of the caspase-3 
inhibitor (Ac-DEVD-CHO), and the remaining pair containing vehicle (DMSO). Fluorescence 
readings from wells containing inhibitor were subtracted from total fluorescence, and results 
calculated as nmol AMC/ min/ per mg protein. 
 
2.5.2.1 Quantification of protein 
The protein concentrations were measured using a BCA assay (Perbio Science, Fisher Scientific, 
Loughborough, UK) following the manufacturer’s instructions. The BCA Protein Assay 
combines the well-known reduction of Cu2+ to Cu1+ by protein in an alkaline medium with the 
highly sensitive and selective colourimetric detection of the cuprous cation (Cu1+) by 
bicinchoninic acid (BCA). In the first step, peptides containing three or more amino acid 
residues form a coloured chelate complex with cupric ions in an alkaline environment containing 
sodium potassium tartrate. In the second step of the colour development reaction, BCA reacts 
with the reduced (cuprous) cation that was formed in step one. The intense purple-coloured 
reaction product results from the chelation of two molecules of BCA with one cuprous ion. The 
BCA/copper complex is water-soluble and exhibits a strong linear absorbance response at 562 
nm with increasing protein concentrations.  
 
Cells were washed with ice-cold phosphate-buffered saline (PBS) and lysed in ice-cold 
commercially obtained lysis buffer (Mammalian Protein Extraction Buffer, GE Healthcare Life 
Sciences, Fisher Scientific) without protease inhibitor. Insoluble material was removed by 
centrifugation at 12,000 g for 15 min at 40C. Clear 96 well assay plates were used. 25 µL of cell 
lysates and standards were added (standard range 25-2000 µg/mL). BCA reagents A and B were 
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mixed together at a ratio of 50:1 before use and 200 µL was added to every well. The plate was 
then sealed and incubated for 30 min in an oven at 370C. Plates were read at 550 nm in a plate 
spectrophotometer (Dynex Jencons PLS Technologies Microplate Reader) 
 
2.6 Eicasonoid analysis 
2.6.1 Extraction of prostaglandins and Measurement of PGD2 
An extraction step of the cell free peritoneal exudates is required to de-proteinate the samples. 
One mL of the cell free peritoneal exudates is acidified with 50µL 2N HCL and kept on ice for 
15 min. The SPE columns ChromabondTM C-18 were primed with 4 mL 100% ethanol followed 
by 4 mL of distilled water at a flow rate of 5-10 mL/min using a vacuum manifold [Varian Ltd, 
UK].  Following this step the acidified exudate is added onto the column at a flow rate of 5 
mL/min. The columns are then washed with 4 mL of distilled water followed by 15% ethanol pH 
3.0. The prostaglandins are then eluted with 2 mL ethyl acetate at a flow rate of 5 mL/min, 
vacuum dried and stored at -80ºC. 
 
2.6.2 Immunoassay for PGD2 
The assay is a competitive enzyme immunoassay [PGD2-Mox EIA kit, Cayman Chemical 
Catalogue no. 512011].  Prior to running the assay prostaglandin D2 is stabilized by 
methoximation to the PGD2-MOX derivative.  This is done by heating a 1:1 solution of the 
sample (suspended in enzyme immunoassay buffer) and methyl oximating reagent at 60ºC for 30 
min. Following methoximation the sample is added in duplicate onto the plate and incubated 
overnight at 4ºC. This assay is based on the competition between PGD2-MOX and a PGD2-
MOX-acetycholinesterase [AChE tracer] conjugate for a limited number of PGD2-MOX-specific 
rabbit antiserum binding sites. Following incubation overnight with the AChE tracer and 
antiserum the plate is washed with PBS (pH 7.4) to remove any unbound reagents and then 200 
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µL of the Elman’s reagent (which contains the substrate to AChE) is added to the well. The 
enzymatic reaction has a yellow colour and typically develops over 90 min in the dark. The 
absorbance is read at 410 nm.  
 
2.6.3 Measurement of 15d-PGJ2 by LC-MS-MS 
Samples stored at -200C were thawed at room temperature and spiked with the internal standard 
d4-15d-PGJ2 (4 ng) and acidified to pH 3. Solid-phase extraction was performed with 3M Varian 
Empore™ high performance extraction disk cartridges and the columns washed with 1 mL H2O, 
1 mL heptane and eluted with 1 mL of ethyl acetate. The eluate was dried under nitrogen and 
analysed by electrospray triple quadruple LC-MS-MS (Sciex API 3000, PerkinElmer, UK). The 
conditions for the LC-MS-MS were: C18 columns 100×0.2mm with elution volume 200 µl/min 
consisting of a mobile phase 0-1 minute distilled H2O pH 3: MeCN 75:25%, followed by a 
gradient mobile phase to 100% MeCN. 15d-PGJ2 was detected and quantified in negative ion 
mode, the electrospray potential was maintained at -4 to 4.5 kV and heated to 500°C.  For MS-
MS analysis, 15d-PGJ2/internal standard were subjected to collision-induced fragmentation 
 
2.7 Measurement of chemokines and cytokines 
The chemokines MIP-1α and MCP-1 were measured by sandwich enzyme linked 
immunosorbent assay (ELISA).  An ELISA was also used to measure IL-10, TNFα and TGFβ-1.  
MCP-1, IL-10 and TNFα ELISA kits were purchased by Beckton, Dickinson UK Ltd, Oxford, 
UK) and the MIP-1α and TGFβ-1 ELISA kits were from R&D Systems, Abingdon, UK. 96-well 
flat-bottom plates (Appleton Woods, Birmingham, UK) were coated with 100µl/well of diluted 
capture antibody in coating buffer (0.2 M sodium phosphate, pH 6.5), sealed and incubated 
overnight at 4οC.  Wells were aspirated and washed 3 times with 10 mM Phosphate buffered 
saline (PBS, 0.01M phosphate buffer, 0.0027M potassium chloride and 0.137M sodium chloride, 
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pH 7.4) and 0.05% v/v Tween-20.  Non-specific binding was blocked with 200 µl/well of assay 
diluent (10% v/v heat inactivated fetal bovine serum in PBS pH 7.4) at room temperature for 1 h, 
followed by 3 washes as above.  Serial dilutions in assay diluent of the MCP-1 and MIP-1α 
standards were added [100 µL per well] in duplicate. The samples were added in the remainder 
of wells and incubated for 2 h followed by 5 aspiration and washes and then incubation with the 
appropriate avidin-horseradish peroxidase-conjugated anti-mouse antibody for 1 h at room 
temperature. Wells were again aspirated and washed. The substrate tetramethylbenzidine (TMB) 
100µl added to each well, plates were incubated at room temperate in the dark for < 30 min until 
adequate colour development was observed.  The reaction was then terminated by the addition of 
50 µl 2N H2SO4, and the plate read at 450 nm with a subtraction at 570 nm. 
 
2.8 Measurement of Purines 
In the series of experiments looking at the role of A2A receptor activation in inflammation and 
resolution, measurements of purines, adenosine, cAMP, AMP and inosine were carried out at the 
laboratory of Professor Edwin Jackson, Centre for Clinical Pharmacology, University of 
Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Proteins in cell free exudates were 
removed by ultrafiltration (30,000 Dalton cut-off).  Purine concentrations in samples were 
measured by high-pressure liquid chromatography (HPLC) using ultraviolet absorption.  
Aliquots of each sample were injected into an Isco high-pressure liquid chromatographic system 
(pump model 2350, gradient programmer model 2360, V4 absorbance detector, 4.6 x 250 mm 
C18 column with 5 :m particle size, ChemResearch Data Management System).  Mobile phase A 
was 0.1 M KH2PO4 (pH=6.1) and mobile phase B was 80 % 0.01 M KH2PO4 (pH=3.5) and 20% 
methanol.  Mobile phase A was maintained at 100% for 11 min, a 2 min linear gradient to 50% 
mobile phase A was initiated, 50 % mobile phase A was maintained for 21 min, a 2 minute linear 
gradient back to 100% mobile phase A was initiated and 100% mobile phase A was maintained 
at least 24 min before injecting the next sample.  The eluant was monitored at a wavelength of 
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254 nm, and the area under the chromatographic peak for cyclic AMP, AMP, adenosine and 
inosine were obtained.  Purine levels were quantified using these areas by using reference to 
standard curves. 
 
2.9 Statistical analysis 
All values described in the text and figures are expressed as the mean ± standard error for n 
(number of) observations. Statistical analysis was performed using GraphPad Prism 3.01 
(GraphPad Software, San Diego, USA). Statistical analysis was tailored for each experiment and 
detailed in each legend. Data was analysed using One way analysis of variance (ANOVA) was 
with Bonferroni post hoc test. Unpaired student t test was also used in chapter three to compare 
two groups. A p value of <0.05 was considered significant. 
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Chapter 3 The characterisation of inflammation in hPGD2S-/- mice in 
response to zymosan induced peritonitis 
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3.1 Introduction 
The innate inflammatory response that Celsus in 40 AD described as rubor (redness), calor 
(heat), dolor (pain), tumour (swelling) is characterised by the mobilisation of granulated 
polymorphonuclear (PMN) cells to neutralise the external stimuli such as invading microbes 
and/or trauma. This acute inflammatory response is closely followed by influx of mononuclear 
cells, macrophages and lymphocytes that may play a role in limiting the intensity of 
inflammation leading to resolution or healing(Serhan, Brain et al. 2007).  
 
There are a diverse array of soluble lipids, vasoactive amines, cytokines and chemokines along 
with counter regulatory factors (glucocorticoids and adrenaline, for instance) that temper the 
severity of the onset phase on the one hand, and ultimately bring about its resolution on the 
other. Among those that drive inflammation, COX 1 and 2 are widely regarded to be pro-
inflammatory by the virtue of the inhibitory actions of non steroidal anti inflammatory drugs 
(NSAIDs). However, work in our laboratory has shown that in a rat carrageen induced pleurisy 
model there are two peaks of COX-2 expression; one coincident with the acute onset phase and a 
second peak at resolution. The larger second peak of COX-2 is associated with the prostaglandin 
PGH2 derived PGD2 that is important for bringing about resolution (Gilroy, Colville-Nash et al. 
1999). 
 
COX metabolises phospholipase A2-derived arachidonic acid to PGH2, which is then converted 
to downstream prostanoids by a series of specific synthases. PGH2 is converted to PGD2 by 
prostaglandin D2 synthase (Straus and Glass 2001). There are two isoforms of PGD2 synthase, 
Lipocalin and haematopoietic.  Lipocalin PGD2S (L-PGD2S) is present in the central nervous 
system, male genital organs as well as in the human heart. The second haematopoietic PGD2S 
(hPGD2S), a 26 kDa cytosolic protein, is present in the spleen, fallopian tubes, microvascular 
endothelium and hematopoietic system and being widely distributed in antigen-presenting cells, 
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Th2 lymphocytes, mast cells, megakaryocytes and various macrophage cell lines where it 
metabolises COX-derived PGH2 to PGD2 (Urade and Hayaishi 2000). The latter’s effect on 
inflammation may be either direct action on the PGD2 receptors, DP1 and DP2 also called 
CRTH2 (chemoattractant receptor-homologous molecule expressed on Th2 cells) or by its non-
enzymatic metabolites, cyclopentenone PGs (cyPGs) 15-deoxy-Δ12, 14-PGJ2 (15d-PGJ2) and Δ12-
PGJ2. They are generated from PGJ2 by albumin-independent and -dependent reactions, 
respectively (Scher and Pillinger 2005).  
 
PGD2 acts via G-coupled receptors, DP1 and DP2 also called CRTH2 (chemoattractant receptor-
homologous molecule expressed on Th2), both of which contain seven transmembrane domains. 
DP1 is anti-inflammatory (Hammad, de Heer et al. 2003) and DP2 has pro-inflammatory 
properties but has also been implicated in modulating allergic responses (Liu, Bleecker et al. 
1990; Fujitani, Kanaoka et al. 2002; Mandal, Zhang et al. 2004). However at the point of starting 
my research work little was known about the precise role of PGD2 receptors in acute 
inflammation.  
 
As mentioned above, the role of PGD2 is not limited to its action via DP1/2. Its metabolite, the 
cyclopentenone prostaglandin 15d-PGJ2 is a potent activating ligand for PPARγ resulting in the 
inhibition of pro-inflammatory NF-κB, AP1 and signal transducers and activators of 
transcriptions (STATs) (Straus and Glass 2001; Scher and Pillinger 2005). It was shown to 
suppress TNF stimulated expression of the adhesion molecules ICAM-1 and VCAM-1 (Pasceri, 
Wu et al. 2000) as well as chemokines such as MCP-1. Furthermore it is a potent inducer of 
leukocyte apoptosis (Kawahito, Kondo et al. 2000; Ward, Dransfield et al. 2002) and directly 
inhibits IκB kinase that is responsible for activation of NF-κB (Rossi, Kapahi et al. 2000). 
However controversy exists as in whether it is present in sufficient quantities to exert immune 
regulatory effects (Bell-Parikh, Ide et al. 2003). 
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It was shown by this laboratory using a rat pleurisy model that PGH2 derived PGD2 and its 
metabolites play a role in facilitating inflammatory resolution (Gilroy, Colville-Nash et al. 1999; 
Gilroy, Newson et al. 2004). NSAIDs, both non-selective and COX-2 selective inhibitors block 
the production of all PGH2 metabolites (PGD2, PGE2, Thromboxane A2 and Prostacyclin). This 
chapter will characterise the role of hPGD2S derived PGD2 and15d-PGJ2 in both acute and 
resolution phase of innate zymosan induced peritonitis. In order to discern this, hPGD2S-/- mice 
and wild type C57 black VI mice were used. 
 
3.2 Materials and Methods 
A detailed description of all experimental methods is described in Chapter 2. Briefly, hPGD2S-/- 
and control wild type C57BL/6 male mice (6 weeks old) were injected with the sterile chemical 
stimulus Zymosan (1mg in 0.5mL PBS). Mice were sacrificed and peritoneum lavaged at 2, 6, 
12, 24, 48 and 72 hours following zymosan injection. Cells were counted by haemocytometer. 
The differential profiles of PMNs, lymphocyte subsets and macrophages were assessed using 
specific fluorescent antibodies and isotype controls and then analysed using flow cytometry. The 
cell-free supernatants were analysed for lipid mediators and cytokines/chemokines at different 
time points using EIA and ELISA respectively. Furthermore, 15d-PGJ2 was measured using LC-
MS-MS. Leukocyte apoptosis was measured by both flow cytometry [with staining for Annexin 
V and PI] and estimation of caspase-3 activity in the cell pellets. For pharmacological rescue 
experiments, a selective agonist for DP1, BW245C (Narumiya and Toda 1985; Boie, Sawyer et 
al. 1995) and for DP2, 15(R)-15-methyl PGD2 (Moretta, Bottino et al. 2002) were used. 
 
Migration of macrophages from the inflamed peritoneal cavity was also examined during the 
resolution. In order to investigate the fate of macrophages when inflammation resolves, the 
fluorescent marker PKH-26L that bind to macrophages was injected 24 h following zymosan 
[coincident with peak macrophage numbers and onset of resolution]. During resolution of 
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peritonitis macrophages migrate out into draining parathymic nodes and therefore both peritoneal 
cells and the nodes were examined by flow cytometry and fluorescent microscopy respectively.  
 
3.3 Results 
In wild type mice, intra-peritoneal administration of zymosan resulted in a self-limiting 
inflammatory response that peaked at 6 h. Total cell numbers in the peritoneal effluent reached 
baseline levels indicant of inflammatory resolution by 48 h. This was in contrast to hPGD2S-/- 
mice where there was an exaggerated peak inflammation compared to wild type mice at 6 hours 
which appeared to resolve by 24 hours. However the excess leukocyte numbers in the knockout 
mice at 24 h persistent during the resolution phase at 48 and 72 h suggestive of failure or delayed 
resolution.  
 
3.3.1 Acute Inflammation 
In the acute phase, 6 h following i.p. zymosan, there was an exaggerated inflammatory response 
in the hPGD2S-/- mice with the total leukocyte numbers being 10.14 ± 2.6 x 106  per mL in 
hPGD2S-/- vs 4.7 ± 0.94 x 106  per mL  in wild type (P<0.001)(Figure 3.1A). Of this, Gr-1 
positive granulocytes were the predominant cell type comprising 7.51 ± 0.81 x 106 /mL in 
knockouts vs 2.81 ± 1.06 x 106 per mL  in WT (P<0.001) (Figure 3.1B). There was no significant 
increase in F4/80 positive macrophages at 6 h (Figure 3.1C). In hPGD2S-/- mice, the increased 
number of PMNs could arise from either enhanced influx and/or impaired clearance from 
inflamed cavity by reduced programmed cell death. However hPGD2S does not influence the 
survival of PMNs at inflammatory sites as there was no difference in total leukocyte apoptosis 
between knockouts and wild types as determined by annexin (ANX) V/PI labelling (Figure 
3.1D) as well as by caspase-3 activity (Figure 3.1E).  This was also confirmed with regards to 
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apoptosis of PMNs which were gated using forward and side scatter based on Gr1 labelling on 
FACS (Figure 3.1 F and G). 
In conclusion in hPGD2S-/- mice, acute inflammation was exaggerated due to excess of PMNs 
but with no difference in the degree of PMN apoptosis. This finding is suggestive on increased 
PMN influx in hPGD2S-/- mice responsible for the increased inflammation. The next step was to 
assess the synthesis of hPGD2S derived lipid mediator PGD2 and its non-enzymatic 
cylcopentenone metabolite 15d-PGJ2 measured in hPGD2S-/- and wild type mice in this model. 
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Figure 3.1 Zymosan induced peritonitis in wild type C57blackVI and hPGD2S deficient mice. A- 
Total cell numbers in hPGD2S-/- and in wild types at (** P<0.001, * P<0.01).  B- Excess of GR-1 
positive cells in hPGD2S-/- mice in the acute phase (**P<0.001).  C- F4/80 positive macrophages. 
The numbers peak at 24 h but persist during resolution in hPGD2S knockout mice (** P<0.0.01, * 
P<0.05). D and E- Leukocyte apoptosis when measured by annexin V/PI labelling assessed by 
FACS and caspase-3 measurement in the cell pellets respectively. F and G detail the FACS plots for 
annexin V/PI labelling for wild type mice and hPGD2S deficient mice PMNs. In each group there 
was no statistical difference. n=6-8 animals per group. Data is represented as the mean ± SEM. 
*P<0.01, **P<0.001 as determined by unpaired t test. 
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3.3.2 hPGD2S-derived lipid mediators in acute inflammation 
In the first instance levels of PGD2 and 15d-PGJ2 were quantified throughout the time course of 
resolving murine peritonitis. PGD2 was maximal 2 h after zymosan injection with levels waning 
by 24 h [Figure 3.2A]. When measured by LC-MS-MS, 15d-PGJ2 was detectable in cell-free 
inflammatory exudates of wild type mice, Figure 3.2B and C. It was elevated at 2 h, maximum 
between 6-24 h and had declined by 48/72 h with average levels of between 0.5-5ng/ml. Both 
PGD2 and 15d-PGJ2 were absent in samples from hPGD2S-/- mice. Given its instability we 
controlled for potential ex vivo degradation of PGD2 to 15d-PGJ2 during sample processing by 
spiking inflammatory fluids in situ with deuterated PGD2 and found that the detected 15d-PGJ2 
was native and not deuterated 15d-PGJ2. These data, coupled with the finding that neither PGD2 
nor 15d-PGJ2 was detectable in the exudates of hPGD2S knockouts (Figure 3.2 A and B) 
confirmed that 15d-PGJ2 is a bona fide PGD2 eicosanoid metabolite formed in vivo during 
resolving inflammation.  
 
In order to understand the mechanisms behind the exaggerated acute peritonitis in the absence of 
PGD2 and 15d-PGJ2, cytokine and chemokine profiles that may play a significant role were 
explored.  
 
 91 
 
Figure 3.2 hPGD2S synthesises 15d-PGJ2 during zymosan-induced resolving peritonitis. Figure A- 
PGD2 levels in wild type C57blackV1 mice and absence in hPGD2S-/- mice.  B-15d-J2 followed the 
peak of PGD2 in wild type mice measured by LC-MS-MS. C- LC-MS-MS spectra – for native 15d-
PGJ2 (upper panel) and deneutrated deuterated 15d-PGJ2 (lower panel. For eicosanoid analysis 
n=6-8 animals were present in each group with the exception of 15d-PGJ2, which had 2-6 samples 
per group. Data is represented as the mean ± SEM. 
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3.3.3 Cytokine and chemokine profile in hPGD2S-/- and wild type mice  
The pro-inflammatory cytokine TNFα and chemokine MCP-1 as well as the anti-inflammatory 
cytokine IL-10 was measured at all time points following zymosan peritonitis in knockout and 
wild type mice.  
 
The measured cytokines and chemokines peaked at 2 h with baseline levels by 24 h. There was a 
significant reduction of peak IL-10 levels (215.7 ± 53.3 pg/mL in hPGD2S-/- vs. 391.7 ± 117.5 
pg/mL in WT, P<0.05)(Figure 3.3A), whereas pro-inflammatory TNFα (362.7 ± 222.6 pg/mL in 
hPGD2S-/- vs. 94.33 ± 76.7 pg/mL)(Figure 3.3B) and MCP-1 (10183±4094 pg/mL in hPGD2S-/- 
vs. 3361 ± 350.2 pg/mL in WT)(Figure 3.3C) were significantly increased in hPGD2S-/- mice. 
Therefore the exaggerated acute inflammatory state in hPGD2S-/- mice at onset of inflammation 
could be explained, at least in part, by an imbalance between anti-inflammatory (IL-10) and pro-
inflammatory (TNFα and MCP-1) mediators with decreased IL-10 and increased TNF-α and 
MCP-1. 
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Figure 3.3 Cytokine and chemokine levels in hPGD2S-/- and wild type mice in zymosan peritonitis 
A- IL-10 B- TNFα  C- MCP-1.  n= 6-8 animals per group. Data is represented as the mean ± SEM. 
*P<0.05, **P<0.01 as determined by unpaired t test. 
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3.3.4 The role of PGD2 receptors- DP1 and DP2 in zymosan peritonitis 
With respect to PMN trafficking it is not clear whether PGD2 exerts its effect via its action on 
DP1 &/or DP2. To further clarify this, a selective agonist for DP1, BW245C (Narumiya and 
Toda 1985; Boie, Sawyer et al. 1995) and for DP2, 15(R)-15-methyl PGD2 (Moretta, Bottino et 
al. 2002) were used. When hPGD2S-/- mice were pre-treated with the DP1 agonist BW245C 
(0.03-0.3 mg/kg) 30 min prior to the i.p. Injection of zymosan, the hyper-inflammatory 
phenotype was rescued back to the wild type levels with reduction in total leukocyte numbers at 
6 h. The greatest effect obtained with the highest dose used, 0.3mg/kg (Figure 3.4A) (7.1 x 106 ± 
1.15 x 106 /mL in BW245C treated mice vs 12.73± 2.55 x 106 /mL in hPGD2S-/- mice treated 
with vehicle). When the same experiments were done with the DP2 agonist 15(R)-15-methyl 
PGD2 there was no response (Figure 3.4B). The anti-inflammatory effect of the DP1 agonist was 
accompanied with a rise in IL-10 [394.5±144.5 pg/mL in BW245C treated vs. 222.7±36.8 pg/mL 
in vehicle (Figure 3.4C) and decrease in MCP-1 (2083±1497 pg/mL in BWC treated vs. 
9892±2236 pg/mL in vehicle) (Figure 3.4D) and TNFα (Figure 3.4E). There was no effect with 
the DP2 agonist, 15(R)-15-methyl PGD2. The anti-inflammatory effect of BW245C was not 
accompanied with any changes in leukocyte apoptosis based on the observed caspase-3 activity 
(Figure 3.4F). The anti-inflammatory role of PGD2 is therefore mediated via the DP1 receptor 
and in this model DP2 receptor does not appear to have a significant role. In conclusion, 
hPGD2S-derived PGD2 controls the balance between pro and anti-inflammatory 
cytokines/chemokines by activating the DP1 receptor. 
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Figure 3.4 The role of DP1 and DP2 receptor agonists in acute zymosan peritonitis. Cell numbers 
hPGD2S knockout mice pre-treated with DP1 receptor agonist BW245C prior to zymosan injection 
(A), DP2 agonist 15(R)-15-methyl PGD2 (B). When cytokines and chemokines were measured at 2 h 
in this model there was an increase in IL-10 (C) and a decreased in MCP-1 (D) and  TNFα (E) 
(**P<0.01, *P<0.05) with BW245c but not with 15(R)-15-methyl PGD2.  The anti-inflammatory 
effect of BW245C was independent of apoptosis when the leukocyte pellets were measured for 
caspase-3 activity (F). n= 6-8 animals per group. *, P<0.05; **, P<0.01, as determined by ANOVA, 
followed by bonferroni test , with data expressed as mean ± SEM. 
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3.3.5 The role of 15-Deoxy-Delta-12, 14-prostaglandin J2 [15d-PGJ2] in acute murine 
peritonitis in hPGD2S-/- mice 
While hPGD2S-derived PGD2 mediates its anti-inflammatory role by activating the DP1 
receptor, it is also converted, non-enzymatically, to 15d-PGJ2. This is a potent inhibitor of NF-
κB DNA and therefore has powerful pro-apoptotic and anti-inflammatory properties. As there 
was no difference in leukocyte apoptosis during acute inflammation in knockout and wild type 
mice, it is not clear whether 15d-PGJ2 plays a role in the exaggerated peritonitis in hPGD2S-/- 
mice. As expected, when 15d-PGJ2 was added exogenously to WT it reduced the cell numbers in 
a dose dependent manner at 6 h (Figure 3.5A) by increasing leukocyte apoptosis as measured by 
annexin V/PI labelling (Figure 3.5B) and caspase-3 activity (Figure 3.5C). This was associated 
with an increase in TGFβ1 (Figure 3.5D) and Il-10 (Figure 3.5E). In the previous experiments 
the exaggerated acute peritonitis in hPGD2S-/- mice was not due to decreased leukocyte 
apoptosis. Therefore 15d-PGJ2 was administered intraperitoneally to hPGD2S-/- and wild type 
mice at doses that do not trigger leukocyte apoptosis and there was no dose dependent reduction 
in cell numbers (Figure 3.5F). The absence of increased apoptosis was confirmed by little 
detectable annexin/PI labelling on PMNs as well as (Figure 3.5G) and little total leukocyte 
caspase-3 activity (Figure 3.5H). 
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Figure 3.5 The role of 15d-PGJ2 in zymosan peritonitis in C57blackVI wild type mice.  A- dose 
dependent reduction in cell numbers in response to 15d-PGJ2 at 6 h Increased leukocyte apoptosis 
as measured by annexinV/PI labelling (B) and by caspase-3 activity (C).  This was associated with a 
significant increase in TGFβ (D)(**P<0.01) and IL-10 (E)(*P<0.05). F- Effect on cell numbers when 
sub-apoptotic dose of 15d-PGJ2 was administered to hPGD2S deficient mice. Figures G and H 
confirm the absence of increased apoptosis in the experiment with hPGD2S deficient mice. n= 6-8 
animals per group. *, P<0.05; **, P<0.01, as determined by ANOVA, followed by bonferroni test, 
with data expressed as mean ± SEM. 
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The above series of experiments confirm that when administered at doses that do not induce 
apoptosis 15d-PGJ2 does not have anti-inflammatory properties and therefore its absence in mice 
hPGD2S-/- may not account for the excess of leukocytes in acute peritonitis. 
 
3.3.6 Resolution of Inflammation 
As mentioned above, in hPGD2S-/- mice there is a second phase of  peritoneal inflammation 
following zymosan with an excess of  total leukocyte numbers at 72 h with 5.32 ± 1.5 x 106  per 
mL in hPGD2S-/-  vs  2.33 ± 0.49 x 106  per mL  in WT(P<0.01) (Figure 3.1A). Whereas the 
exaggerated acute phase of inflammation was predominantly due to an excess of PMNs, the 
delayed resolution in knockout mice was due to persistence of F4/80 positive macrophages 
(Figure 3.1C) and accumulation of lymphocytes (Figures 3.6A-G). 
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Figure 3.6 Lymphocyte profile of wild type and hPGD2S-/- mice following zymosan peritonitis by 
FACS. - Specific lymphocyte subtype markers was used to profile lymphocyte subsets, T cells (CD3, 
Figure A), B cells- CD45/Ly220 (B), CD4 (C), CD8 (D), CD4+CD25+ (E). For gamma delta T cells 
(F) and NK cells (G) the 48-hour time point was profiled. The appropriate iso-type was used. *, 
P<0.05; **, P<0.01, as determined by ANOVA, followed by bonferroni test , with data expressed as 
mean ± SEM.  
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3.3.7 Lymphocytes profile during resolution phase 
The relative abundance of different subsets of lymphocytes were examined by FACS by 
labelling with CD3 for T cells, CD45 (B220) and CD19 for B cells. As for T cells subsets, CD4, 
CD8 and CD25 were examined. All subsets were significantly elevated in knockout mice at 
resolution phase. (Table 3.1) (Figures 3.6A-G). The persistence of lymphocytes during resolution 
has also been noted in carrageenan-induced paw inflammation in COX-2 deficient mice and its 
role is not clear (Wallace, Bak et al. 1998).  
 
 
  WT hPGD2S -/-   
  
mean ± SD [ 
x104/mL] 
mean ± SD [ 
x104/mL]   
CD3 6.86  ± 4.49 21.92 ± 11.18 P<0.05 
CD4 3.1 ± 1.77 13.29 ± 7.59 P<0.05 
CD8 1.27 ± 0.58 4.74 ± 1.43 P<0.05 
CD4CD25 0.89 ± 0.58 6.5 ± 6.03 P=0.05 
CD45 
(Ly220) 7.61 ± 5.82 38.74 ± 26.54 P<0.01 
Table 3.1 Lymphocyte subsets in hPGD2S -/- and wild type mice.  
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3.3.8 Failure of Macrophage efflux from the inflamed peritoneal cavity 
As mentioned earlier peritonitis fails to resolve in hPGD2S deficient mice with significantly 
increased numbers of macrophages (Figure 3.1C) and lymphocytes (Figure 3.6). Macrophage 
numbers were significantly increased at 24 h in hPGD2S-/- (3.06 ± 1.58 x 106 per mL vs. 1.33 ± 
0.19 x 106 per mL, P<0.01) persisting up to 72 h (2.46 ± 0.83 x 106 in hPGD2S-/- per mL vs.  
0.87± 0.27 x 106 per mL in WT, P<.0.05) (Figure 3.1C).  
 
The increased (though non-significant) macrophage numbers during the acute phase of 
inflammation in hPGD2S-/- mice may have arisen from elevated MCP-1 (Figure 3.3C) and 
MIP1β levels (Figure 3.7A). All cytokines and chemokines measured peaked very early in acute 
inflammation. However, the persistence of significant numbers of macrophages in the resolution 
phase may be due to enhanced influx into the peritoneal cavity and/or failure to clear to the 
draining lymphatics. The principle clearance route for macrophage in the inflamed peritoneum as 
it is either local programmed cell death or clearance via the draining lymphatics to the 
parathymic lymph node or spleen (Bellingan, Caldwell et al. 1996; Bellingan, Xu et al. 2002). To 
investigate the latter, the selective macrophage label PKH26-PCL was used. When PKH26-PCL 
was injected i.p at the peak of macrophage accumulation (24 h), it revealed increased numbers of  
labelled macrophages in the peritoneal cavities of hPGD2S-/- mice (Figure 3.7B) and a 
corresponding reduction in the parathymic node of these cells compared to wild types at 72 h 
(Figure 3.7C). Adding BW245C or 15d-PGJ2 to hPGD2S-/- mice reduced peritoneal macrophage 
accumulation (Figure 3.7D) and increased numbers of PKH26-PCL macrophages in the para-
thymic lymph nodes (Figure 3.7E). The DP2 receptor agonist had no effect.  
 
Therefore, in addition to inhibiting PMN trafficking as well as pro- and anti-inflammatory 
cytokine synthesis, PGD2 also plays a role in inflammatory resolution by triggering the enhanced 
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efflux of macrophages from the peritoneal cavity into the draining lymphatics by the agonism of 
the DP1 receptor. 
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Figure 3.7 Efflux of macrophages during resolution in hPGD2S-/- and wild type mice following 
zymosan peritonitis- In hPGD2S-/- mice increased macrophage numbers could arise from enhanced 
accumulation following raised synthesis of MIP-1β  [A] as well as MCP-1 [Figure 3.3C] and/or 
failure of efflux into the para-thymic nodes during resolution. To determine the latter, mice were 
injected i.p. with the macrophage label PKH-PCL26 at 24 and 36 h after zymosan. A significantly 
greater number of PKH-PCL positive macrophages were recorded in the peritoneal cavity of 
hPGD2S-/- mice (B) compared to wild types at 72h and correspondingly fewer labelled 
macrophages found by histology in the para-thymic lymph nodes of the knockouts [C]. Adding 
BW245C (DP1 receptor agonist) or 15d-PGJ2 to the inflamed cavity of hPGD2S-/- mice reversed the 
accumulation of macrophages in the peritoneum (D) and resulted increased numbers of labelled 
macrophages in para-thymic lymph nodes [E]. n = 10 animals per group; * P≤  0.05; **P≤0.01 as 
determined by ANOVA followed by Bonferoni test with data expressed as mean ± SEM. 
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3.3.9 Effect of hPGD2S on resident macrophages and lymphocytes ex vivo 
In the peritonitis model, 15d-PGJ2 was not anti-inflammatory when it was administered at doses 
that do not trigger leukocyte apoptosis. However it is likely that hPGD2S derived lipid mediators 
PGD2 and 15d-PGJ2 may have differential effects on the sub-populations of leukocytes. Thus, to 
garner some insight in to how PGJ2 exerts its biological effects on peritoneal leukocytes ex vivo 
was examined.  
 
In the naïve (non-inflamed) peritoneum T and B lymphocytes constitute about 40% of the total 
cell population (∼ 1.0x106) with the remaining being resident macrophages which was 
determined using CD3, B220 and F4/80 labelling quantified by FACS. Firstly peritoneal 
leukocytes were lavaged followed by separation of T and B-lymphocytes as well as macrophages 
as described in 2.4.2.2, 2.4.2.3 and 2.4.4.3 respectively. The peritoneal leukocytes were 
stimulated with either LPS or zymosan (B cells and macrophages) or anti CD3 antibody (T 
cells). Cytokines were measured 24 h later in response to BW245C (DP1 receptor agonist), 
15(R)-15-methyl PGD2 (DP2 receptor agonist) or 15d-PGJ2. 
 
When stimulated with anti-CD3, IL-10 from hPGD2S-deficient peritoneal T cells was 
significantly lower than wild types but was reversed by BW245C (DP1 agonist, 1.0 µM); neither 
15(R)-15-methyl PGD2 (DP2 receptor agonist, 2 µM) nor 15d-PGJ2 (1 µM) had any effect, 
Figure 3.8A. Similarly, IL-10 secretion from zymosan or LPS-stimulated hPGD2S-deficient 
peritoneal B cells (265±20 and 178±12 pg/mL, respectively) was lower compared to wild types 
(387±25 [P≤0.05] and 625±35 [P≤0.01] pg/mL, respectively) and was rescued by BW245C only 
[figure 3.8B-C]. When TNFα was measured from zymosan or LPS-stimulated hPGD2S-deficient 
B cells, the levels (1625±175 and 1260±152 pg/mL, respectively) was higher compared to wild 
types (1160±105 [P≤0.05] and 810±65 pg/mL [P≤0.05], respectively) and were reduced by 
BW245C and 15d-PGJ2 but not with 15(R)-15-methyl PGD2 (Figure 3.8D-E).  
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In vitro experiments were also carried out in both peritoneal and bone marrow derived 
macrophages. The results were similar for both types of macrophages and with both LPS and 
zymosan stimulation. In contrast to T and B-lymphocytes, IL-10 from stimulated peritoneal 
macrophages was not elevated by BW245C (Figure 3.8F). Similarly there was no effect either 
with DP2 receptor activation or by 15d-PGJ2. Also there was a differential effect of the pro-
inflammatory cyto/chemokine expression of macrophages with the DP1 agonist and 15d-PGJ2 
with BW245C showing a dose dependent reduction in TNFα with zymosan and LPS (Figure 
3.8G). However, when the effect on MCP-1 was examined only 15d-PGJ2 had an effect with 
zymosan (Figure 3.8H).  
 
These data show that hPGD2S-derived lipid mediators exert differentially protective effects on 
peritoneal-resident (and bone marrow derived) macrophages as well as lymphocytes thereby 
controlling the balance of cytokines and chemokines that orchestrate innate inflammatory 
responses. 
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Figure 3.8 The differential effect of hPGD2S on the inflammatory phenotype of peritoneal 
leukocytes. IL-10 release from anti-CD3 stimulated hPGD2S deficient T cells (A) as well as LPS 
stimulated B cells (B and C) were not only lower than that from wild types but were rescued by 
DP1 activation (BW245C). DP2 receptor activation with 15(R)-15-methyl PGD2 or 15d-PGJ2 had 
no effect. Conversely, TNFα  release from hPGD2S deficient B cells (D and E) was greater than that 
from wild types and was reversed with BW245C and 15d-PGJ2 but not 15(R)-15-methyl PGD2. In 
macrophages, whereas there was no difference in IL-10 with no effect from BW245C (F), TNFα 
and MCP-1 levels were higher in hPGD2S KO (G and H) with reduction in levels with BW245C (G) 
and 15d-PGJ2 (H) respectively. These data show the differential regulatory effect of hPGD2S-
derived lipid mediators on inflammatory leukocyte phenotype. Cells were isolated from n=3-10 
animals and all experiments done in triplicate on two separate occasions to confirm original 
findings. *, P≤0.05; **, P≤0.01, as determined by ANOVA, followed by Bonferroni  test, with data 
expressed as mean ± SEM.   
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3.3.10 Conclusions 
A. hPGD2S-/- mice have an exaggerated peritoneal inflammatory response compared to WT 
with zymosan 
B. Enhanced inflammatory response is due to an excess of PMNs with decreased IL-10 and 
increased TNFα in hPGD2S-/-  mice 
C. Excess of PMNs is not due to a difference in apoptosis between hPGD2S-/-  and WT mice 
D. PGD2 exerts its anti-inflammatory role by activating the G-coupled DP1 receptor and 
modulates the balance between anti-inflammatory IL-10 and pro-inflammatory TNFα and 
MCP-1. 
E. 15d-PGJ2 in sub-apoptotic dose does not exert an influence in the difference of acute 
peritonitis in hPGD2S-/- and WT mice. 
F. Resolution phase is delayed in hPGD2S-/- mice and is due to an excess of macrophages 
and lymphocytes. 
G. In hPGD2S-/- mice the persistance of macrophages in zymosan peritonitis is due to 
enhanced influx due to increased chemokine production and impaired efflux into draining 
parathymic nodes. The latter is also modulated by the activation of the DP1 receptor. 
H. Ex-vivo experiments with separated inflammatory cells suggest differential effects of 
PGD2 and 15d-PGJ2.  Both activated T and B cells produce less IL-10 in hPGD2S-/- 
reversed by the DP1 agonist whereas in activated macrophages it had no effect on IL-10 
expression. TNFα production was increased in B lymphocytes from hPGD2S-/- compared 
to WT, reversed by the DP1 agonist.  
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3.4 Discussion 
This study demonstrates a central role for hPGD2S in controlling onset and resolution of innate 
immune-mediated peritoneal inflammation. Firstly, the protective nature of hPGD2S is mediated 
via DP1 and 15d-PGJ2, which control the balance of pro- and anti-inflammatory cytokine 
synthesis. This is in contrast to the contradictory role of PGD2 in allergic models of 
inflammation (Liu, Bleecker et al. 1990; Fujitani, Kanaoka et al. 2002; Mandal, Zhang et al. 
2004). For instance PGD2 can be either pro or anti-inflammatory depending on the disease 
aetiology and the expression of the different eicosanoid receptor (Morris, Rajakariar et al. 2006). 
Signalling through DP2 (CRTH-2) causes bronchoconstriction as well as Th2 type cells and 
eosinophil cell accumulation inflammation (Liu, Bleecker et al. 1990; Fujitani, Kanaoka et al. 
2002; Mandal, Zhang et al. 2004). In contrast, PGD2 activation of DP1 may also suppress 
asthmatic symptoms by targeting lung dendritic cells resulting in increased Treg cells that 
dampen inflammation in an IL-10-dependent manner (Hammad, Kool et al. 2007). As mentioned 
before, there is no data in the role of PGD2 in innate inflammation. In zymosan peritonitis PGD2 
acting via the DP2 (CRTH2) receptor had no role in modulating the acute or resolution phase of 
inflammation. In fact more recent work done in our laboratory show that the DP2 receptor is not 
expressed in peritoneal inflammation. Therefore in acute inflammation both this study and work 
elsewhere, DP1 agonists may be an attractive and novel anti-inflammatory target capable of 
modulating both innate and adaptive immune responses of different aetiologies (Hammad, Kool 
et al. 2007). 
 
PGD2 is unstable in vivo and metabolises non-enzymatically to 15d-PGJ2 a potent anti-
inflammatory, pro-apoptotic agent (Kawahito, Kondo et al. 2000; Ward, Dransfield et al. 2002). 
However in hPGD2S-/- mice, surprisingly, there was no difference in leukocyte apoptosis 
compared to wild type during acute inflammation and when 15d-PGJ2 was administered at sub-
apoptotic doses there was no effect. However in vitro studies show PGD2 agonists and 15d-PGJ2 
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has differential effects on leukocyte sub populations when cytokine/chemokine levels were 
measured (Jackson, Parhami et al. 1999; Zhang, Wang et al. 2001; Ahmed, McGettrick et al. 
2011). Controversy exists over whether 15d-PGJ2 is synthesised in vivo and whether it possesses 
relevant patho/physiological functions. This arose, in part, when earlier work in our laboratory 
originally reported that COX 2-derived PGD2 and 15-dPGJ2 brought about acute inflammatory 
resolution (Gilroy, Colville-Nash et al. 1999). The controversy arise because the publication 
suggested that COX 2 was protective at a time when the emphasis was on developing COX 2 
inhibitors, but also because we used an ELISA to quantify 15d-PGJ2. In particular, the reactive 
nature of 15d-PGJ2 raised questions regarding the accuracy of using an antibody-based 
measuring system. This, coupled with subsequent reports using physical methods to show only 
negligible levels of 15d-PGJ2 in various biological systems, collectively questioned the 
importance of 15d-PGJ2 in biology (Bell-Parikh, Ide et al. 2003). However, in this study using 
LC-MS-MS on samples obtained from a resolving inflammation model demonstrates that 15d-
PGJ2 does exist in vivo at levels up to 5ng/mL. We controlled for degradation of unstable PGD2 
to 15d-PGJ2 during sample processing by spiking inflammatory fluids in situ with deuterated 
PGD2 and found that the detected 15d-PGJ2 was native and not deuterated 15d-PGJ2. These data, 
coupled with the finding that neither PGD2 nor 15d-PGJ2 was detectable in the exudates of 
hPGD2S knockouts (Figure 3.2A and B) and that the hyper-proliferative phenotype of hPGD2S-/- 
T cells from a delayed type hypersensitivity reaction was reversed with 15d-PGJ2, confirms that 
15d-PGJ2 is an endogenously-generated protective PGD2 metabolite formed in vivo during 
resolving inflammatory reactions. The importance of this finding cannot be underestimated. 
cyPGs, derived from PGs of the A or D series possess anti-inflammatory (Straus and Glass 
2001), anti-viral (Santoro 1997) as well as anti-cancer (Conti 2006) properties by activating 
either nuclear-membrane bound PPARs (Ricote, Li et al. 1998) or by forming covalent adducts 
with thiols via the unsaturated carbonyl group in the cyclopentenone moiety (Cernuda-Morollon, 
Pineda-Molina et al. 2001; Perez-Sala, Cernuda-Morollon et al. 2003). Importantly, protein 
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modification by cyPGs does not occur randomly with cyPGs targeting defined cysteine residues 
within certain proteins in an apparently pH dependent manner (Bickley, Ciucci et al. 2004). 
Moreover, structural determinants of either the protein or the cyPG may be important for the 
specificity of protein modification such that cyPGs with diverse structures could selectively 
modify distinct proteins in cells. Thus, levels of cyPGs in the extra-cellular environment may 
only represent the “tip-of-the-iceberg” and that their true level in biological systems may be 
much higher. Moreover, the lack of detectable cyPGs in biological fluids does not necessarily 
exclude their existence within cells and their potential to exert meaningful biological effects. 
Indeed, in a series of experiments we estimate that of 15d-PGJ2 added exogenously to biological 
systems greater than 50% binds BSA. Moreover, in cardiomyocyte cell cultures, greater than 
80% binds to culture media supplemented with 10% FCS with about 16% binding to or being 
metabolized by cardiomyocytes leaving less than 4% detectable by LC-MS-MS. It is for this 
reason that we need to add quantitatively more 15d-PGJ2 back to inflammatory models to mimic 
the biological effects of endogenously produced 15d-PGJ2 as illustrated in Figure 3.2B. We 
suggest that the role of 15d-PGJ2 in self-limiting inflammatory responses is many-fold and does 
not necessarily overlap with that of PGD2, controlling chemokine and cytokine synthesis as well 
as intracellular signalling and leukocyte apoptosis. On this theme, we found that exogenous 15d-
PGJ2 exerts pro-resolution effects if used pharmacologically by enhancing leukocyte apoptosis, 
the net outcome being similar to that found recently with the cyclin-dependent kinase inhibitor 
roscovitine, which enhanced PMN apoptosis and hastened resolution (Rossi, Sawatzky et al. 
2006). 
 
Though the control of phagocyte clearance is poorly understood, there was an excess of 
macrophages in the inflamed peritoneum of hPGD2S-/- mice and a corresponding deficit of these 
cells in the draining lymph nodes compared to controls. This could have resulted from 
accelerated monocyte influx, mediated by elevated MCP-1 and MIP-1β (Figure 3C and Figure 
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7A) and/or failed lymphatic efflux. Using a phagocytosable fluorescent cell tracker, the 
peritoneal pool of accumulated macrophages in hPGD2S-/- mice at resolution was found to be 
reduced by BW245C or 15d-PGJ2 and was associated with an increase in macrophages in the 
parathymic lymph node.  We therefore suggest that DP1 is a robust pharmacological target that, 
in addition to stemming PMN trafficking could be used to disseminate macrophages from sites 
of chronic inflammation where macrophages play a pathogenic role. A similar result was found 
recently with omega-3 polyunsaturated fatty-acid-derived resolvin E1 and protectin D1, which 
facilitated leukocyte trafficking to lymph nodes and spleen collectively underscoring the pro-
resolution properties of lipid mediators in acute inflammation (Schwab, Chiang et al. 2007).  
 
In summary, we provide proof that hPGD2S synthesises 15d-PGJ2 during mammalian defence 
responses and together with PGD2, acting through the DP1 receptor, plays a central role in 
controlling the onset of acute inflammation, its resolution by controlling the balance of pro- 
versus anti-inflammatory cytokines in addition to macrophage clearance via draining lymphatics. 
In doing so, we highlight the potentially anti-inflammatory and pro-resolution properties of 
cyPGs  and DP1 receptors.  
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Chapter 4 Biphasic trafficking of lymphocytes during acute inflammation 
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4.1 Introduction 
Inflammation is controlled by a balance of pro- and anti-inflammatory signals resulting in the 
development of an immune response followed by temporally released pro-resolution factors that 
lead to inflammation switching off and injured tissues returning to normal physiology (Nathan 
2002; Gilroy, Lawrence et al. 2004; Gilroy, Feldmann et al. 2010). In chapter 3, I demonstrated a 
pivotal role for PGD2 in innate inflammation both at onset and during resolution via its action on 
the DP1 receptor in modulating PMN trafficking and clearance of macrophages 
respectively(Rajakariar, Hilliard et al. 2007). Its role in lymphocyte expression and trafficking is 
less clear.  
 
In the naïve mouse peritoneal cavity, lymphocytes constitute half the cell population of which 
approximately 70-80% are B lymphocytes. Predominant B lymphocyte population is of B-2 
subset with surface expression of CD23 that contributes to overall 80- 99% of circulating B cells 
(von Boehmer and Melchers 2010). However another subset, B1, characterized by the surface 
expression of CD5 is the predominant B lymphocytes in the pleural and peritoneal cavity 
(Hayakawa, Hardy et al. 1983; Wortis and Berland 2001). One of the major impetuses for this 
current investigation stemmed from the observation of lymphocytes repopulating peritoneum as 
inflammation abates in zymosan peritonitis. This has also been observed previously in our 
laboratory (Gilroy, Colville-Nash et al. 2003) and by others (Takada, Hiromatsu et al. 1993; 
Wallace, Bak et al. 1998; McLoughlin, Jenkins et al. 2005; Hoffmann, Priller et al. 2007), 
suggesting that lymphocytes might help to switch off acute inflammation. Traditionally less 
weight has been placed on the role of lymphocytes in innate inflammation. Given their roles in 
the early defence to bacteria and viruses, innate-type lymphocytes including B1 cells merit 
further exploration for their potential roles in host defence and restorative physiology as its 
becoming clear that diminished innate lymphocyte function or enhanced lymphocyte death by 
apoptosis, for instance, has being postulated to play a central role in the pathogenesis of burn 
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injury (Ditschkowski, Kreuzfelder et al. 1999; Godshall, Scott et al. 2003) and sepsis (Hotchkiss, 
Tinsley et al. 1999; Hotchkiss, Chang et al. 2000), respectively. 
 
The objective of this chapter is to characterize the lymphocyte profile in the acute and resolution 
of zymosan induced peritonitis and the role of PGD2 in lymphocyte trafficking. Firstly 
lymphocyte profile in a human model of peritonitis will be examined. By using flow cytometry, 
lymphocyte subtypes will be characterized in a mouse zymosan peritonitis model and the role of 
PGD2 will be investigated. Zymosan peritonitis in lymphocyte deficient RAG1-/- will lead to 
further insights in the role of repopulating lymphocytes in inflammatory resolution. 
 
4.2 Material and Methods 
Detailed experimental methods are described in chapter 2.  Briefly, peritonitis was induced in 
mice by the i.p. injection of type A zymosan (1 mg, for all experiments unless otherwise stated), 
group B streptococcus (GBS) or LPS (1 mg/kg). Ethical approval [P/03/136A] was obtained for 
collection of human peritonitis samples from St. Bartholomew’s & the Royal London Hospitals 
from chronic kidney disease (CKD) stage 5 patients undergoing peritoneal dialysis. To 
determining the fate of peritoneal T and B cells, cavities of mice bearing a 4 h zymosan-induced 
peritonitis was lavaged with sterile PBS to remove accumulated inflammatory cells and oedema. 
5 mL of pre-warmed 5% trypsin was then added to the peritoneal cavity for 10 min followed by 
an equal volume of complete medium to acquire cells adhered to the peritoneal lining/greater 
omental lymphoid organ. Cells were then analysed by FACS.  Cytokines were measured by 
ELISA according to manufacturer’s instructions (eBiosciences, Hatfield, UK). Antibodies, 
CD3/CD19 (AbD Serotec, Oxford, UK), B cells (Ly220, AbD Serotec), CD5 (BD Bioscience), 
MAC-1/CD11b (BD Bioscience), NK and gamma/delta cells (gift from Dr. T. Hussell, Kennedy 
Institute, UK), GR1 (BD Bioscience, UK) or F4/80 (Caltag Medsystems, Buckingham, UK) 
using respective isotype antibodies as controls (AbD Serotec) were used. For apoptosis, cells 
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were incubated with annexin V/propidium iodide (Becton Dickinson), and run on Becton 
Dickinson FACScalibur with data analysed by Cellquest.  For pharmacological rescue 
experiments, a selective agonist for DP1, BW245C (Narumiya and Toda 1985; Boie, Sawyer et 
al. 1995) and for DP2, 15(R)-15-methyl PGD2 (Moretta, Bottino et al. 2002) were used.  
 
4.2.1 Adoptive transfer of lymphocytes 
Contents of resolving phase peritoneal cavities of wild type animals were isolated and 
macrophages separated from remaining lymphocytes by adherence to the bottom of 6-well tissue 
culture plates. Non-adherent cells were removed and used to isolate T and B cells as well as NK 
and gamma/delta T cells for adoptive transfer to gp91phox knockouts using FACS and relevant 
antibodies to confirm that their composition and ratios reflects that present in situ at resolution. 
Resolving phase lymphocytes were enriched at a concentration of 1.0x106/mL and 0.5 mL 
injected in to gp91phox knockouts.  
 
4.3 Results 
4.3.1 Lymphocyte profile in human peritonitis 
Peritonitis is the most common complication in CKD-5 patients on peritoneal dialysis. Clinical 
assessment of these patients was based on patients presenting with abdominal pain, cloudy 
dialysate and leucocyte count of greater than 100/mm3. In patients who develop peritonitis, the 
overnight effluent was examined for different cell types. In all cases studied, peritonitis resolved 
by day 5 determined by the appearance of a clear dialysate and abatement of abdominal 
symptoms (Figure 4.1A). At the onset of peritonitis as expected PMNs was the predominant cells 
type (Figure 4.1B). It became apparent that as inflammation decreases, lymphocyte numbers 
increase (Figure 4.1C). Therefore as observed in animal models, lymphocytes re-populate the 
site of injury as inflammation resolves. 
 116 
 
 
Figure 4.1 Peritoneal cellular profile in patients undergoing peritoneal dialysis who develop acute 
resolving peritonitis. A- Total leukocyte profile.  B- The PMN and C- Total lymphocyte numbers. 
Data expressed as mean ± SEM. 
 
4.3.2 Lymphocyte profile in murine zymosan peritonitis 
Total cells numbers and lymphocytes were examined in a resolving zymosan murine peritonitis 
(Figure 4.2A), which again demonstrated a biphasic response with reduction in lymphocyte 
numbers in peak inflammation with repopulation during resolution. Lymphocytes constitute 
about 50% of the total cell population with the remaining being resident macrophages.   
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4.3.2.1 T Lymphocytes  
In the naïve murine peritoneum (0 h) CD4+ and CD8+ cells were found as well as lower numbers 
of CD4+/CD25+, gamma/delta T cells and NK cells (Figure 4.2B-G). As lymphocytes 
repopulated the peritoneum, there were more CD4+/CD25+, gamma/delta T cells and NK cells 
found during resolution (Figure 4.2E-G). 
 
4.3.2.2 B Lymphocytes 
The majority of lymphocytes in the naïve cavity are B cells constituting about 70-80% of the 
total lymphocyte population labelling positively for CD19 as well as B220. Of these B cells 
about 80% are B220low/CD5+/MAC-1low, indicative of a B1 phenotype with the remainder being 
B220high/MAC-1- B2 cells (Figure 4.3A-D). As inflammation initiates (1-4 h), B cells disappear 
but repopulate the peritoneum again between 12-24 h (Figure 4.3E). Notably there were more B1 
cells expressing higher levels of MAC-1 than in the naïve state (Figure 4.3C). As inflammation 
in this model peaks between 6-12h and subsequently resolves, lymphocytes appear to repopulate 
the peritoneum during or just after resolution. Experimentally enhancing the severity of the 
inflammatory response within the peritoneum by injecting three doses of zymosan (0.1, 1.0 and 
10 mg) to three separate groups of mice and therefore prolonging resolution, is associated with 
delayed lymphocyte repopulation, Figure 4.3F. Whether this is a delay or suppression is unclear.  
 
Thus, from the above experiments we show a shift in lymphocyte populations from the naïve to a 
resolving state constituting more innate-type lymphocytes as well as a different phenotype of B1 
cells.  
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Figure 4.2 T lymphocyte profile in murine zymosan-induced peritonitis. A- During peak PMN rich 
inflammation, lymphocyte numbers reached a nadir and re-populate during resolution phase.  B-G- 
The profile of T lymphocytes, CD3, CD4, CD8, CD4+/CD25+, gamma/delta T cells and NK cells. . n 
= 6–8 animals per group. Data expressed as mean ± SEM.    
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Figure 4.3 B lymphocyte profile in murine zymosan-induced peritonitis. A-D FACS plot of B cells, 
which constitute 80% of total lymphocyte population that label for CD19 as well as B220. Of these 
B cells about 80% are B220low/CD5+/MAC-1low, indicative of a B1 phenotype with the remainder 
being B220high/MAC-1- B2 cells. E- Total B lymphocyte profile during resolving inflammation. F- 
Inflammatory response within the peritoneum by injecting three separate doses of zymosan (0.1, 1.0 
and 10 mg) that prolongs resolution and delays lymphocyte repopulation (72 h) n = 6–8 animals per 
group. 
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4.3.3 Peritoneal lymphocyte disappear in response to PGD2 
Investigating how lymphocytes disappear we recorded equivalent numbers of T and B 
lymphocytes in the peritoneal cavity hPGD2S knockout mice at 6h as in the naïve cavity (0h) of 
wild types (Figure 4.4A-E). Furthermore in the peritonitis time course, even though lymphocyte 
numbers reduced during the acute phase, there still was an excess in the hPGD2S-/- mice. Adding 
BW245C (DP1 agonist) to hPGD2S-/- reduced lymphocytes at 6h with the clearance effects of 
DP1 being on B cells, Figure 4F. 15(R)-15-methyl PGD2 (DP2 agonist) had no effect on 
lymphocyte numbers in knockouts indicating that DP1 receptor activation is responsible for B 
cells disappearance early in acute inflammation. The fate of CD3 positive cells remains less 
clear. Two possibilities include adherence to the omental lymphoid organ, the so-called 
“leukocyte disappearance reaction” typical of peritoneal macrophages during acute peritonitis 
and lymphocyte apoptosis. To investigate the former, 5% trypsin was added to a 4 h inflamed 
cavity for 10mins recovered displaced macrophages but not lymphocytes, Figure 4G. As for 
apoptosis there was no difference in percentage annexin V/PI labelling between hPGD2S-/- and 
wild type mice. Therefore, I suspect that within a few hours of inducing an inflammatory 
response, peritoneal resident B cells disappear in a PGD2/DP1 dependent manner but that the fate 
of CD3 positive cells remains unclear.    
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Figure 4.4 PGD2 controls the clearance of peritoneal-resident lymphocytes. Figures A-E  In 
response to inflammatory stimuli, lymphocytes in the peritoneum disappear between 6-24 h. 
However, lymphocyte numbers in hPGD2S knockouts at 6 h (filled bars) were found to be 
equivalent to that present in the naïve cavity of wild types (open bars) suggesting a role for either 
PGD2 and/or15d-PGJ2 in the initial clearance of lymphocytes. Figure F Adding back BW245C (DP1 
receptor agonist) to hPGD2S knockouts caused a reduction in B cells. Figure G FACS analysis of 
leukocytes following trypsinisation of the peritoneal cavity at 4h following zymosan injection 
(bottom panel). n = 8 animals per group. Data expressed as mean ± SEM.    
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4.3.4 Resolution phase lymphocytes are protective against super-infection 
To examine the role of lymphocytes in acute inflammation, zymosan was injected into the 
peritoneal cavity of lymphocyte-deficient RAG1-/- (recombination activation gene -2) mice. 
RAG proteins initiate the recombination process of the gene elements encoding the variable (V), 
diversity (D), and joining (J) segments. This leads to the generation of a diverse repertoire of 
antigen-speciﬁc receptors at the surface of T and B lymphocytes. RAG1-/- mice therefore lack T 
and B cells due to an early block of lymphocyte development and proliferation but have natural 
killer (NK) cells. In RAG1-/- mice inflammation at onset was greatly exaggerated, being twice 
that in wild types (Figure 4.5A) with the principle cell type being PMNs (Figure 4.5B). This 
exaggerated response in RAG1 knockouts was associated with decreased exudate IL-10 and 
elevated TNFα levels (Figure 4.5C). However, despite an elevated inflammatory response in 
knockouts, inflammation in wild types and RAG1-/- resolved uniformly from 24 h onwards 
(Figures 4.5A and B) suggesting that lymphocytes have no role in switching off acute 
inflammation. As demonstrated above the phenotype of lymphocytes in the peritoneum during 
resolution differs slightly from that in the naïve cavity. Therefore pursuing the idea that 
lymphocyte may protect against secondary infection, in a second experiment RAG1-/- and wild 
type mice were injected with a sub-lethal dose of GBS 48 h after zymosan injection. Thus, live 
bacteria were introduced into the inflamed cavity as inflammation resolved and its effects 
determined 24 h later (Figure 4.5D). Injecting GBS into RAG1-/- mice 48 h after receiving 
zymosan showed an approximate doubling of inflammatory cell accumulation compared with 
wild types treated in the same way (Figure 4.5D). This resulted in a lower bacterial load in the 
plasma of GBS-treated RAG1-/- (Figure 4.5E) but substantially accelerated mortality (Figure 
4.5F). Furthermore, wild types mice that received zymosan followed by bacteria displayed fewer 
signs of illness compared to those that received GBS alone, which exhibited 50% mortality by 24 
h with the remaining animals dying by 48 h. Results from these studies suggest that lymphocytes 
modulate host responses to injury/infection but are not required to bring about resolution i.e. 
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clear PMNs and macrophages from inflamed sites. In terms of controlling initial leukocyte 
trafficking in response to non-specific stimuli, protection is conferred by resident lymphocytes 
with resistance to secondary infection being exerted by repopulating, phenotypically different 
resolution-phase lymphocytes.  
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Figure 4.5 Zymosan peritonitis in lymphocyte-deplete RAG1-/- mice. Figures A-B Inflammation in 
RAG2-/- compared to wild type.  C- Imbalance of IL-10 versus TNF.  D- Cell numbers when RAG2-/- 
and wild types were injected with GBS during resolution (48 h after zymosan injection). E- 
Reduced bacterial colonisation in plasma but increased mortality in RAG1-/- mice (F). n = 6-8 
animals per group with experiments repeated on two separate occasions to confirm original 
findings; *, P≤0.05; **, P≤0.01, as determined by ANOVA, followed by Bonferroni test, with data 
expressed as mean ± SEM.    
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4.3.5 Deficiency of repopulating lymphocytes in non-resolving chronic granulomatous 
disease  
Finally, the relevance of these findings to human inflammatory diseases was determined by 
examining the role of lymphocytes in gp91phox knockout mice, an experimental model of human 
chronic granulomatous disease caused by defects in the phagocyte respiratory burst oxidase, 
which generates microbicidal superoxide (Segal, Geisow et al. 1981; Dinauer 1993). Hence, 
chronic granulomatous disease patients lack antimicrobial capacity and the ability to combat 
bacterial and fungal infections. Moreover, this defect is associated with inflammatory 
granulomas in lung, liver and skin, which, in some instances may arise from sterile stimuli 
suggesting that their formation may be due to incomplete degradation of inflammatory debris 
and/or impaired resolution of inflammation (Gallin, Buescher et al. 1983; van de Loo, Bennink et 
al. 2003). gp91phox knockouts were injected i.p. with sterile zymosan and found to have elevated 
leukocyte numbers compared to controls, with inflammation failing to resolve (Figure 4.6A). 
Fewer lymphocytes were found at 48 h–96 h in gp91phox knockout mice, the time-frame of 
resolution and lymphocytes repopulation in wild types (Figure 4.6B). This was confirmed on 
FACS analysis (Figure 4.6C).  Lymphocytes obtained from the resolution phase (72 h) of normal 
strain-matched wild type controls and therefore comprising B1 cells, NK and gamma/delta T 
cells as well as CD4+/CD25+ cells were transferred back to gp91phox knockouts (72 h) and 
challenged with LPS. Inflammation was reduced in knockouts that received resolution-phase 
lymphocytes compared to gp91phox mice alone, Figure 4.6D. These results in a chronic 
inflammatory model, suggest that during on going, non-resolving inflammation the absence of 
lymphocytes may account for susceptibility to super-infection and the associated hyper-
inflammatory response. 
  
 126 
 
Figure 4.6 The absence of repopulating lymphocytes during non-resolving inflammation. Figure A- 
Zymosan was injected into the peritoneal cavity of gp91phox knockout mice, which, when compared 
to controls showed a more aggressive inflammatory response that failed to resolve. B- The 
lymphocyte number in gp91phox and wild type mice during the course of peritonitis. Figure C- 
FACS analysis of cell types present during resolution gp91phox knockout and wild type mice. D- 
Effect of adoptive transfer of lymphocytes obtained from the resolution phase (72 h) into the 
peritoneal cavity of gp91phox knockouts (72 h) and subsequently challenged, intraperitoneally, with 
LPS. *, P≤0.05; **, P≤0.01 as determined by ANOVA, followed by Bonferroni test, with data 
expressed as mean ± SEM. 
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4.3.6 Conclusions 
1. In the naïve mouse peritoneal cavity, lymphocytes constitute half the cell population of 
which approximately 70-80% are B lymphocytes, of B1 subset. 
 
2. In both human and murine peritonitis, peak inflammation is characterized by peak influx 
of PMNs and depressed lymphocyte numbers, which then re-populate the peritoneal 
cavity during resolution. 
3. Exacerbation of murine peritonitis with higher doses of zymosan lead to persistently 
decreased number of lymphocytes. This is also mirrored in sterile peritonitis in a murine 
model of CGD, NADPH oxidase knockouts (gp91phox knockout mice). 
4. Both B and T lymphocytes re-populate during the resolution phase. 
5. During resolution 
a. There is a greater number of CD4+CD25+ and gamma-delta T cells as well as NK 
cells 
b. CD5+ B-1 cells which comprise of over 80% of naïve B cells, re-populate the 
resolving peritoneal cavity with greater MAC-1 expression 
6. The disappearance of B cells during peak inflammation is PGD2 receptor DP-1 dependent 
7. Re-populating lymphocytes protect the resolving peritoneal cavity against secondary 
infection based on the exaggerated inflammation and lethality when lymphocyte deplete 
RAG1-/- mice were challenged with GBS during resolution from zymosan peritonitis 
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4.4 Discussion 
The evidence presented shows that lymphocytes play a pivotal role in controlling the onset of 
innate immune-mediated inflammation as demonstrated by the exaggerated response to zymosan 
in lymphocyte deficient RAG1-/- mice by regulating cytokine synthesis. It also has an important 
role in host susceptibility to secondary infection. Analysis of lymphocyte subsets in the naïve 
peritoneal cavity of mice revealed that B cells constitute about 70-80% of the total lymphocyte 
population of which the majority have a B1 phenotype with the remainder being B2 cells. CD3 
positive cells as well as NK and gamma/delta cells make up the remaining 20% of lymphocytes. 
This profile differs to that found at resolution, which comprises more innate-type lymphocytes 
and B1 cells expressing MAC-1. It was no clear which lymphocyte or combination of 
lymphocytes bestowed protection at onset or at resolution. In the previous chapter peritoneal 
CD3 T cells and in particular B220 positive B cells were found to elaborate high levels of IL-10 
in a DP1 dependent manner. This may explain the reduction in IL-10 in lymphocyte deficient 
RAG1-/- mice and subsequent increase in PMN influx in these animals. Thus, given the relative 
proportion of T cells versus B1 cells in the inflamed cavity and the ability of B cells to 
synthesize comparatively high levels of IL-10 we suspect that B lymphocytes may one of the 
predominant cell types modulating acute inflammatory responses to non-specific stimuli.   
 
As PMNs begin to accumulate in response to zymosan, B cells disappeared in a PGD2-dependent 
manner as there was equivalent numbers of B cells in the inflamed cavity of hPGD2S-/- at 6h as 
there was in the naïve cavity of wild types. This accumulation of B cells in hPGD2S knockouts 
was reversed by BW245C, a DP1 receptor agonist with DP2 (CRTH2) playing no role in this 
setting. While the mechanism of PGD2-dependent B cell clearance is unknown, a TLR-mediated 
transient down-regulation of integrins and CD9 on B1 cells was shown to be required for 
detachment of these cells from local peritoneal matrix and their subsequent efflux from the 
inflamed cavity (Ha, Tsuji et al. 2006). Furthermore B1 cell renewal is dependent on IL-5 and 
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recent work has identified a new lymphoid subset called fat associated lymphoid cluster (FALC) 
that stimulate B1 cell proliferation by producing IL-5. Whether BW245C alters CD9 expression 
needs further investigation but given that B cells disappear concomitantly with PGD2 synthesis, 
it is possible that DP1 activation may play a role in regulating this pathway of B1 cell 
detachment and efflux. The fate of CD3 cells, on the other hand, is less clear. While their 
attachment to the peritoneal lining can certainly be excluded, there is the possibility that these 
cells may die locally by programmed cell death in response to 15d-PGJ2, which is synthesized 
concomitant with their disappearance (Chapter 3, Figure 3.3B) and a potent inducer of 
lymphocyte apoptosis (Chen, Shen et al. 2005). However, future detailed work is required to 
definitively identify whether they die locally or clear via draining lymphatics. Thus PGD2 exerts 
a dual role on resident B cells at least – regulating their inflammatory cytokine release as well as 
their efflux from the inflamed peritoneal cavity. 
 
The mechanism by which lymphocytes exert their protective effects in these experiments is 
unclear. Certainly, there is a cytokine imbalance favouring pro-inflammatory TNFα but reduced 
IL-10 in RAGs. This may help explain the enhanced influx of PMNs compared to wild types in 
T/B cells deficient mice. Indeed, in chapter 3, I have shown that both T and B lymphocyte are 
capable of elaborating inflammatory cytokines, which, in the inflamed peritoneum at least, serve 
to limit PMN influx. However, in addition to cytokines/chemokines, cell adhesion molecules 
facilitate PMN adhesion and accumulation at sites of inflammation. The protective effect of 
resolution phase lymphocytes demonstrated in this study is in contrast to the finding of the 
presence of effector memory T cells in peritoneal dialysis patients with increased expression of 
pro-inflammatory chemokine receptor CCR5 (Roberts, Baird et al. 2009). Furthermore, there is 
evidence showing that lymphocytes trigger cell adhesion molecule expression. For instance, 
intracellular adhesion molecule 1 expression in Plasmodium-infected mice is reduced in the 
brain but not the lung of RAG1-/- mice while P-selectin expression is attenuated in both organs in 
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these animals (Bauer, Van Der Heyde et al. 2002). Equally, T cells were shown to enhance the 
expression of TNFα-triggered endothelial cell adhesion molecule expression, with these effects 
varying between vascular beds (Horie, Chervenak et al. 1997). However in this study the RAG2 
mice are sterile and do not possess immunological memory as opposed to dialysis patients who 
develop recurrent infections which may explain the difference. Furthermore, it is important to 
highlight the different profile of lymphocytes present in the peritoneum (B1, B2 and small 
numbers of CD4/CD25 cells) that exert a predominantly protective effect in both the naïve and 
post-resolution state.  
 
The trigger for lymphocyte repopulation is unclear but critical determinants of resolution such as 
PMN apoptosis or signals released by macrophages during phagocytosis of apoptotic leukocytes 
may play a central role. However, we have shown previously that inducible cyclooxygenase is 
expressed during and is essential for the resolution of acute inflammation (Gilroy, Colville-Nash 
et al. 1999; Gilroy, Colville-Nash et al. 2003; Gilroy, Newson et al. 2004), while others have 
reported that lipoxygenase-lipoxygenase interaction products of arachidonic as well as 
eicosapentaenoic and docosahexanoic acid dampen the severity of inflammatory onset and 
trigger resolution (Ariel, Fredman et al. 2006; Schwab and Serhan 2006; Schwab, Chiang et al. 
2007). Taking a closer look at whether cyclooxygenase or lipoxygenase play a role in 
lymphocyte re-population, we found that not only is COX 2 expressed during the resolution 
phase of zymosan-induced peritonitis but that its inhibition with either NS-398 of the non-
selective COX inhibitor indomethacin, impairs lymphocyte repopulation, in particular CD3 
positive cells.  
 
Comparing repopulating lymphocytes with those in the naïve cavity revealed more NK cells, 
gamma/delta T cells and CD4+/CD25+ cells in addition to B1 cells with higher Mac-1 labelling 
than that found at onset. The functional relevance of increased Mac-1 expression on resolving B1 
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cells is not apparent at this stage but may reflect a state of differentiation/activation or a specific 
requirement for migration back to the resolved peritoneum. However, re-populating lymphocytes 
have no role in actively bringing about resolution but protect against super-infection. In these 
experiments of innate inflammation, GBS was given into the resolving peritoneal cavities of wild 
types as well as RAG1-/- mice. Interestingly, the degree of inflammation in wild types that 
received zymosan followed by GBS was not significantly greater than the level of inflammation 
in resolving wild types not given GBS. In contrast, the degree of inflammation in RAG1-/- mice 
that received zymosan followed by GBS was almost twice that of inoculated wild types. This 
suggests that resolution-phase lymphocytes confer protection against secondary infection. This 
was confirmed by injecting live bacteria to RAG1-/- mice undergoing resolution, which 
subsequently died faster than wild types treated in the same manner (Figure 4.5F). Interestingly, 
in lymphocyte deficient RAG1-/- when acute lung injury with LPS was studied, peak 
inflammation was no different compared to wild type but resolution was delayed, which was 
normalized with CD4+CD25+Foxp3+ cells. Therefore, in order to work out the critical 
determinants that confer protection from secondary infection adoptive transfer experiments need 
to be carried out with subpopulation of lymphocytes i.e. B1, B2, and CD4+CD25+. It is also 
unknown why the proportion and profile of repopulating lymphocytes is different to that at onset. 
Perhaps as resolving tissues are physiologically altered as a consequence of the inflammatory 
event they underwent, host defence mechanisms need to be fundamentally different to guard 
against super-infection by recruiting more protective lymphocytes. On this theme, it is not really 
understood at which point of the inflammatory cascade acutely inflamed tissues revert back to 
their original state. Certainly, a population of macrophages (about 1x106) were found to linger 
for at least three weeks after zymosan peritonitis apparently resolved peritoneal cavity, 
supporting the idea that although the original response was acute and transitory in terms of PMN 
influx and efflux, its effects may be longer lasting than originally believed. This may explain a 
different profile and greater proportion of lymphocytes that assist in modulating future 
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inflammatory events. This may explain why inflammation in the resolving phase conferred 
greater protection against GBS lethality than un-inflamed or naïve mice (Figure 4.5D and F). 
 
Taking these findings to a more clinically relevant setting, it became clear that unlike wild type 
mice, there was a deficit of repopulating lymphocytes in non-resolving gp91phox knockouts mice 
bearing zymosan-induced peritonitis. Replenishing gp91phox knockouts with resolution-phase 
lymphocytes taken from strain-matched controls and then challenging animals with LPS 
conferred protection compared to sham operated gp91phox knockouts mice. Data from this study 
confirms that not only does lymphocyte repopulation fail to occur in non-resolving inflammation 
but that resolving-phase lymphocytes protect against exaggerated inflammatory responses to 
super-infection (Figures 4.5D and 4.6D). On this note, defects in innate lymphocyte functioning 
have been suggested to lead to secondary infections associated with burn injury (Schneider, 
Glenn et al. 2007) while increased lymphocyte apoptosis contributes to the pathogenesis of 
sepsis (Hotchkiss, Tinsley et al. 1999; Hotchkiss, Chang et al. 2000) underlining the crucial role 
lymphocytes play in host defence against non-specific injury. Moreover, as NK cells were 
originally described for their ability to lyse tumour cells (Moretta, Bottino et al. 2002) and 
gamma/delta T cells have well-known tumour surveillance properties (Carding and Egan 2002; 
Hayday and Tigelaar 2003), their absence from sites of non-resolving inflammation may be one 
of the predisposing factors to the development of inflammation-related cancer (Lin and Karin 
2007). Thus, one of the hazards of on going acute inflammation and consequently failed 
lymphocyte repopulation may be increased susceptibility super-infection and even cancer as a 
result of lymphocyte apoptosis, lymphocyte immuno-paralysis or as presented here, a failure of 
protective lymphocytes to repopulate post resolution.  
  
In summary, this study demonstrates a biphasic role for lymphocytes during innate immune-
mediated inflammation, summarized in Figure 4.7. The first phase controls PMN trafficking with 
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lymphocytes then vacating the peritoneal cavity in response to PGD2 activating its DP1 receptor. 
The second phase is characterized by lymphocyte repopulation occurring after inflammation 
begins to resolve in a different proportion and profile to that of the naïve state. Importantly, 
repopulating lymphocytes have no role in bringing about resolution but protect against secondary 
infection.  
 
 
Figure 4.7 A summary of the scheme of events that occurs in acute inflammation with reference to 
lymphocyte trafficking. As inflammation ensues resident lymphocytes begin to disappear, with B1 
cells clearing via draining lymphatics with the fate of CD3 cells remaining unclear at this stage. 
Once inflammation begins to resolve lymphocytes re-populate the site of injury in a profile different 
to that in the naïve state.    
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Chapter 5 The profile of adenosine and its metabolites in peritoneal 
inflammation of gp91phox-/- mice, a model of non resolving inflammation  
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5.1 Introduction 
Failed resolution is hypothesised to lead to tissue injury and chronic inflammation (Lawrence 
and Gilroy 2007). This is potentially derived from dysregulated resolution pathways of which 
CGD is a good example. This is an inherited immunodeficiency syndrome caused by a defect in 
the oxygen metabolic-burst machinery resulting in the inability to neutralise infection leading to 
persistent and recurrent inflammatory responses and granulomatous tissue formation (Segal 
1996). Activity of NADPH oxidase system (gp91phox, p22phox, p47phox and p67phox) is either 
absent or dysregulated in these patients with the most common being X-linked CGD (~65%) 
with defects in the gene encoding gp91phox. Fortunately, for the purpose of understanding the 
aetiology of CGD, gp91phox deficient mice display all the hallmarks of the human condition in 
response to infection (Pollock, Williams et al. 1995). Interestingly, there are reports showing that 
inflammation in CGD mice is also prolonged and dysregulated in response to sterile stimuli, 
suggesting potential irregularities in endogenous anti-inflammatory and/or pro-resolution 
pathways (Morgenstern, Gifford et al. 1997; van de Loo, Bennink et al. 2003). I carried out a 
series of studies in gp91phox-/- mice and found that of the factors known to control resolution, few 
appeared to be consistently dysregulated with the exception of adenosine and cAMP, levels of 
which are significantly lower in experimental CGD compared to wild types.  
 
Under physiological conditions, adenosine is continuously formed both intra and extracellularly. 
The intracellular production is mediated either by 5'-nucleotidase, which dephosphorylates AMP 
or by hydrolysis of S-adenosyl-homocysteine (Fredholm, AP et al. 2001). Adenosine generated 
within cells is transported into the extracellular compartment via bi-directional transporters 
through facilitated diffusion that efficiently equilibrates intra and extracellular levels of 
adenosine. Following trauma, there is a decrease of intracellular ATP, accompanied by an 
accumulation of 5'-AMP and subsequently adenosine by the above pathways, which may be 
sequentially metabolized to inosine, hypoxanthine and xanthine. Expressed on cells of the 
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hematopoietic system, adenosine receptors (A1, A2A, A2B, A3) belong to the family of G-protein-
coupled heptahelical transmembrane receptors, which either stimulate (Gs) or inhibit (Gi) 
adenylyl cyclase, the enzyme that catalyzes the formation of cAMP (Fredholm, AP et al. 2001). 
Adenosine A1 and A3 receptors are high and low affinity receptors for adenosine, respectively, 
with both being inhibitors of adenylyl cyclase. High-affinity A2A and low-affinity A2B receptors, 
on the other hand, activate adenylyl cyclase, thereby increasing intracellular levels of cAMP, 
resulting in potent immune-suppression and regulation of inflammatory leukocyte trafficking. 
Besides controlling adenylyl cyclase, adenosine receptors are also coupled by distinct G-proteins 
to several other effector systems, including calcium and potassium channels, phospholipase C, 
D, A2, cGMP, phosphodiesterases, and mitogen-activated protein kinases that modulate different 
cell functions. Thus, adenosine, released after tissue injury or low oxygen tension associated 
with inflammation, has been regarded by some to act as a first line sensor of immune damage 
where it prevents further damage by inhibiting activated immune cells with its immune-
suppression mediated by A2A receptor elevation of cAMP (Hasko and Cronstein 2004; Sitkovsky 
and Lukashev 2005). 
 
In this chapter, the biphasic synthesis of both adenosine and cAMP, first at the traditional early 
onset phase of acute inflammation and again during resolution was demonstrated, with synthesis 
of these immunosuppressive agents being significantly lower in CGD (gp91phox-/-) mice 
associated with a severe and prolonged innate immune response to a sterile stimuli. We also 
show that hyper-inflammation in gp91phox-/- mice can be rescued by A2A receptor activation as 
defined by reduction in inflammatory leukocytes. Importantly, A2A receptor activation in 
gp91phox-/- mice did not bring about resolution as this drug strategy was not associated with 
innate-type lymphocyte repopulation that is typical of events that occur during normal resolution 
in wild type leading to tissue homeostasis.  
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5.2 Material and Methods 
The detailed material and methods are described in chapter 2. Peritonitis was induced in 
gp91phox-/- and wild type mice with intra-peritoneal zymosan 1mg following pre-treatment with 
the A2A receptor agonist CGS 21680 (2 mg/kg) with/without ZM241385 (2 mg/kg, A2A receptor 
antagonist) 30 min previously. The peritoneal cavity was lavaged at 4 h and cell number counted 
using a haemocytometer. For experiments in the resolution phase, inflammation was firstly 
induced with zymosan followed by CGS 21680 or vehicle (DMSO) at 24 and 36 h. The 
peritoneal cavity was lavaged at 48 h following zymosan. Caffeine as well as its stable analogue, 
8-(3-chlorostyryl)-caffeine (CSC) was dosed at 3 mg/kg. For eicasonoid analysis, the samples 
stored at -200C were thawed at room temperature and acidified to pH 3. Samples were extracted 
using C18 columns (Waters). For PGD2, samples were then treated with methoxylamine 
hydrochloride (MOX HCL) and the resulting stable PGD2-MOX measured by EIA. PGE2 was 
measured by EIA (Cayman Chemicals) while lipoxin A4 was quantified by ELISA (Neogen 
Europe, Ayr, UK). Proteins in exudates were removed by ultrafiltration (30,000 Da cut-off). 
Purine concentrations in samples were measured by HPLC carried out in the laboratory of 
Professor Edwin Jackson at University of Pittsburgh Medical Centre, Pittsburgh, USA. 
Cytokines were measured by ELISA as per manufacturer instructions. Leukocytes were 
incubated with antibodies for 30 min to either CD3/CD19 (Abd Serotec, Oxford UK), B cells 
(Ly220, Abd Serotec, Oxford UK), GR1 (BD Pharmingen, UK) or F4/80 (Caltag laboratories, 
CA, USA) using respective isotype antibodies as controls (Abd Serotec, Oxford UK) and 
compensated as appropriate for dual labelling. For apoptosis, cells were incubated with annexin 
V/PI (Becton Dickinson) and analysed on Becton Dickinson FACScalibur with data analysed by 
Cellquest.   
 
 138 
5.3 Results 
5.3.1 Exaggerated inflammatory response in gp91phox-/- mice 
Zymosan injection into the mouse peritoneal cavity of gp91phox-/- mice and wild type controls 
resulted in an exaggerated inflammation (Chapter 4, Figure 4.6A) with significantly lower 
lymphocyte numbers (Chapter 4, Figure 4.6B). In the acute phase there was a significant excess 
of PMNs (Ly6G positive cells) in knockout animals with numbers declining up to 96 h (Figure 
5.1A). F4/80 positive macrophage numbers were similarly increased at onset in knockouts with 
levels remaining elevated throughout the entire response (Figure 5.1B), underlining the non-
resolving nature of inflammation that is characteristic of CGD. As there was little difference in 
leukocyte apoptotic rates as determined by annexin V/PI labelling between both animals, Figure 
5.1C, failure of resolution in gp91phox-/-  mice most likely resulted from continual influx and/or 
failed clearance of inflammatory leukocytes.  
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Figure 5.1 Zymosan induced peritonitis in gp91phox-/- and wild type C57black VI mice. Figures A -B- 
Inflammation is more severe and fails to resolve in gp91phox-/- mice with more exaggerated influx of 
Ly6G-positive PMNs in gp91phox-/- mice along with F4/80-positive monocyte-derived. 
 
5.3.2 Reduced synthesis of purines and cAMP in gp91phox-/- mice 
The exaggerated inflammatory response in CGD is explained by defects in phagocytic oxidase 
resulting in impaired bacterial killing and consequently delayed removal of the injurious agent. 
However for resolution to occur there are endogenous braking systems that counter-regulate 
acute inflammation. Therefore, I screened for alterations in levels of anti-inflammatory and pro-
resolution mediators in gp91phox-/- and wild type mice bearing a zymosan-triggered peritonitis 
was studied. With the exception of PGE2 (Figure 5.2C), there was little evidence for defects in 
0 
5 
10 
15 
%
 a
po
pt
os
is
 (A
nx
V
/P
I) 
24 48 72 96 h 
k/o 
w/t 
C 
P
M
N
 (x
10
6 )
 
6 24 48 72 96 h 
0 
2.5 
5.0 
7.5 
w/t 
k/o 
6 24 48 72 96 h 
M
Ф
 (x
10
6 )
 
0 
2.5 
5.0 
7.5 
w/t 
k/o 
A B 
 140 
arachidonic acid metabolism being involved in the inflammatory profile of CGD, with no 
significant difference in PGD2 (Figure 5.2A) and Lipoxin A4 (Figure 5.2B) in gp91phox-/- and 
wild type mice with zymosan induced peritonitis. However, there was a significant reduction in 
levels of cAMP in gp91phox-/- mice compared to wild type animals (Figure 5.2D). Specifically, 
intracellular cAMP was elevated during the early onset phase of zymosan-induced peritonitis in 
wild type controls (4-6 h), waning as inflammation progressed and became elevated again post-
resolution (Figure 5.2D). In gp91phox-/- mice bearing a zymosan-triggered peritonitis, cAMP was 
significantly lower than wild types at onset and failed to show the post-resolution elevation seen 
in wild types (Figure 5.2D).  The biphasic profile of cAMP in wild type mice and significantly 
lower levels in gp91phox-/- mice was not due to PGD2, LX-A4 or PGE2 the latter which in fact was 
elevated in the knockouts. However, there was a biphasic profile of adenosine synthesis 
mirroring that of cAMP – being raised at onset and then again at resolution (Figure 5.2E). 
Adenosine showed lower levels in gp91phox-/- mice than wild types and is a well described 
immuno-modulator of acute inflammation serving to dampen PMN function and prevent 
chemical-induced collateral liver injury. Therefore these studies show a biphasic synthesis of 
adenosine and cAMP in resolving models of acute inflammation, with significantly reduced 
levels when zymosan peritonitis was induced in gp91phox-/- ,a model of CGD.  
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Figure 5.2 Arachidonic acid and adenosine metabolism in gp91phox-/- mice compared to wild types.  
Figures A-C PGD2, lipoxin and PGE2 were determined and found not to show a consistent 
reduction in gp91phox-/- mice compared to wild types. D- cAMP was elevated at the early onset phase 
of a murine peritonitis and then again at resolution in wild type animals, but was significantly 
lower in gp91phox-/- mice at both phases. E- Adenosine measured following zymosan peritonitis with 
levels being reduced in gp91phox-/- mice (black columns) compared to wild types (empty columns). 
n = 6–10 animals per group. P≤0.01; **, P≤0.001, as determined by ANOVA, followed by 
Bonferroni test, with data expressed as mean ± SEM. 
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5.3.3 Adenosine and cAMP profiles in human resolving peritonitis 
In the previous chapter, when the inflammatory cell profile of CKD stage 5 patients on 
peritoneal dialysis who developed peritonitis were studied, the cell numbers were greatest at the 
start which was PMN rich (day 1) and resolution by day 5 with lymphocyte re-population 
(Chapter 4, Figure 4.1A-C).  cAMP (Figure 5.3A) as well as adenosine, (Figure 5.3B) were 
measured in these samples and the levels were elevated as inflammation resolved. While these 
results corroborate that found in mice, we have no data on the very early onset (~ 6 h) phase in 
humans to assess whether the adenosine and cAMP in human inflammation mirror the biphasic 
profile found in murine peritonitis. However, as in rodents, levels of cAMP and adenosine were 
elevated as inflammation resolved.  
 
 
 
Figure 5.3 Expression of adenosine and cAMP concomitant with resolution of human peritonitis. 
Figures A-B- Analysis of cell-free exudates revealed a peak in cAMP and adenosine as 
inflammation resolved in peritonitis samples obtained from patients undergoing chronic 
ambulatory peritoneal dialysis and who experienced transient infection that resolved within a few 
days. n= 6-8 patients with data expressed as mean ± SEM. 
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5.3.4 Adenosine, via A2A is anti-inflammatory and not resolution-toxic  
Adenosine exerts its action through four receptors, A1, A2 (A2A and A2B) and A3. The A2A 
receptor has received the most attention, as its activation leads to the up-regulation of cAMP and 
thereby mediating its anti-inflammatory effect. In rats bearing a carrageenin-induced pleurisy, 
when rolipram, a PDE4 inhibitor (elevator of cAMP) as well as CGS 21680, a specific A2A 
receptor agonist were administered 30 min prior to carrageenin injection, it dampened leukocyte 
trafficking to the inflamed cavity at onset i.e. 4 h (Figure 5.4A). This was associated with an 
expected rise in cAMP, Figure 5.4B. Therefore, I proceeded to investigate this in the mouse 
zymosan peritonitis model. At 4 h following i.p. zymosan, CGS 21680 dampened inflammation 
in an A2A receptor dependent manner as co-administration of the receptor antagonist ZM 241385 
reversed the anti-inflammatory effect (Figure 5.4C). This was associated with a significant 
increase in anti-inflammatory IL-10 (Figure 5.4D). Other drugs, including theophylline as well 
as beverages are known to alter cAMP signalling and therefore may unwittingly affect 
inflammation depending on its effect of levels. A single cup of coffee, for instance, contains 
about 100 mg of caffeine implying that an average person drinking one cup of coffee per day 
will ingest caffeine at 1.5mg/kg. To investigate whether caffeine, a methylxanthine with 
antagonistic effects on the A2A receptor (Fredholm, Battig et al. 1999) affects acute 
inflammation, caffeine as well as its stable analogue, 8-(3-chlorostyryl)-caffeine (CSC) at 3 
mg/kg were administered 30 min before i.p. zymosan injection and found that both worsened 
inflammation possibly by decreasing protective IL-10 levels (Figures 5.4E and F). Using a 
continual pharmacological dosing regimen, mice were administered not only 30 min before 
zymosan injection but were also given caffeine and CSC again at 12 h and 18 h after zymosan 
and their effects assessed at 24 h. CGS 21680 maintained a dampening of acute inflammation 
without interfering with resolution (Figure 5.4G). On the other hand, caffeine at doses 
representative of reasonable caffeine daily intake as well as its analogue, CSC, maintained their 
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pro-inflammatory effects (Figures 5.4G). Taking the doses of caffeine up to 10 and 30 mg/kg 
resulted in a loss of pro-inflammatory effects. 
 
Therefore from these experiments, A2A agonists can be seen to exert anti-inflammatory effects 
not only during the early onset phase of acute inflammation, the phase traditionally tested 
experimentally for novel anti-inflammatories, but, importantly do not appear to interfere with 
pro-resolution pathways.  
  
 145 
 
Figure 5.4 Investigation of Adenosine, via A2A being anti-inflammatory and not resolution-toxic. 
Figures A-B- Effect of selective A2A agonist CGS 21680 as well as the PDE4 inhibitor rolipram, 
which increases cAMP were dosed at 10 and 30 mg/kg respectively, to rats bearing a carrageenin-
induced pleurisy. Figure C- A2A receptor activation in a zymosan-induced peritonitis and the effects 
of CGS 21680 with or without ZM241385 (A2A receptor antagonist) determined 4 h later revealing, 
again, that (C) CGS 21680 is anti-inflammatory in this model concomitant with an elevation in anti-
inflammatory IL-10 (D). Figures 4E-G the A2A receptor antagonist (E) caffeine and its (F) stable 
analogue, CSC worsened inflammation and depressed IL-10, respectively, when administered in a 
similar manner to receptor agonists. A2A receptor activation maintained its anti-inflammatory 
effects and did not interfere with resolution pathways as injection of (G) CGS 21680, given 30mins 
before zymosan and again 12 h and 18 h later continued to dampen inflammation while caffeine 
and its analogue worsened the response as determined at 24 h.  n = 8 animals per group; *, P≤  0.05; 
**, P≤0.01, *** P<0.001 as determined by ANOVA, followed by Bonferroni test. 
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5.3.5 Anti inflammatory but not pro-resolution effect of adenosine via A2A in gp91phox-/- 
mice  
Being anti-inflammatory is not the same as possessing pro-resolution properties (Gilroy, 
Lawrence et al. 2004). The objective of this final set of experiments was to determine whether 
drugs that signal through A2A and raise cAMP are able to rescue the hyper-inflammatory 
phenotype typical of gp91phox-/- mice and importantly, whether they bring about resolution of 
peritoneal inflammation. Thus, CGS 21680 was dosed orally 30 min before zymosan 
administration to gp91phox-/- and wild types with inflammation assessed 4 h later. Data revealed 
that leukocyte influx was greater in knockouts than wild types and that A2A receptor activation in 
knockouts reversed inflammation back to levels seen in drug-treated wild types (Figure 5.5A), 
with lowering of PMN numbers, Figure 5.5B. The A2A receptor agonist, CGS 21680 was then 
administered to  gp91phox-/- mice and controls during the equivalent of resolution in wild types. In 
wild types, CGS 21680, given at 24 h and again at 36 h after established inflammation had no 
effect on leukocyte numbers at 48 h i.e. CGS 21680 was neither anti-inflammatory nor 
resolution-toxic in normal animals. An identical dosing regime in knockouts revealed that CGS 
21680 was not only anti-inflammatory in these animals but that it lowered inflammation below 
that of controls (Figure 5.5C) concomitant with an elevation of cAMP (Figure 5.5D). However 
this anti-inflammatory effect was not associated with lymphocyte re-population which is typical 
of innate resolution as described in the previous chapter. 
  
 147 
 
Figure 5.5 Demonstration of Adenosine, via A2A being anti-inflammatory but not pro-resolution in 
gp91phox-/- mice. Figure A-B- Wild type and gp91phox-/- mice were injected with zymosan i.p. when 
pre-treated with A2A agonist CGS 21680. CGS does rescue the hyper-inflammatory profile of 
knockout mice by the reduction of PMN numbers. Figure C-D Both administered to both animal 
types therapeutically i.e. 24 h and 36 h after zymosan and its effects on resolution and cAMP 
determined at 48 h. However there was an absence of lymphocyte re-population. n = 6 animals per 
group;  *, P≤  0.05; **, P≤0.01, as determined by ANOVA, followed by Bonferroni test, with data 
expressed as mean ± SEM. 
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5.3.6 Conclusions 
1. In human and murine peritonitis both adenosine and cAMP demonstrate a biphasic 
response with levels raised at onset and during resolution of inflammation. 
2. Peritoneal inflammation in NADPH gp91phox-/- mice was exaggerated compared to wild 
type with peak increase in PMN numbers and failure of resolution with persistent 
macrophage numbers 
3. PGD2 a product of the cyclooxygenase pathway of arachidonic acid metabolism is not 
involved in the increased inflammation or impaired resolution in this model of CGD 
4. Both adenosine and cAMP were decreased in NADPH gp91phox-/- mice in zymosan 
peritonitis. 
5. The acute hyper-inflammatory phenotype of NADPH gp91phox-/- mice was reversed by the 
A2A receptor agonist CGS 21680 
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5.4 Discussion 
Here we report an immediate increase in adenosine and cAMP at the early onset phase of acute 
inflammation that wanes as the response progresses only to increase again as inflammation 
resolves with levels being significantly lower in experimental CGD (gp91phox-/- mice). Whether 
this is a direct result of an interaction between NADPH oxidase systems and adenosine synthesis 
is unlikely as levels of cAMP in isolated cells from CDG patients were similar, on a cell-for-cell 
basis, to normal healthy volunteers. The persistence of inflammation in CGD is either due to an 
inherent defect in counter-regulatory/pro-resolution pathways or more likely the failure to clear 
inflammatory stimuli resulting in a persistent, almost frustrated innate immune response that 
consequently nullifies endogenous protective pathways. As emphasised previously one of the 
most critical determinants for resolution of inflammation is clearance of the inflammatory 
stimulus (Gilroy, Lawrence et al. 2004; Serhan and Savill 2005). CGD is an example of where 
defects in clearance may be one of the primary causes of exacerbated and prolonged responses. 
Certainly, PMNs from CGD patients have impaired phagocytosis of immune-complexes while 
CGD macrophages are equally defective in their clearance of apoptotic PMNs (Brown, Goldblatt 
et al. 2003). Equally, the formation of granulomatous synovitis in response to intra-articular 
zymosan injection in NADPH oxidase-deficient mice was suggested to result from incomplete 
zymosan clearance from the joint due to impaired phagocytosis (van de Loo, Bennink et al. 
2003). This, therefore, suggests that dysregulation in cAMP and adenosine is secondary to that of 
an overwhelming inflammatory event, whose pro-inflammatory signals deactivates or overrides 
endogenous anti-inflammatory and/or pro-resolution pathways. 
 
From the above argument it should not be assumed that all endogenous protective pathways are 
depressed during CGD.  Among some of the signals that counter-balance inflammatory onset 
and/or trigger resolution, neither PGD2 nor native lipoxin A4 levels were statistically different in 
gp91phox-/- mice compared to wild types at onset with the exception of PGD2, which showed a 
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trend towards a reduction in knockouts as inflammation resolved. That notwithstanding, data 
presented here shows a more consistent dysregulation in the synthesis of adenosine/cAMP in 
gp91phox-/- mice in response to sterile zymosan. I went on to investigate and show that A2A 
receptor activation rescues the hyper-inflammatory response in gp91phox-/- mice without 
subverting resolution in wild type animals. This latter point is important as existing anti-
inflammatories, NSAIDS for instance, while being protective by virtue of their ability to dampen 
the early onset phase of acute inflammation, delay resolution and prolong inflammation (Gilroy, 
Colville-Nash et al. 1999). A2A receptor activation, on the other hand, is anti-inflammatory 
without being resolution-toxic thereby displaying broader pharmacological flexibility and 
potentially fewer side effects in terms of prolonging inflammation. However, these data are 
counter-intuitive based on current understanding of cAMP in inflammatory leukocyte longevity 
and clearance as derived from in vitro studies. For instance, elevating cAMP in PMNs delays 
their apoptosis (Martin, Dransfield et al. 2001) while raising cAMP in monocyte-derived 
macrophages impairs their phagocytic capacity (Rossi, McCutcheon et al. 1998)  suggesting that 
activating A2A during inflammation and consequently elevating cAMP would lengthen the life 
span of PMN, impair their clearance and prolong inflammation. Despite these data from isolated 
cell systems, in vivo-derived data (Figures 5.4 and 5.5) clearly show that A2A receptor activation 
is anti-inflammatory without being resolution-toxic, and that activation of this receptor at any 
phase of CGD dampens inflammation. This implies that CGD is in a constant state of perpetual 
acute inflammation and that A2A receptors inhibit PMN influx. The current treatment regime for 
CGD patients is antibacterial and antifungal prophylaxis (Goldblatt 2002), but for exacerbations 
of inflammatory events, perhaps concomitant A2A receptor activation would dampen associated 
inflammatory responses without subverting pro-resolution pathways. At the very least, such 
patients should avoid A2A antagonist such as caffeine (and perhaps other dietary methylxanthines 
such as theobromine) as it may nullify whatever protection residual adenosine may confer in 
CGD during inflammatory events. 
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As mentioned previously, being anti-inflammatory in pharmacological terms is distinct from 
being pro-resolution (Gilroy, Lawrence et al. 2004). This was demonstrated in the previous 
chapter because in the resolving peritoneum not only there is a disappearance of PMN via 
apoptosis and macrophages via lymphatic drainage, but also the influx of innate-type 
lymphocytes. These repopulating lymphocytes do not switch off inflammation but modulate 
post-inflammatory responses to bacteria in the context of secondary infection. The lymphocytes 
disappear in response to inflammatory stimuli not before secreting cytokines that modulate the 
severity of the inflammatory response such that in RAG1-/- mice, for instance, inflammation is 
more exaggerated in terms of PMN trafficking. Therefore, as inflammation resolves, we suspect 
that repopulating lymphocytes simply reflect the inflamed tissue reverting to its prior 
physiological state under the control of as yet un-identified endogenous factors. Interestingly, we 
found no repopulating lymphocytes in the peritoneal cavity of gp91phox-/- mice at the equivalent 
time points of resolution in wild types. The activation of A2A was certainly anti-inflammatory in 
gp91phox-/- mice by virtue of it inhibition of PMN numbers. However, when administered 
therapeutically at the equivalent phase of resolution in wild types, it did not bring about 
resolution in gp91phox-/- as defined by its inability to trigger lymphocyte repopulation. Along 
these lines, activating A2A with CGS 21680 at an earlier time point which exerted classic anti-
inflammatory effects as defined by reduced PMN numbers (Figure 5.4C and 5.5A-B) was also 
without effect on lymphocyte numbers. This suggests that other factors, besides that which signal 
cAMP are responsible for lymphocyte repopulation and reversion to homeostasis. 
 
The finding of adenosine being secreted and cAMP expressed during the early onset phase of the 
zymosan-induce peritonitis was not surprising given the established role these factors play in 
counter-regulating innate-immune mediated tissue damage (Cronstein 1994; Sitkovsky and 
Lukashev 2005). The reappearance of cAMP and adenosine again at resolution, however, is a 
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reflection of our growing understanding of resolution being an active, immuno-suppressive event 
controlled by endogenous counter-regulatory stop signals.  
 
From data presented in this study, A2A is shown to be anti-inflammatory whilst not affecting pro-
resolution pathways. However, it is well known that caffeine is a non-specific A2A receptor 
antagonist as it can antagonise A1 as well as A2A but possesses a lower affinity for the A3 
receptor (Fredholm, Battig et al. 1999). Resulting from its non-specific inhibition of A2A caffeine 
may therefore worsen inflammation and negatively affect pro-resolution pathways. Indeed, 
dosing animals with 3 mg/kg caffeine or its stable analogue just before zymosan injection 
exaggerated the inflammatory response 4 h later and also impaired resolution. This is important 
as the amount of caffeine administered to the mice was equivalent to a realistic 1-2 cups of 
coffee. Increasing doses of caffeine to unrealistic 10-30 mg/kg, as was also done in this current 
study, caused a loss of caffeine’s pro-inflammatory impact as at these levels and higher (100 
mg/kg) caffeine may become a PDE4 inhibitor resulting in cAMP elevation, as shown in vivo 
(Ohta, Lukashev et al. 2007). Given the wide consumption of caffeine in the form of coffee and 
tea at least, we need to be aware of the data presented here and by others (Ohta, Lukashev et al. 
2007) which emphasised that interfering with endogenous protective pathways such as adenosine 
at realistic levels of socially-consumed beverages will hamper innate immune responses. 
However, any attempts to increase caffeine intake in the hope of inhibiting PDE4 in order to 
dampen inflammation via cAMP elevation would require prohibitively high quantities of the 
drug. Thus, the most likely result of social caffeine consumption would be pro-inflammatory and 
resolution toxicity. Whether this leads to impaired ability to combat infections concomitant with 
prolonging resolution require further investigation. 
 
In conclusion, when the endogenous anti-inflammatory pathways were examined in CGD, both 
adenosine and its intracellular signalling molecule, cAMP, show dysregulation. The reduced 
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levels of adenosine and downstream cAMP synthesis in a murine model of CGD lead to a state 
of pro-inflammation and PMN trafficking with no apparent attempts at resolution due to the 
persistence of the inflammatory stimulus. Rescuing this hyper-inflammatory state with A2A 
agonists shows powerful anti-inflammation that does not bring about resolution as it inhibits 
PMN trafficking but does not initiate lymphocyte repopulation and reversal to homeostasis. 
Nonetheless it does suggest a potential treatment regime to dampen the hyper-innate immune 
component of CGD-associated infections.  
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Summary  
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Inflammation is fundamentally a beneficial response leading to removal of the offending factor. 
Resolution of inflammation is an active regulated process that is essential to maintain tissue 
integrity and function. Zymosan peritonitis, a resolving model of innate inflammation was an 
ideal platform to study the cellular profile during acute inflammation and the mediators that 
enable its resolution. In the naïve state, the peritoneal cavity consists of resident lymphocytes 
and macrophages. During acute inflammation, PMN influx peaked at 6-12 hours following 
zymosan, concomitant with a drop in lymphocyte numbers during this period. Resolution is 
signalled by the influx of phagocytosing macrophages and re-population with lymphocytes.  
 
Previous work in our department showed a role for COX-2 derived PGD2 and its cyclopentenone 
metabolite 15d-PGJ2 during resolution of acute inflammation in a pleurisy model. Hematopoietic 
prostaglandin D2 synthase (hPGD2S) metabolises cyclooxygenase (COX)-derived PGH2 to PGD2 
and 15-deoxyΔ12-14 PGJ2 (15d-PGJ2). Unlike COX, the role of hPGD2S in host defence remains 
ambiguous. For instance, PGD2 can be either pro- or anti-inflammatory depending on disease 
aetiology while the existence of 15d-PGJ2 and its relevance to pathophysiology remains highly 
controversial. In chapter 3, studies on hPGD2S knockout mice reveal that 15d-PGJ2 is indeed 
synthesised in self-resolving peritonitis, detected using LC-MS-MS. As metabolism of PGD2 to 
15d-PGJ2 can occur ex-vivo, by spiking inflammatory fluids in situ with deuterated PGD2, the 
detected 15d-PGJ2 was proven to be native and not deuterated 15d-PGJ2. PGD2 working on its 
DP1 receptor controls the balance of pro- versus anti-inflammatory cytokines that regulate 
leukocyte influx as well as monocyte-derived macrophage efflux from the inflamed peritoneal 
cavity to draining lymph nodes leading to resolution. Specifically, inflammation in hPGD2S 
knockouts is more severe during the onset phase arising from a substantial cytokine imbalance 
resulting in enhanced PMN and monocyte trafficking. Moreover, resolution is impaired being 
characterised by macrophage and surprisingly lymphocyte accumulation. Hence, data from this 
study places hPGD2S at the centre of controlling the onset as well as the resolution of acute 
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inflammation where it acts as a crucial checkpoint controller of cytokine/chemokine synthesis as 
well as leukocyte influx and efflux. In doing so we provide definitive proof that 15d-PGJ2 is 
synthesised during mammalian inflammatory responses and highlight DP1 receptor activation as 
a potential novel anti-inflammatory strategy.   
 
As mentioned above, lymphocyte numbers vary during the resolving innate inflammation and 
despite sub-populations of lymphocytes possessing innate immune-regulatory properties, seldom 
are their role in acute inflammation and its resolution discussed. In chapter 4, PGD2 may have a 
role in the disappearance of lymphocytes in acute inflammation. In lymphocyte-deficient RAG2-
/- mice, peritoneal T/B lymphocytes control PMN trafficking by regulating cytokine synthesis. 
Once inflammation ensues in normal mice, lymphocytes disappear in response to DP1 receptor 
activation by prostaglandin D2. However, upon resolution lymphocytes repopulate the cavity 
comprising B1, NK, gamma/delta T, CD4+/CD25+ and B2 cells. Repopulating lymphocytes does 
not appear to have a role in resolution as inflammation in RAG2-/- and wild types resolve 
uniformly. However, repopulating lymphocytes are critical for modulating responses to super-
infection. In gp91phox-/- mice, an animal model of chronic granulomatous disease, a genetic 
condition of impaired phagocytosis, not only is resolution delayed compared to wild types but 
there is a failure of lymphocyte reappearance. This predisposes to an exaggerated immune 
responses upon secondary challenge that is rescued by resolution-phase lymphocytes. The 
transition in T/B cells from acute inflammation to resolution has a central role in modulating the 
severity of early onset and orchestrating responses to secondary infection. As lymphocyte 
repopulation is also evident in human peritonitis, the phenotype of resolution phase lymphocytes 
and its function in modulating recurrent infection require further investigation. 
 
In chronic granulomatous disease (CGD) there is failure to generate reactive oxygen metabolites 
resulting in recurrent infections and persistent inflammatory events. Therefore, gp91phox-/- mice 
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is an ideal platform to investigate critical mediators that lead to failure of resolution and chronic 
inflammation (Chapter 5). As responses to sterile stimuli in murine models of CGD also result in 
non-resolving inflammation, we investigated whether defects in endogenous counter-regulatory 
mechanisms and/or pro-resolution pathways contribute to the aetiology of CGD. To this end I 
carried out a series of experiments that demonstrated, in the first instance that adenosine and 
cAMP, which dampen innate immune-mediated responses, show a biphasic profile in resolving 
peritonitis; peaking at onset, waning as inflammation progresses and rising again at resolution. In 
resolving human peritonitis there was also elevations in adenosine and cAMP. In gp91phox-/- 
mice, an experimental model of CGD, levels of adenosine and cAMP were significantly lower at 
onset and again at resolution. Corroborating the finding of others, we show that adenosine, 
signalling through its A2A receptor and therefore elevating cAMP is not only anti-inflammatory 
but, importantly, it does not impair pro-resolution pathways, properties typical of nonsteroidal 
anti-inflammatory drugs. Conversely, antagonising the A2A receptor worsens acute inflammation 
and prolongs resolution. Taking this further, activating the A2A receptor in gp91phox-/- mice was 
dramatically anti-inflammatory regardless of the phase of the inflammatory response A2A 
agonists were administered i.e. onset or resolution demonstrating wide and robust 
pharmacological flexibility that is unlikely to subvert pro-resolution pathways.  
 
This thesis therefore demonstrates that just like acute inflammation, resolution is an active 
process with a critical role PGD2 and 15d-PGJ2 in enabling this both by governing the influx and 
efflux of cells involved in the inflammatory process. Failure of this does lead to chronic 
inflammation as demonstrated by CGD mice, where the intracellular levels of adenosine and 
downstream cAMP are significantly reduced. The interplay between cyclo-oxygenase pathway 
and adenosine require further investigation. 
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Limitations of the study 
 
Collection of samples from patients who develop peritonitis 
 
One of the goals of the study was to determine the role of PGD2 and 15d-PGJ2 in patients on 
peritoneal dialysis who develop peritonitis, the most common complication of this modality. 
However there was variability in the timing of collection of the peritoneal effluent compared to 
the onset of symptoms. Patients in all cases developed peritonitis whilst at home. They then drain 
out the bag and bring it over to the hospital. Firstly this could happen any time during the day. 
There was a significant time lag between onset and collection of samples and during that period 
it is not stored in a controlled temperature leading to degradation of mediators of inflammation 
and resolution. This may explain why both PGD2 and 15d-PGJ2 were not detected in human 
peritoneal effluents.  
 
The role of PGD2 and 15d-PGJ2 in human peritonitis 
 
In the context of human peritonitis, the role of PGD2 and 15d-PGJ2 is not known. Furthermore 
there is a genetic heterogeneity in the expression of PGD2 synthase expression in human and this 
is not known in the patients studied. For instance, in Japanese children, a single nucleotide 
polymorphism in the second intron of the hPGD2 synthase gene located in 4q22.3 predicted a risk 
of asthma (Noguchi, Shibasaki et al. 2002). 
 
In the murine model, I was able to demonstrate the role of PGD2 in efflux of macrophages during 
resolution of peritoneal inflammation. This is an attractive area to investigate in humans but 
there were no techniques available to do so. 
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Role of re-populating lymphocytes in resolution of inflammation 
 
In chapter 4, I was able to show that repopulating lymphocytes did not enable resolution but was 
protective against a secondary insult based on experiments in lymphocyte deplete Rag1-/- mice. 
Adoptive transfer of resolution phase lymphocytes into the peritoneal cavity of gp91phox 
knockouts was protective against a second insult. However repopulating lymphocytes comprise 
of B1 cells, NK and gamma/delta T cells as well as CD4+/CD25+ cells. It was not clear which 
sub-population was directly responsible or whether all members of the resolution phase 
lymphocytes was necessary for this beneficial action. 
 
 
Future work 
 
1. Investigation of genetic polymorphism of PGD2 synthase expression in patients with 
chronic kidney disease  
 
This will allow an exploration of mutations to the PGD2 synthase gene and risk of developing 
recurrent infections including peritonitis  
 
2. Use LC-MS-MS to determine 15d-PGJ2 levels of inpatients on peritoneal dialysis 
that develop peritonitis.  
 
This would make it easier to collect and store samples in a timely manner to minimize 
degradation of mediators of inflammation. This will allow to compare the lipid mediator profile 
in both resolving and non-resolving peritonitis 
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3. Pilot clinical studies with PGD2 agonists in peritoneal inflammation 
 
4. Compare lymphocytes function from resolving and non-resolving peritonitis by ex-
vivo culture.  
 
When patients present with peritonitis and are admitted, the dialysis effluent is removed every 6 
hours in patients on continuous ambulatory peritoneal dialysis. Therefore discreet cell 
populations can be harvested from the effluent and cultured ex-vivo. If the peritonitis fails to 
resolve, the catheter is surgically removed at day five days following onset. Therefore cellular 
samples can be obtained for the first five days of the acute peritonitis episode. 
 
5. Investigating mediators responsible for resolution of inflammation in patients on 
dialysis. 
 
Based on measurement of inflammatory markers (eg: highly sensitive c-reactive protein) dialysis 
patients (either on haemo or peritoneal) are significantly inflamed compared to individuals 
without chronic kidney disease.  It is likely that there is an imbalance between the pro and anti 
inflammatory pathways in arachidonic acid metabolism (both COX and lipoxygenase). Using a 
cantharidin-induced skin blisters, we can investigate non inflamed versus chronically inflamed 
patients on dialysis and compare with non inflamed healthy volunteers for cellular as well lipid 
mediator profile (PGD2, 15d-PGJ2 and LXA4) 
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Hematopoietic prostaglandin D2 synthase (hPGD2S) metabolizes
cyclooxygenase (COX)-derived PGH2 to PGD2 and 15-deoxy12–14
PGJ2 (15d-PGJ2). Unlike COX, the role of hPGD2S in host defense is
ambiguous. PGD2 can be either pro- or antiinflammatory depend-
ing on disease etiology, whereas the existence of 15d-PGJ2 and its
relevance to pathophysiology remain controversial. Herein, studies
on hPGD2S KO mice reveal that 15d-PGJ2 is synthesized in a
self-resolving peritonitis, detected by using liquid chromatogra-
phy–tandem MS. Together with PGD2 working on its DP1 receptor,
15d-PGJ2 controls the balance of pro- vs. antiinflammatory cyto-
kines that regulate leukocyte influx and monocyte-derived mac-
rophage efflux from the inflamed peritoneal cavity to draining
lymph nodes leading to resolution. Specifically, inflammation in
hPGD2S KOs is more severe during the onset phase arising from a
substantial cytokine imbalance resulting in enhanced polymorpho-
nuclear leukocyte and monocyte trafficking. Moreover, resolution
is impaired, characterized by macrophage and surprisingly lym-
phocyte accumulation. Data from this work place hPGD2S at the
center of controlling the onset and the resolution of acute inflam-
mation where it acts as a crucial checkpoint controller of cytokine/
chemokine synthesis as well as leukocyte influx and efflux. Here,
we provide definitive proof that 15d-PGJ2 is synthesized during
mammalian inflammatory responses, and we highlight DP1
receptor activation as a potential antiinflammatory strategy.
antiinflammatory  cyclooxygnease  drug development  eicosanoids 
innate immunity
Cyclooxygenase (COX) metabolizes phospholipase A2-derivedarachidonic acid to prostaglandin (PG)H2, which is further
metabolized by a series of downsteam synthases to the prostanoids.
Indeed, the expression of the particular downstream enzyme and its
coupling either to constitutively expressed COX1 or to inducible
COX2 will determine the profile and levels of arachidonic metab-
olites released by cells. Thus, targeting COX will diminish most if
not all prostanoids, which, in the case of new-generation COX2
inhibitors, resulted in prostacyclin abatement, enhanced risk of
cardiovascular side effects, and the eventual withdrawal of selective
COX2 inhibitors from clinical usage. In this event, attention has
now shifted to understanding the role of COX downstream syn-
thases in inflammation and the cardiovascular system in the hope
of adding more selectivity with fewer side effects.
In an attempt to understand the role of COX-related down-
stream synthase in host defense, we found that the COX2/
hematopoietic PGD2 synthase pathway resolves both acute innate
(1, 2) and adaptive immune responses (3). Hematopoietic PGD2
synthase (hPGD2S) metabolizes COX-derived PGH2 to PGD2 (4),
which may activate two G protein-coupled receptors, DP1 and DP2.
DP1 regulates dendritic cell function (5), and DP2 promotes allergic
inflammation (6–8). Although controversial, it is believed that
PGD2 is initially converted to PGJ2 and 15-deoxy-PGD2 (15d-
PGD2) in an albumin-independent manner. Thereafter, the cyclo-
pentenone PGs (cyPGs) 15-deoxy-12, 14-PGJ2 (15d-PGJ2) and
12-PGJ2 are generated from PGJ2 by albumin-independent and
-dependent reactions, respectively (9). Although 15d-PGJ2 is a
putative ligand for peroxisome proliferator-activated receptor
(PPAR) (10), the skepticism with cyPGs lies in whether 15d-PGJ2
is formed in pathophysiological settings at sufficient levels to exert
meaningful biological effects in mammalian systems.
Investigating the role of hPGD2S in acute inflammation, we
provide definitive proof using liquid chromatography–tandem MS
(LC-MS/MS) that 15d-PGJ2 is synthesized in vivo. In a series of
mechanistic studies, we show that along with PGD2 acting on its
DP1 receptor, 15d-PGJ2 controls the balance of cytokines and
chemokines that regulate leukocyte trafficking during acute in-
flammation as well as the efflux of macrophage to draining
lymphatics leading to its resolution such that in hPGD2S-deficient
mice, inflammation is grossly exaggerated and fails to resolve.
These data not only prove that cyPGs exist in mammalian systems
and exert potent antiinflammatory and proresolution properties,
but data from this work also highlight the potential of activating
DP1 receptors as a future antiinflammatory strategy.
Results
hPGD2S-Derived Lipid Mediators in Acute Inflammation. In the first
instance, levels of PGD2 and 15d-PGJ2 were quantified
throughout the time course of resolving murine peritonitis.
PGD2 was maximal 2 h after zymosan injection, with levels
waning by 24 h (Fig. 1A). Contrary to common belief, 15d-
PGJ2 was detectable in cell-free inf lammatory exudates of
wild-type mice by LC-MS/MS (Fig. 1 B and C). It was elevated
at 2 h, maximum between 6 and 24 h, and had declined by 48
h/72 h, with average levels of between 0.5 and 5 ng/ml. PGD2
and 15d-PGJ2 were absent from experimental WT controls (0
h). Given its instability (9), we controlled for potential ex vivo
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degradation of PGD2 to 15d-PGJ2 during sample processing by
spiking inf lammatory f luids in situ with deuterated PGD2 and
found that the detected 15d-PGJ2 was native and not deuter-
ated 15d-PGJ2. These data, coupled with the finding that
neither PGD2 nor 15d-PGJ2 was detectable in the exudates of
hPGD2S KOs (Fig. 1 A and B), confirmed that 15d-PGJ2 is a
bona fide PGD2 eicosanoid metabolite formed in vivo during
resolving inf lammation.
hPGD2S Tempers the Severity of Acute Inflammation Through DP1 and
15d-PGJ2. We sought to determine the role that PGD2 and 15d-PGJ2
play in inflammation. hPGD2S/ mice show a more aggressive
early (4–6 h) response to zymosan, characterized by a 2-fold
increase in polymorphonuclear leukocyte (PMN) influx compared
with WT (Fig. 2A). By 48 h, PMN numbers in KOs were reduced
to levels similar to that found in WT (Fig. 2A, Inset), indicating that
although hPGD2S controls early PMN influx it does not influence
their survival or clearance from inflammatory sites. This was
confirmed by detecting little difference in PMN apoptosis by
annexin V/propidium iodide (PI) labeling as well as total leukocyte
apoptosis by the same technique and by caspase-3 activity [sup-
porting information (SI) Fig. 5]. Increased inflammation in
hPGD2S/ mice at onset was associated with a decrease in
antiinflammatory IL-10 (Fig. 2B) and an increase in proinflamma-
tory TNF (Fig. 2C) and monocyte chemoattractant protein 1
(MCP-1) (Fig. 2D). This hyperinflammatory phenotype in KOs was
rescued to that of WT at 6 h by a selective DP1 (BW245C, Fig. 2E)
but not a DP2 receptor agonist [15(R)-15-methyl PGD2] (Fig. 2F),
independently of apoptosis. Treatment of hPGD2S/ mice with
BW245C also restored the imbalance in TNF and MCP-1 vs. IL-10
to levels found in WT (Fig. 2 G–I). Thus, by signaling through the
DP1 receptor, hPGD2S-derived PGD2 controls the onset phase of
acute inflammation and its balance of pro- and antiinflammatory
cytokines and chemokines. A range of other cytokines and che-
mokines were measured, and their relative levels in wild types and
hPGD2S KOs are presented in SI Table 1. 15d-PGJ2 also reduced
cell numbers in the peritoneal cavity of mice but by increasing
leukocyte apoptosis as determined by both annexin V/PI labeling
and caspase activity, which resulted in a concomitant elevation in
IL-10 and TGF1, cytokines typically released by macrophage
upon recognition of apoptotic leukocytes (SI Fig. 6 A–F). We
believe that these data do not represent the true role of 15d-PGJ2
in vivo because there is little difference in total cell apoptosis
between WT and KOs at onset (5.05 0.6% of controls expressing
phosphatidylserine vs. 3.9  0.64% for KOs). These potentially
misleading data may arise from injecting a bolus dose of exogenous
and highly reactive electrophilic 15d-PGJ2 vs. its controlled endog-
enous release by intracellular hPGD2S. To understand how endog-
enous 15d-PGJ2 works in situ and to bypass the apoptosis-inducing
effects caused by a single bolus injection, we examined its effects on
peritoneal leukocytes ex vivo below.
hPGD2S Exerts Its Protective Effects on Resident Macrophages and
Lymphocytes. In the naı¨ve or uninflamed murine peritoneum, T and
B lymphocytes constitute 40% of the total cell population
(1.5  106), with the remaining being resident macrophages,
determined by using CD3/CD19, B220, CD5, and F4/80 labeling
quantified by FACS. In the case of the peritoneal cavity, resident
macrophages dictate the magnitude of the ensuing response with
peritoneal lymphocytes possessing innate immune regulatory ef-
fects (11–13). In this event, we next determined on which cell types
within the peritoneum PGD2 and 15d-PGJ2 exert their antiinflam-
matory effects. Separated peritoneal T and B cells as well as
macrophages were stimulated with either LPS or zymosan (B cells
and macrophages) or anti-CD3 antibody (T cells). Cytokines were
measured 24 h later in response to BW245C (DP1 receptor
agonist), 15(R)-15-methyl PGD2 (DP2 receptor agonist), or 15d-
PGJ2 at concentrations that do not increase apoptosis (SI Fig. 7).
IL-10 from hPGD2S-deficient peritoneal T cells was significantly
lower than WT but was reversed by BW245C (DP1 agonist); neither
15(R)-15-methyl PGD2 (DP2 receptor agonist) nor 15d-PGJ2 had
any effect (Fig. 3A). Similarly, IL-10 secretion from zymosan or
LPS-stimulated hPGD2S-deficient peritoneal B cells (265 20 and
178 12 pg/ml, respectively) was lower compared with WT [387
25 (P 0.05) and 625 35 (P 0.01) pg/ml, respectively] and was
rescued by BW245C only (Fig. 3 B and C). Conversely, synthesis of
TNF from these zymosan- or LPS-stimulated hPGD2S-deficient B
cells (1,625  175 and 1,260  152 pg/ml, respectively) was higher
compared with WT [1,160  105 (P  0.05) and 810  65 pg/ml
(P  0.05), respectively] but were reduced by BW245C and 15d-
PGJ2 but not with 15(R)-15-methyl PGD2 (Fig. 3 D and E). In
contrast to T and B lymphocytes, IL-10 from peritoneal macro-
Fig. 1. hPGD2S synthesizes 15d-PGJ2 during
zymosan-induced resolving peritonitis. (A
and B) hPGD2S-derived PGD2 (A) and 15d-
PGJ2 (B) were extracted from the cell-free
inflammatory exudates and quantified by
EIA and electrospray triple quadruple LC-MS/
MS, respectively. Ex vivo degradation of
PGD2 to 15d-PGJ2 during sample processing
was controlled for by spiking inflammatory
fluids in situ with deuterated PGD2. (C) LC-
MS/MS spectra of detected 15d-PGJ2, which
was found to be native and not deuterated.
For eicosanoid analysisn 6–8 animals were
present in each group with the exception of
15d-PGJ2, which had 2–6 samples per group.
Data are represented as the mean  SEM.
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phages was not elevated by BW245C (Fig. 3F), DP2 receptor
activation, or by 15d-PGJ2 (data not shown). However, these cells
did show a reduction in TNF and MCP-1 after treatment with
BW245C and 15d-PGJ2, respectively (Fig. 3 G and H). Similar
results were obtained by using bone marrow-derived macrophages
from these animals. These data show that hPGD2S-derived lipid
mediators exert differentially protective effects on peritoneal-
resident macrophages as well as lymphocytes, thereby controlling
the balance of cytokines and chemokines that orchestrate innate
inflammatory responses.
hPGD2S Deficiency Severely Compromises Resolution. Finally, one
striking finding of these studies was impaired resolution in
hPGD2S/ mice characterized by macrophage (Fig. 4A) as well as
lymphocyte accumulation (0.24  0.04  106 T and B cells in WT
vs. 0.8 0.1 106 in KOs; P 0.01). SI Fig. 8 shows a breakdown
of lymphocyte subtypes in these animals. The implication of lym-
phocyte accumulation during resolution in hPGD2S/ mice is
unknown at this stage but is reminiscent of results published
showing the persistence of lymphocytes in the inflamed paws of
COX2 KO mice (14) and raises questions regarding the long-term
impact of COX inhibitors on the progression of chronic inflam-
matory diseases. Although increased macrophage numbers during
resolution in hPGD2S/ mice may have arisen from elevated
MCP-1 (Fig. 2D) and macrophage inflammatory protein 1
(MIP-1 levels) (Fig. 4B), a failure to clear to the draining
lymphatics (15, 16) may also provide an explanation. To investigate
this hypothesis, the selective macrophage label PKH26-PCL (15,
16) was injected i.p. at the peak of macrophage accumulation (24
h), revealing increased numbers of PKH26-PCL-labeled macro-
phages in the peritoneal cavities of hPGD2S/ mice (Fig. 4C) and
a corresponding reduction in the parathymic load of these cells
compared with WT at 72 h (Fig. 4D). Adding BW245C or 15d-PGJ2
to hPGD2S/ mice alleviated peritoneal macrophage accumula-
tion (Fig. 4E) and increased numbers of PKH26-PCL macrophages
in the parathymic lymph nodes (Fig. 4F). The DP2 receptor agonist
was without effect. Notably, BW245C can be added 6 h, 12 h, or 24 h
after inflammation and will exert a macrophage clearance effect at
all of these time points, attributing a robust proresolution property
to DP1 (data not shown). Thus, hPGD2S-derived PGD2 and
15d-PGJ2 play a role in clearing inflammatory macrophages from
the inflamed peritoneum to local draining lymph nodes.
Discussion
We describe a central role for hPGD2S in controlling the onset and
resolution of innate immune-mediated inflammation. First, we
show that the protective nature of hPGD2S is mediated by DP1 and
15d-PGJ2, which control the balance of pro- and antiinflammatory
cytokine synthesis. These data contrast with the pathogenic role
PGD2 plays in allergic inflammation through DP2 (6–8). However,
as with the entire field of eicosanoid biology, lipid mediators can be
either protective or pathogenic depending on disease etiology, cell
types present, and eicosanoid receptor expression (17). For in-
stance, signaling through DP2 causes bronchoconstriction as well as
Th2 and eosinophil cell accumulation (6–8). In contrast, PGD2
activation of DP1 may also suppress asthmatic symptoms by tar-
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Fig. 2. PGD2 acting by the DP1 receptor controls the balance of pro- vs. antiinflammatory mediators and leukocyte trafficking during acute inflammation. (A)
Intraperitoneal zymosan resulted in a self-limiting inflammatory response that peaked at 6–12 h. Inflammation in hPGD2S/mice (K/O) was 2-fold greater than in WT
at 6 h and failed to resolve, with the early-onset phase characterized by predominantly GR1-positive PMNs with higher numbers of monocytes/macrophages compared
with WT (see Fig. 4A). (Inset) Appropriate isotype control antibodies. (B–D) Cell-free exudate levels of IL-10 (B) were lower in hPGD2S/ mice whereas TNF (C) and
MCP-1 (D) were higher. (E–I) The hyperinflammation in hPGD2S/ mice was redressed by the DP1 receptor agonist BW245C (E) but not by the DP2 agonist
15(R)-15-methyl PGD2 (F), resulting in a corresponding (G–I) equilibration of inflammatory cytokines and chemokines to levels similar to controls. n 6–8 animals per
group; *, P 0.05; **, P 0.01, as determined by ANOVA followed by Bonferroni t test, with data expressed as mean SEM.
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geting lung dendritic cells, resulting in increased Treg cells that
dampen inflammation in an IL-10-dependent manner (18). We
found no difference in the numbers of CD4/CD25 cells between
hPGD2S/ and WT in experimental peritonitis (SI Fig. 9), and we
propose that in acute inflammation at least, the protective effects
of PGD2 are directed toward modulating resident leukocyte in-
flammatory phenotypes and are not reliant on recruitment of Treg
cells. On this theme, PGD2 along with PGE2 can also induce PMN
15-lipoxygenase expression in a partly cAMP-dependent manner,
causing the subsequent release of antiinflammatory and proreso-
lution lipoxin A4 (19). It is conceivable, therefore, that some of the
protective and cytokine regulatory effects of PGD2 in acute in-
flammation may also arise from its induction of other families of
protective lipid mediators. Thus, from the current data and that
published by others (5, 18), we suggest that DP1 receptor activation
may be an attractive antiinflammatory target capable of modulating
both innate and adaptive immune responses of different etiologies.
In particular, we found that DP1 activation exerts its antiinflam-
matory effects at many stages throughout the inflammatory re-
sponse, i.e., when administered either prophylactically or therapeu-
tically, thereby demonstrating greater pharmacological flexibility
than, for example NSAIDs, which although effective during acute
stages of inflammation, subvert proresolution pathways (1, 19).
Controversy exists over whether 15d-PGJ2 is synthesized in vivo
and whether it possesses relevant patho/physiological functions.
This debate arose, in part, when we originally reported that
COX2-derived PGD2 and 15-dPGJ2 brought about acute inflam-
matory resolution (1). Controversy also arose not so much because
we suggested that COX2 was protective at a time when the
emphasis was on developing COX2 inhibitors, but because we used
an ELISA to quantify 15d-PGJ2. In particular, the reactive nature
of 15d-PGJ2 raised questions regarding the accuracy of using an
antibody-based measuring system. This result, coupled with subse-
quent reports using physical methods to show only negligible levels
of 15d-PGJ2 in various biological systems (20), questioned the
importance of 15d-PGJ2 in biology. In this work we show, by using
LC-MS/MS on samples obtained from a resolving inflammation,
that 15d-PGJ2 does exist in vivo at levels up to 5 ng/ml. We
controlled for degradation of unstable PGD2 to 15d-PGJ2 during
sample processing by spiking inflammatory fluids in situ with
deuterated PGD2, and we found that the detected 15d-PGJ2 was
native and not deuterated 15d-PGJ2. These data, coupled with the
finding that neither PGD2 nor 15d-PGJ2 was detectable in the
exudates of hPGD2S KOs (Fig. 1 A and B) and that the hyperpro-
liferative phenotype of hPGD2S/ T cells from a delayed-type
hypersensitivity reaction was reversed with 15d-PGJ2 (3), confirm
that 15d-PGJ2 is an endogenously generated protective PGD2
metabolite formed in vivo during resolving inflammatory reactions.
The importance of this finding cannot be underestimated. cyPGs,
derived from PGs of the A or D series possess antiinflammatory
(21), antiviral (22), and anticancer (23) properties by activating
either nuclear membrane-bound PPARs (24) or by forming cova-
lent adducts with thiols through the unsaturated carbonyl group in
the cyclopentenone moiety (25, 26). Importantly, protein modifi-
cation by cyPGs does not occur randomly with cyPGs targeting
defined cysteine residues within certain proteins in an apparently
pH-dependent manner (27). Moreover, structural determinants of
either the protein or the cyPG may be important for the specificity
of protein modification such that cyPGs with diverse structures
could selectively modify distinct proteins in cells. Thus, levels of
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from stimulated hPGD2S-deficient T
cells (A) as well as B cells (B and C)
was not only lower than that from
wild types but was rescued by DP1
activation (BW245C). DP2 receptor
activation with 15(R)-15-methyl
PGD2 was without effect in these
experiments. (D and E) Conversely,
TNF release from hPGD2S-defi-
cient B cells was greater than that
from wild types and was reversed
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rophages, whereas hPGD2S had lit-
tle effect on IL-10 (F), BW245C re-
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cretion (H). These data show the
differential regulatory effects of
hPGD2S-derived lipid mediators on
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cyPGs in the extracellular environment may only represent the tip
of the iceberg, and their true level in biological systems may be
much higher. The lack of detectable cyPGs in biological fluids does
not necessarily exclude their existence within cells and their poten-
tial to exert meaningful biological effects. Indeed, in a series of
experiments we estimate that of 15d-PGJ2 added exogenously to
biological systems,50% binds BSA. Moreover, in cardiomyocyte
cell cultures, 80% binds to culture medium supplemented with
10% FCS with 16% binding to or being metabolized by cardio-
myocytes, leaving	4% detectable by LC-MS/MS (SI Fig. 10). It is
for this reason that we need to add quantitatively more 15d-PGJ2
back to inflammatory models to mimic the biological effects of
endogenously produced 15d-PGJ2. This requirement is illustrated
in SI Fig. 6, where more 15d-PGJ2 is injected i.p. than is detectable
in peritoneal fluids (Fig. 1B). We suggest that the role of 15d-PGJ2
in self-limiting inflammatory responses is manifold and does not
necessarily overlap with that of PGD2, controlling chemokine and
cytokine synthesis as well as intracellular signaling and leukocyte
apoptosis. We found that exogenous 15d-PGJ2 exerts proresolution
effects if used pharmacologically by enhancing leukocyte apoptosis,
the net outcome being similar to that found with the cyclin-
dependent kinase inhibitor roscovitine, which enhanced PMN
apoptosis and hastened resolution (28).
In addition to tissue resident histiocytes, there is the influx of
monocytes during inflammation, which differentiate into large
granular macrophages designed to phagocytose effete leukocytes.
The fate of Reiter cells (macrophages containing dead cells) during
resolution is poorly understood, with evidence that macrophages
can undergo programmed cell death (29) and/or clearance from the
peritoneum to the parathymic lymph nodes in a very late antigen
(VLA)-4- and VLA-5-dependent manner (15, 16). Although the
control of phagocyte clearance is poorly understood, we found an
excess of macrophages in the inflamed peritoneum of hPGD2S/
mice and a corresponding deficit of these cells in the draining lymph
nodes compared with controls. This result could have arisen from
accelerated monocyte influx, mediated by elevated MCP-1 and
MIP-1 (Figs. 2D and 3B) and/or failed lymphatic efflux. Using a
phagocytosable fluorescent cell tracker, the peritoneal pool of
accumulated macrophages in hPGD2S/ mice at resolution was
found to be reduced by BW245C or 15d-PGJ2 and was associated
with an increase in macrophages in the parathymic lymph node. We
therefore suggest that DP1 is a robust pharmacological target that,
in addition to stemming PMN trafficking, could be used to dissem-
inate macrophages from sites of chronic inflammation where
macrophages play a pathogenic role. A similar result was found
recently with -3 polyunsaturated fatty acid-derived resolvin E1
and protectin D1, which facilitated leukocyte trafficking to lymph
nodes and spleen, collectively underscoring the proresolution prop-
erties of lipid mediators in acute inflammation (30).
Lymphocytes were also found to accumulate in hPGD2S/mice
at resolution, which we suspect resulted from enhanced influx in
response to elevated chemokines in these animals rather than
increased local lymphocyte proliferation because there was no
significant difference in thymidine incorporation in hPGD2S/
lymphocytes compared with controls (data not shown). Indeed,
there was a trend toward a reduction in lymphocytes from KOs in
these experiments, in contrast to results obtained with hPGD2S-
deficient lymphocytes from an antigen-induced arthritis model (3),
which showed elevated proliferation in hPGD2S KO mice. These
differences are most likely the result of a differential role for both
hPGD2S-derived lipid mediators and lymphocyte subsets and ac-
tivation states in inflammatory disease of dissimilar etiologies.
In summary, we provide proof that hPGD2S synthesizes 15d-
PGJ2 during mammalian defense responses and together with
PGD2, acting through the DP1 receptor, plays a central role in
controlling the onset of acute inflammation and its resolution by
controlling the balance of pro- vs. antiinflammatory cytokines as
well as macrophage clearance through draining lymphatics. Here,
we have highlighted the potentially antiinflammatory and proreso-
lution properties of cyPGs as well as DP1 receptors.
Materials and Methods
Animal Maintenance and Induction of Inflammation. hPGD2S KO mice were
generated as described (3). Animals were bred under standard conditions and
maintained in a 12 h/12 h light/dark cycle at 22  1°C and given food and tap
water ad libitum in accordance with United Kingdom Home Office regulations.
Peritonitis was induced by the i.p. injection of 1 mg of type A zymosan (Sigma) in
0.5 ml of sterile PBS. Cells were obtained by using 2 ml of sterile PBS to wash out
the inflamed peritoneal cavity, and they were enumerated by hemocytometer at
the time points stated in Results.
Eicosanoid Analysis. Samples stored at 20°C were thawed at room temper-
ature and spiked with 4 ng of the internal standard d4–15d-PGJ2 and acidified
to pH 3. Solid-phase extraction was performed with Varian 3M Empore
high-performance extraction disk cartridges, and the columns were washed
with 1 ml of H2O and 1 ml of heptane and eluted with 1 ml of ethyl acetate.
The eluate was dried under nitrogen and analyzed by electrospray triple/
quadruple LC-MS/MS (Sciex API 3000; PerkinElmer). The conditions for the
LC-MS/MS were: C18 columns (100 0.2 mm) with elution volume 200 l/min
consisting of a mobile phase 0–1 min of distilled H2O (pH 3), MeCN 75:25%,
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Fig. 4. hPGD2S deficiency compromises inflam-
matory resolution. (AandB) Although PMNs dom-
inate the inflamed peritoneal cavity at the early-
onset phase in hPGD2S/ (K/O) mice (Fig. 2A,
Inset) F4/80 positive macrophages were the pre-
dominant cell types during resolution (A) WT, wild
type. Increased macrophage numbers in
hPGD2S/micecouldarisefromenhancedMIP-1
(B) as well as MCP-1 (Fig. 2D) synthesis and/or a
failure to exit the peritoneum to the parathymic
lymphnodes (15,16).Todeterminethe latter,mice
were injected i.p. with the macrophage label PKH-
PCL26 at either 24 h or 48 h. (C) A significantly
greater number of PKH26-PCL-positive macro-
phages (double labeling with FITC-labeled F4/80)
were recorded in the cavity of hPGD2S/ mice
compared with WT at 72 h. (D) Correspondingly
fewer labeled macrophages were found by histol-
ogy in the parathymic lymph nodes of the KOs. (E
and F) Adding BW245C (DP1 receptor agonist) or
15d-PGJ2 tothe inflamedcavityofhPGD2S/mice
reversed the accumulation of macrophages in the
peritoneum (E) and resulted in increased numbers of labeled macrophages in parathymic lymph nodes (F). n  10 animals per group; *, P  0.05; **, P  0.01, as
determined by ANOVA, followed by Bonferroni t test, with data expressed as mean SEM.
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followed by a gradient mobile phase to 100% MeCN. 15d-PGJ2 was detected
and quantified in negative ion mode, and the electrospray potential was
maintained at 4 to 4.5 kV and heated to 500°C. For MS-MS analysis, 15d-
PGJ2/internal standards were subjected to collision-induced fragmentation.
Tetradeuterated (d4) 15d-PGJ2, PGD2, and 15d-PGJ2 were purchased from
Cayman Chemicals. Varian 3M Empore high-performance extraction disk
cartridges were purchased from JVA Analytical, Ltd. All other common labo-
ratory chemicals were purchased from Sigma. For PGD2, samples were ex-
tracted C18 columns, treated with methoxylamine hydrochloride (MOX HCl),
and the resulting stable PGD2-MOX was measured by EIA (Cayman Chemicals).
Cytokine/Chemokine, FACS, and Caspase Activity Analysis. Cytokines and che-
mokines were measured initially by multiplex cytokine array analysis (Bio-Rad)
using the manufacturer’s protocols. Specific mediators of interest [IL-10, TNF
(eBiosciences), and MCP-1 (Becton Dickinson)] were further quantified by ELISA
according to manufacturer’s instructions. FACS was carried out on Becton Dick-
inson FACSCalibur with data analyzed by Cellquest. Leukocytes were incubated
with antibodies to CD3 (Serotec), B cells (Ly220; Serotec), natural killer and / T
cells (gift from T. Hussell, Kennedy Institute, U.K.), GR1 (BD PharMingen), or F4/80
(Caltag Laboratories) using isotype antibodies (Serotec) and compensated as
appropriate for dual labeling. For apoptosis, cells were incubated with annexin
V/PI (Becton Dickinson). For caspase 3 activity, frozen cell pellets were lysed in
ice-cold RIPA buffer [20 nM Tris (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, 0.5%
(wt/vol) sodium deoxycholate, 0.1% SDS Promega)] for 10 min. After centrifuga-
tionat16,000g for15minat4°C, supernatantswereaspirated,andproteinwas
quantified by the Bradford reaction. Samples were incubated with 50 M sub-
strate in caspase assay buffer [213.5 mM Hepes (pH 7.5), 31.25% (wt/vol) sucrose,
and 0.3125% CHAPS] for 1 h, and fluorescence was measured on a microplate
reader (FluostarGalaxy;BMGLaboratoryTechnologies)withexcitationat380nm
and emission set at 460 nm. For each sample, four replicates were assayed, with
two replicates containing 50M the caspase-3 inhibitor (Ac-DEVD-CHO) and the
remaining pair containing vehicle. Fluorescence readings from wells containing
inhibitor were subtracted from total fluorescence, and results were calculated as
nmol of aminomethyl couramin (AMC) per mg of protein per min.
Leukocyte Separation and in Vitro Culturing. Bone marrow-derived or perito-
neal macrophages were isolated by adherence to the bottom of 6-well tissue
culture plates after incubation for 90 min at 37°C in a humid incubator.
Nonadherent cells were removed and used to isolate T and B lymphocytes. The
adherent cells were eluted with Versene, washed with 2% FCS in HBSS, and
resuspended at 107 cells per ml. These cells were further depleted of contam-
inant T and B cells by using magnetic beads coated with rat monoclonal
antibodies to mouse CD3 or B220 (Dynal Biotech, Ltd.). T and B lymphocytes
were isolated by using the Dynal mouse B cell (or T cell) negative isolation kit
according to the manufacturer’s instructions. In brief, a mixture of rat mono-
clonal antibodies with specificity to all mouse non-B cells (or non-T cells when
isolating T cells) was added to cell suspensions and incubated for 20 min at 4°C.
Cells coated with the added monoclonal antibodies were then removed with
magnetic beads coated with sheep polyclonal antibody to rat Ig. The purity of
the cells was regularly95%. B lymphocytes and macrophages were counted
by hemocytometer and cultured in RPMI medium 1640 with 10% (vol/vol) FCS
and antibiotics [100 units/ml benzylpencillin, 10g/ml streptomycin, 2.5g/ml
amphotericin (all from Sigma–Aldrich)] in sterile 24-well culture plates (VWR)
and incubated at 37°C in a humidified atmosphere of 95% air and 5% CO2.
Cells were incubated with the selective DP1 agonist (BWC245; Cayman), DP2
agonist [15(R)-15 methyl PGD2; Cayman), or 15d-PGJ2 (Cayman) with medium
as control and then stimulated with 100 g/ml zymosan type A (Sigma), 1
g/ml LPS, or vehicle. The experiment was terminated 24 h later, and super-
natant was stored at 80°C until further use. The protocol for T cells was
similar apart from stimulation with anti-CD3 antibody.
Macrophage Clearance Assays. Two milliliters of 500 nM macrophage-specific
stain PKH26-PCL (Sigma) was injected into the inflamed peritoneal cavity with
cells and parathymic lymph nodes isolated at time points stated in results
section. Cells staining positive for PKH26-PCL (FL2 channel) were identified
with FITC-labeled F4/80 (FL1 channel). Staining was found almost exclusively
within macrophages. Parathymic lymph nodes were extracted and snap fro-
zen in OCT1, and serial sections (minimum 15 sections per node) were exam-
ined for the presence of fluorescent PKH26-PCL-labeled macrophages. All
sections were scored blindly by two independent observers by using an
Olympus Axioscop microscope and our validated analog scale (16).
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Resolving the problem of persistence in the switch from
acute to chronic inflammation
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T
he rapid induction of an inflam-
matory response is crucial for
effective host defense. A wide
range of proinflammatory agents
ensure that this response occurs. Promi-
nent among these are members of the
prostaglandin and leukotriene family that
are enzymatically derived from arachi-
donic acid (AA, C20:4) (1). At the onset
of inflammation, AA is metabolized via
either cyclooxygenases (COX) to produce
prostaglandins (PGs) and thromboxanes
or lipoxygenases to generate leukotrienes
(LTs) (1). These ecicosanoids induce and
help establish the inflammatory infiltrate.
However, at some point during the in-
flammatory cascade, inhibition and ulti-
mately resolution of the inflammatory
response must occur; otherwise, tissue
homeostasis cannot occur and inflamma-
tion persists.
Until relatively recently, the resolution
of inflammation was thought to occur
mainly as a result of the passive with-
drawal of proinflammatory mediators. It
is now clear that the inflammatory pro-
gram contains key checkpoints as well as
temporal and spatial switches that regu-
late its onset, maintenance, and resolution
(2). A key finding in recent years is that
the biosynthetic pathways required for
inflammation to resolve often require the
prior production of lipid mediators pro-
duced during the induction phase of in-
flammation. In particular, PGE2 and
PGD2, which are responsible for inflam-
mation induction, subsequently stimulate
antiinflammatory circuits by inducing
the lipoxin-producing enzyme 15-
lipoxygenase in neutrophils. This class
switch in eicosanoid production, from
LTs and PGs to lipoxins (3), provides
temporal and spatial checkpoints during
the inflammatory cascade (see Fig. 1).
In this issue of PNAS, Rajakariar et al.
(4) provide yet another twist in the res-
olution story with the demonstration
that class switching may not always be
required for resolution to be initiated.
They provide compelling evidence that,
within a single eicosanoid family
pathway initiated by COX-2 and subse-
quently regulated by the enzyme hema-
topoietic PGD2 synthase (hPGD2S),
proresolving mediators PGD2 and 15-
deoxy12–14 PGJ2 (15d-PGJ2) are pro-
duced at sufficient levels in vivo to drive
the resolution of acute inflammation.
The concept that antagonists that limit
the extent of a biological cascade are gen-
erated as the cascade develops is familiar
in other self-limiting pathways such the
complement and coagulation cascades.
However, homeostasis takes an unex-
pected twist in inflammation. Events at
the onset of acute inflammation establish
biosynthetic circuits for a series of chemi-
cal mediators that later serve not only as
antagonists but also as agonists for an
opposing program: resolution. These pro-
resolution agonists don’t just inhibit the
cascade, they actively dismantle it. There-
fore, antiinflammation and proresolution
are not equivalent. The agonists that ac-
tively promote resolution (an emerging
family of proresolving lipid mediators,
including lipoxins, resolvins, and protec-
tins) are inherently different from the
antagonists that limit the extent of the
inflammatory response, at both the mo-
lecular and the cellular level (2).
Ever since the discovery that aspirin
exerts many of its antiinflammatory ac-
tions through inhibition of the COX en-
zymes (5), there has been keen interest in
developing specific inhibitors of these en-
zymes. However, the logic for such an
approach did not account for the fact that
the inducible COX-2 enzyme is also re-
sponsible for the production of antiin-
flammatory eicosanoids, some of which
are important in maintaining vascular ho-
meostasis (6). In a provocative paper pub-
lished in 1999, Gilroy et al. (7) suggested
that COX-2 may have antiinflammatory
properties. Subsequent findings by Fuku-
naga et al. (8) and Schwab et al. (9) have
since demonstrated that blocking prosta-
glandin biosynthesis with COX-2 inhibi-
tors, although effective at the very early
stages of the inflammatory cascade, delays
the onset of resolution (8) and/or impairs
phagocyte removal of dead cells (9). In
effect, these potent COX-2 selective
agents lead to friendly fire by being ‘‘reso-
lution toxic.’’
In a series of seminal papers, Gilroy
and colleagues have built on their original
observations to present a convincing case
that some of the downstream products
from the COX-2-derived PGD2 family,
and in particular 15d-PGJ2, are important
in the resolution of acute inflammatory
responses (9, 10). Critics of these studies
have pointed out that a molecular mecha-
nism that detailed how PGD2 leads to
resolution was missing. More damning
were the comments that the antibody-
based methods used to measure these
metabolites, and the negligible levels of
15d-PGJ2 found in various biological sys-
tems, made the biological importance of
their original observations questionable
(11). Using both genetic and biochemical
studies, Rajakariar et al. (4) now provide
compelling evidence, complete with a
molecular mechanism that should silence
the critics.
hPGD2S metabolizes COX-derived
PGH2 to PGD2. However, the role of
hPGD2S in host defense remains unclear
because it and its metabolites appear to
display both pro- and antiinflammatory
properties, depending on the disease
model and the way in which they are ad-
ministered (12). This ambiguous role for
hPGD2S is even more problematic be-
cause PGD2 is further metabolized nonen-
zymatically to produce PGs of the J series,
including PGJ2 and 15d-PGJ2, whose rele-
vance to pathophysiology has remained
highly controversial. In an attempt to clar-
ify the role of hPGD2S in inflammation,
Rajakariar et al. (4) used mice deficient in
the enzyme to unequivocally demonstrate
that hPGD2S is responsible for the pro-
duction of all PGD2 and 15d-PGJ2 during
zymosan-induced resolving peritonitis.
Using liquid chromatography–tandem MS
(LC-MS/MS), they provide physical evi-
dence for in vivo formation of 15d-PGJ2
in resolving exudates in a peritonitis
model of inflammation at levels up to 5
ng/ml (15 nM). They noticed that mac-
rophage emigration from the inflamed
tissues to draining lymph nodes was de-
layed in hPGD2S knockout mice. This
delay was rescued by addition of DP1-
specific agonists, emphasizing the impor-
tant role of DP1 in controlling both the
onset of acute inflammation and its reso-
lution. Surprisingly, lymphocyte numbers
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increased in the hPGD2S knockout mice
at a time when resolution was at its
peak in wild-type mice. Although the
authors were unable to pinpoint why
this increase occurred, they suggest that
it was not due to changes in prolifera-
tion or cell death. Clearly these issues
will need to be addressed in the future,
particularly as pharmacological interven-
tion with exogenous 15d-PGJ2 leads to
accelerated leukocyte apoptosis, but at
doses that are substantially higher than
those formed naturally in the peritoneal
exudates (13).
Although these results will excite those
who work in the field of inflammation
biology, and in particular its pathobiology
and molecular pharmacology, they are of
broad interest to investigators in many
other fields, including host defense and
cancer. For example, cyclopentone iso-
prostanes derived from PGs of the A and
D series have been shown to possess anti-
viral and anticancer properties working
through the activation of nuclear-
membrane-bound peroxisome prolifera-
tor-activated receptors (12). However, the
most exiting implication of these new find-
ings is that they will encourage a shift in
focus from the development of even more
antiinflammatory, and potentially ‘‘resolu-
tion-toxic’’ drugs, toward ‘‘resolution-
friendly’’ replacement therapies (14).
Perhaps only then will the next generation
of aspirin- and steroid-like compounds
with the ability to both inhibit the induc-
tion of inflammation and jump-start its
resolution emerge. It would appear that in
the field of inflammation resolution, Cin-
derella has finally arrived at the ball.
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Fig. 1. Temporal and spatial regulation of resolution. (A) Current paradigm: Breaches in host defense such as pathogen invasion, host trauma, or loss of barrier
function initiate the inflammatory response with AA rapidly converted to PGs and LTs (e.g., LTB4) via COX enzymes. LTB4 is a potent chemoattractant of
neutrophils to the site of inflammation (red arrow). As the inflammatory response progresses, a temporal switch from initiation to resolution occurs with the
transcellular generation of lipoxins (LXA4) that inhibit the further recruitment of polymorphonuclear neutrophils (PMNs) (blue line). As the inflammatory
response continues, monocytes are recruited via the release of the monocyte chemotactic protein-1. Macrophages release proinflammatory cytokines IL-6 and
TNF, but engulfment of apoptotic PMNs causesmacrophages to change to a nonphlogistic phenotype releasing TGF-, IL-10, and lipoxin. At the end of an acute
inflammatory response, macrophages and lymphocytes leave the site of inflammation via the draining lymphatics, stimulated by lipoxins (blue arrow). (B) New
addition to the paradigm: At the onset of the inflammatory response, PGD2 is generated fromAA via COX to PGH2 and then converted to PGD2 by hPGD2S. PGD2
is metabolized nonenzymatically to 15-dPGJ2. PGD2 acts on the DP1 receptor expressed onmacrophages and lymphocytes, whereas 15-dPGJ2 is likely to interact
with peroxisome proliferator-activated receptor-. Working in tandem, they decrease proinflammatory cytokines such as TNF and increase antiinflammatory
cytokines such as IL-10, but like the lipoxin family, they also promote egress of macrophages and lymphocytes to the draining lymphatics (blue arrows).
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Novel biphasic role for lymphocytes revealed during resolving inflammation
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Acute inflammation is traditionally de-
scribed as the influx of polymorpho-
nuclear leukocytes (PMNs) followed by
monocyte-derived macrophages, leading
to resolution. This is a classic view, and
despite subpopulations of lymphocytes
possessing innate immune-regulatory
properties, seldom is their role in acute
inflammation and its resolution dis-
cussed. To redress this we show, using
lymphocyte-deficient RAG1/ mice, that
peritoneal T/B lymphocytes control PMN
trafficking by regulating cytokine synthe-
sis. Once inflammation ensues in normal
mice, lymphocytes disappear in response
to DP1 receptor activation by prostaglan-
din D2. However, upon resolution, lympho-
cytes repopulate the cavity comprising
B1, natural killer (NK), / T, CD4/CD25,
and B2 cells. Repopulating lymphocytes
are dispensable for resolution, as inflam-
mation in RAG1/ and wild-type mice
resolve uniformly. However, repopulating
lymphocytes are critical for modulating
responses to superinfection. Thus, in
chronic granulomatous disease using
gp91phox/ mice, not only is resolution
delayed compared with wild-type, but
there is a failure of lymphocyte re-
appearance predisposing to exaggerated
immune responses upon secondary
challenge that is rescued by resolution-
phase lymphocytes. In conclusion, as lym-
phocyte repopulation is also evident in
human peritonitis, we hereby describe a
transition in T/B cells from acute inflam-
mation to resolution, with a central role in
modulating the severity of early onset
and orchestrating responses to second-
ary infection. (Blood. 2008;111:4184-4192)
© 2008 by The American Society of Hematology
Introduction
Inflammation is controlled by a balance of proinflammatory and
antiinflammatory signals, resulting in the development of an
immune response followed by temporally released proresolution
factors that lead to inflammation switching off and injured
tissues returning to normal physiology.1 In this setting, attention
is traditionally placed on phagocytes such as polymorpho-
nuclear leukocytes (PMNs) and monocyte-derived macro-
phages, with comparatively less weight place on the importance
of lymphocytes in acute inflammation and its resolution. Given
their roles in early defense to bacteria and viruses, innate-type
lymphocytes including B1 cells merit further exploration for
their potential roles in host defense and restorative physiology,
as it is becoming clear that diminished innate lymphocyte
function or enhanced lymphocyte death by apoptosis, for
instance, has being postulated to play a central role in the
pathogenesis of burn injury2,3 and sepsis,4,5 respectively.
One of the major impetuses for this current investigation
stemmed from our previous observations6 and those made by
others7-10 showing lymphocytes repopulating sites of tissue injury
as inflammation abates, suggesting that lymphocytes might help to
switch off acute inflammation. Investigating this possibility in
experimental peritonitis, T and B lymphocytes, normal residents of
the naive peritoneum, were found to regulate the severity of the
early onset phase of acute inflammation by elaborating anti-
inflammatory cytokines and dampening PMN influx. However,
once PMNs begin to accumulate, resident lymphocytes disappear
in response to PGD2 working through its DP1 receptor. As
inflammation resolves, a unique profile of lymphocytes begin to
repopulate the cavity. Repopulating lymphocytes, however, do not
bring about resolution but replenish resolving tissues with the
necessary cellular players (CD3, B1 cells, natural killer [NK] and
/ T cells as well as CD4/CD25 T cells) to control future innate
immune-mediated responses. We provide relevance of these find-
ings to human health by showing the absence of repopulating
lymphocytes in nonresolving inflammation, which predisposes to
secondary infection, resulting in severe inflammatory responses.
Although lymphocytes in adaptive immunity are well understood,
their role in innate immunity and resolution is highlighted here, as
is their functional control by lipid mediators, of which there is a
growing body of evidence. For instance, in addition to PGD2,11
lipoxins and aspirin-triggered epi-lipoxins inhibit human T-cell
TNF secretion,12 while docosahexanoic acid–derived protectin
D1 blocks T-cell migration and TNF and IFN secretion and
promotes apoptosis in human T cells.13 Thus, from these current
studies and those published by others,12,13 we highlight the
regulatory role played by n-3 and n-6 polyunsaturated fatty acid
metabolites on lymphocyte function during acute inflammation and
its resolution.
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Methods
Animal maintenance, induction of inflammation human
peritonitis sampling
Hematopoietic prostaglandin D2 (PGD2) synthase (hPGD2S) knockout mice
were generated as previously described.14 All other animals were bred
under standard conditions and maintained in a 12-hour/12-hour light/dark
cycle at 22 (1)°C and given food and tap water ad libitum in accordance
with United Kingdom Home Office regulations. Peritonitis was induced by
the intraperitoneal injection of either type A zymosan (1 mg for all
experiments unless otherwise stated), group B streptococcus (GBS), or LPS
(1 mg/kg; Sigma-Aldrich, St Louis, MO), and cells were enumerated by
haemocytometer at time points stated in “Results” by sterile phosphate-
buffered saline (PBS) washout. Ethical approval (P/03/136A) for collection
of human peritonitis samples was obtained from St Bartholomew’s and the
Royal London Hospitals from patients with end-stage renal failure undergo-
ing peritoneal dialysis. For pharmacologic rescue experiments, BW245C
(DP1 agonist15,16) or 15(R)-15-methyl PGD2 (DP2 agonist17) in 100 L of
PBS (pH 7.2)/BSA 0.1% was injected at equal doses at 30 minutes prior to
and after the zymosan.
Trypsinization of peritoneal cavity
To determining the fate of peritoneal T and B cells, cavities of mice bearing
a 4-hour zymosan-induced peritonitis was lavaged with sterile PBS to
remove accumulated inflammatory cells and edema. A total of 5 mL
prewarmed 5% trypsin was then added to the peritoneal cavity for
10 minutes, followed by an equal volume complete medium to acquire cells
adhered to the peritoneal lining/greater omental lymphoid organ. Cells were
then analyzed for composition by fluorescence-activated cell sorter (FACS).
FACS analysis and cytokine/chemokine analysis
Cytokines were measured by enzyme-linked immunosorbent assay (ELISA)
according to the manufacturer’s instructions (eBioscience, San Diego, CA).
FACS was carried out on a Becton Dickinson Facscalibur with data
analyzed by CellQuest (BD, Franklin Lakes, NJ). Leukocytes were
incubated with antibodies for 30 minutes to either CD3/CD19 (Serotec,
Oxford, United Kingdom), B cells (Ly220; Serotec), CD5 (BD PharMin-
gen, San Diego, CA), MAC-1/CD11b (BD PharMingen), NK and / cells
(gift from Dr T. Hussell, Kennedy Institute, London, United Kingdom),
GR1 (BD PharMingen), or F4/80 (Caltag Laboratories, Burlingame, CA)
using respective isotype antibodies as controls (Serotec) and compensated
as appropriate for dual labeling. For apoptosis, cells were incubated with
annexin V/propidium iodide (BD PharMingen) and analyzed on Becton
Dickinson Facscalibur with data analyzed by CellQuest.
Leukocyte separation and analysis
Contents of resolving-phase peritoneal cavities of wild-type animals were
isolated, and macrophages were separated from remaining lymphocytes by
adherence to the bottom of 6-well tissue-culture plates. Nonadherent cells
were removed and used to isolate T and B cells as well as NK and /
T cells for transfer back in to gp91phox knockout mice using FACS and
relevant antibodies to confirm that their composition and ratios reflects that
present in situ at resolution. Resolving-phase lymphocytes were enriched at
a concentration of 106/mL and 0.5 mL injected into gp91phox knockout mice.
In addition, one of the problems with identifying discrete populations of
cells such as those found at sites of inflammation by FACS from a larger
mixed cell population is that the fluorescence of one cell type after labeling
with a fluorescent antibody may be masked by the natural fluorescence of
others. In order to confirm the cell types identified using cell-surface
antigen markers, peritoneal lymphocytes and macrophages were also
isolated and put back into the FACS with their forward- and side-scatter
signatures compared against specifically labeled cells. Thus, after lympho-
cytes were removed from 6-well plates, adherent cells, mainly macro-
phages, were eluted with Versene, washed with 2% fetal calf serum (FCS)
in Hanks balanced salt solution (HBSS) and resuspended in Dulbecco
modified Eagle medium (DMEM). These cells were further depleted of
contaminant T and B cells using magnetic beads coated with rat monoclonal
antibodies to mouse CD3 or B220 (Dynal Biotech, Paisley, United
Kingdom). T and B lymphocytes were isolated using the Dynal mouse
B-cell (or T-cell) negative isolation kit according to the manufacturer’s
instructions (Dynal Biotech). In brief, a mixture of rat monoclonal
antibodies with specificity to all mouse non-B cells (or non-T cells when
isolating T cells) cells were added to cell suspensions and incubated for
20 minutes at 4°C. Cells coated with the added monoclonal antibodies were
then removed with magnetic beads coated with sheep polyclonal antibody
to rat Ig. Purity of the cells were regularly greater than 95%.
Bacterial culturing
The clinical GBS isolate, NCTC10/84 (serotype V) was grown in Todd
Hewitt Broth (THB) without agitation at 37°C to an OD600 of 0.4,
equivalent to 108 cfu/mL. Bacteria collected by centrifugation were washed
with sterile PBS. Mice were inoculated intraperitoneally with 3  107 cfu
NCTC in 30 L PBS. For survival experiments, mice were inoculated by
intraperitoneal injection with 5  107 cfu NCTC in 0.3 mL PBS.
Results
Biphasic trafficking of lymphocytes during acute inflammation
We6 and others7-10 have previously observed lymphocytes repopu-
lating sites of injury as inflammation resolves, but without attribut-
ing a functional relevance to their reappearance. Trafficking of
lymphocytes during resolution is apparent in inflammation associ-
ated with human chronic ambulatory peritoneal dialysis where, as
inflammation decreases (Figure 1A,B), lymphocyte numbers in-
crease (Figure 1C). Clinical assessment of these patients was based
on patients presenting with abdominal pain, cloudy dialysate, and
leukocyte count of more than 100/mm3. In all cases, peritonitis
resolved by day 5 as determined by the appearance of a clear
dialysate and abatement of abdominal symptoms. Similar results
were evident in resolving experimental murine peritonitis (Figure
1D). Experiments were therefore carried out to establish the role
these cells play in innate immune-mediated inflammation by
characterizing, in the first instance, the profile of lymphocyte
populations throughout the time course of an acute zymosan-
induced peritonitis. In the naive murine peritoneum (0 hours),
lymphocytes constitute about 50% of the total cell population, with
the remaining being resident macrophages. Of the CD3 cells,
CD4 and CD8 cells were found as well as lower numbers of
CD4/CD25, / T cells, and NK cells (Figure 1E-J). However,
the majority of lymphocytes in the naive cavity are B cells
constituting about 70% to 80% of the total lymphocyte population
labeling positively for CD19 as well as B220 (Figure 1K). Of these
B cells, about 80% are B220low/CD5/MAC-1low, indicative of a
B1 phenotype, with the remainder being B220high/MAC-1 B2
cells. As inflammation initiates (1-4 hours), T and B cells disappear
but repopulate the peritoneum again between 12 and 24 hours
(Figure 1D). Notably, there were more CD4/CD25, / T cells,
and NK cells found during resolution (Figure 1H-J) as well as B1
cells expressing higher levels of MAC-1 than in the naive state
(Figure 1K), collectively referred to hereafter as resolution-phase
lymphocytes. Figure S6 (available on the Blood website; see the
Supplemental Materials link at the top of the online article) shows
FACS analysis of lymphocyte cell-surface labeling. As inflamma-
tion peaks between 6 and 12 hours in this model and subsequently
resolves (Figure 1D), it is argued that lymphocytes repopulate the
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peritoneum during or just after resolution occurs. Indeed, experimen-
tally enhancing the severity of the inflammatory response within
the peritoneum by injecting 3 separate doses of zymosan (0.1, 1.0,
and 10 mg), therefore prolonging resolution, is associated with
reduced lymphocyte repopulation (Figure 1L). Whether this is a
delay or suppression is unclear at this stage. However, from the
data presented here, we suggest that lymphocytes repopulate sites
of inflammation once resolution occurs. Therefore, this questions
what controls lymphocyte influx, which we suggest may be factors
released by stromal and/or hematopoietic cells once restitution
processes are under way. If so, lymphocyte repopulation is an
active process and, until resolution occurs, lymphocyte repopula-
tion is suppressed. Thus, from these experiments we show a shift in
lymphocyte populations from the naive to a resolving state
constituting more innate-type lymphocytes as well as a different
phenotype of B1 cells.
Lymphocytes are dispensable for resolution but mediate
responses to superinfection
To examine the role of lymphocytes in acute inflammation,
zymosan was injected into the peritoneal cavity of lymphocyte-
deficient RAG1/ mice. Inflammation at onset was greatly
exaggerated in these animals, twice that in wild-type (Figure 2A),
with the principal cell type being PMNs (Figure 2B). This
exaggerated response in RAG1 knockout mice was associated with
decreased exudate IL-10 and elevated TNF levels (Figure 2C).
Surprisingly, inflammation in wild-type and RAG1/ mice re-
solved uniformly from 24 hours onward (Figure 2A,B), suggesting
that lymphocytes have no role in switching off acute inflammation
and that regardless of how many PMNs traffic to sites of tissue
injury, resolution pathways are sufficiently adept at dealing with
their disposal. Pursuing the idea that lymphocytes may protect
against secondary infection, in a second experiment, RAG1/ and
wild-type mice were injected with a sublethal dose of GBS
48 hours after zymosan injection. Thus, live bacteria were intro-
duced into the inflamed cavity as inflammation resolved, and its
effects determined 24 hours later (Figure 2D). Wild-type mice that
got zymosan followed by bacteria displayed fewer signs of illness
compared with those that received GBS alone, which exhibited
50% mortality by 24 hours, with the remaining animals dying by
48 hours. However, injecting GBS into RAG1/ mice 48 hours
after receiving zymosan showed an approximate doubling of
inflammatory cell accumulation compared with wild-type mice
treated in the same way (Figure 2D). This resulted in a lower
bacterial load in the plasma of GBS-treated RAG1/ (Figure 2E)
but substantially accelerated mortality due to the concomitant
hyperinflammatory response (Figure 2F). Results from these
studies suggest that inflammation in the resolving phase exerts
greater defense against bacterial infection and lethality than do
naive tissues. In addition, in terms of controlling initial leukocyte
trafficking in response to nonspecific stimuli, protection is con-
ferred by resident lymphocytes, with resistance to secondary
infection exerted by repopulating, resolution-phase lymphocytes.
Therefore, lymphocytes modulate host responses to injury/
infection but are not required to bring about resolution (ie, clear
Figure 1. Biphasic trafficking of lymphocytes during acute inflammation. (A-C) Patients undergoing chronic ambulatory peritoneal dialysis and who developed peritonitis
that resolved were found to have lymphocytes at the time of recovery of clinical symptoms. Pursuing this observation in murine zymosan-induced peritonitis (D), T and B cells
native to the naive peritoneal cavity were found to disappear within hours of stimulus injection. Once inflammation resolves, lymphocytes repopulate the peritoneum but
comprise more (E-J) CD4/CD25 and / T cells as well as NK cells, than is present in the naive cavity (0 hours) as well as (K) MAC-1 B cells. (L) Experimentally enhancing
the severity of the inflammatory response within the peritoneum by injecting 3 separate doses of zymosan (0.1, 1.0, and 10 mg) prolonged resolution and delayed lymphocyte
repopulation (72 hours), suggesting that lymphocytes repopulate only after resolution occurs. n 	 6 to 8 animals per group; *P  .05; **P  .01, as determined by analysis of
variance (ANOVA), followed by Bonferroni t test, with data expressed as means plus or minus SEM.
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Figure 2. Lymphocytes control early onset of innate inflammation but are dispensable for its resolution. (A,B) Although inflammation doubled in RAG1/ during the
onset phase in response to zymosan, coincident with (C) an imbalance of IL-10 versus TNF, inflammation normalized with that of wild-type mice from 24 hours onward,
suggesting no role for lymphocytes in actively bringing about resolution (ie, clearing PMNs or macrophages). (D) However, RAG1/ and wild-type mice were injected with GBS
during resolution (48 hours after zymosan injection), resulting in enhanced leukocyte accumulation in RAG1/ but not wild-type mice 24 hours later. (E) This was associated
with reduced bacterial colonization in plasma but (F) increased mortality in RAG1/ mice as a result of the concomitant hyperinflammatory response. We therefore argue that
lymphocytes are not required for bringing about resolution and propose that their reappearance hails the end of the inflammatory event and an attempt at restorative physiology.
Their role in this setting is in protecting against secondary infection or injury with B cells, CD4/CD25 cells, and / T cells as well as NK cells playing a likely role in this setting.
n 	 6 to 8 animals per group, with experiments repeated on 2 separate occasions to confirm original findings. *P  .05; **P  .01, as determined by ANOVA, followed by
Bonferroni t test, with data expressed as means plus or minus SEM.
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PMNs and macrophages from inflamed sites). The different profile
and proportion of lymphocyte repopulating during resolution is
necessary to combat secondary infection.
Peritoneal lymphocytes disappear in response to
PGD2 STOPPED
Investigating how lymphocytes disappear, we recorded equivalent
numbers of T and B lymphocytes in the peritoneal cavity of
hPGD2S knockout mice at 6 hours as in the naive cavity (0 hours)
of wild-type (Figure 3A-E). hPGD2S metabolizes cyclooxygenase-
derived PGH2 to PGD2,18 which activates 2 G-protein–coupled
receptors, DP1 and DP2 (CRTH2).19,20 PGD2 is further dehydrated
to the cyclopentenone PG, 15-deoxy-
12,14-PGJ2 (15d-PGJ2),21,22
with levels of PGD2 and 15d-PGJ2 peaking within the first few
hours of acute peritonitis coincident with lymphocyte disappear-
ance.11 Incidentally, the existence of 15d-PGJ2 in mammalian
systems has been hotly debated over the years, but in these
experiments, we used liquid chromatography–mass spectrometry–
mass spectrometry (LC-MS-MS) to definitively confirm its pres-
ence in resolving inflammation.11 Adding BW245C (DP1
agonist15,16) to hPGD2S knockout mice reduced lymphocytes at
6 hours, with the clearance effects of DP1 on B cells (Figure 3F).
15(R)-15-methyl PGD2 (DP2 agonist17) had no effect on lympho-
cyte numbers in knockout mice, indicating that DP1 receptor
activation is responsible for B-cell disappearance early in acute
inflammation. The fate of CD3 cells remains less clear. For
instance, CD3 cells were examined for their adherence to the
greater omental lymphoid organ, the so-called leukocyte disappear-
ance reaction typical of peritoneal macrophages during acute
peritonitis.23 But, addition of 5% trypsin to a 4-hour inflamed
cavity for 10 minutes recovered displaced macrophages but not
lymphocytes (Figure S7). Another possibility was that CD3 cells
underwent programmed cell death in response to 15d-PGJ2, a
highly reactive electrophile and, in our experience, a potent inducer
of lymphocyte apoptosis. Although CD3 cells from hPGD2S/
mice remained low for annexin V/propidium iodide labeling up to
6 hours, on a percentage basis there was a trend toward an increase
in annexin V labeling within the equivalent population in wild-type
mice. However, this did not reach significance due to the dimin-
ished numbers of peritoneal CD3 cells in wild-type mice available
Figure 3. PGD2 controls the clearance of peritoneal
resident lymphocytes. In response to inflammatory
stimuli, lymphocytes in the peritoneum disappear be-
tween 6 and 24 hours. (A-E) However, lymphocyte
numbers in hPGD2S knockout mice at 6 hours (f) were
found to be equivalent to that present in the naive cavity
of wild-type mice (), suggesting a role for either PGD2
and/or 15d-PGJ2 in the initial clearance of lymphocytes.
(F) Adding back BW245C (DP1 receptor agonist) to
hPGD2S knockout mice caused a reduction in B cells.
Attempts made to identify the fate of CD3 cells gener-
ated inconclusive results, with data suggesting that they
may die locally by programmed cell death (data not
included). n 	 8 animals per group. *P  .05 as deter-
mined by Bonferroni t test, with data expressed as
means plus or minus SEM.
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for analysis (data not included). Therefore, we can suggest that
within a few hours of inducing an inflammatory response, perito-
neal resident B cells disappear in a PGD2/DP1-dependent manner,
but that the fate of CD3 cells remains unclear.
Deficiency of repopulating lymphocytes in nonresolving
chronic granulomatous disease
Finally, the relevance of these findings to human inflammatory
diseases was determined by examining the role of lymphocytes in
gp91phox knockout mice, an experimental model of human chronic
granulomatous disease caused by defects in the phagocyte respira-
tory burst oxidase, which generates microbicidal superoxide.24,25
Hence, patients with chronic granulomatous disease lack antimicro-
bial capacity and the ability to combat bacterial and fungal
infections. Moreover, there is the associated occurrence of inflam-
matory granulomas in lung, liver, and skin, which in some
instances may arise from sterile stimuli, suggesting that their
formation may be due to incomplete degradation of inflammatory
debris and/or impaired resolution of inflammation.26,27 gp91phox
knockout mice were injected intraperitoneally with sterile zymosan
and found to have elevated leukocyte numbers compared with
controls, with inflammation failing to resolve (Figure 4A). See also
Figure S8 for comparison of cell types in both animals at
resolution. Fewer lymphocytes were found at 48 to 96 hours in
gp91phox knockout mice, the time frame of resolution and lympho-
cyte repopulation in wild-type mice (Figure 4B). Lymphocytes
obtained from the resolution phase (72 hours) of normal strain-
matched wild-type controls which were therefore composed of B1,
NK, and / T cells as well as CD4/CD25 cells, were transferred
back to gp91phox knockout mice (72 hours) and challenged with
LPS. Inflammation was reduced in knockout mice that received
resolution-phase lymphocytes compared with gp91phox mice alone
(Figure 4C). These results suggest that during ongoing, nonresolv-
ing inflammation, the absence of lymphocytes may account for
susceptibility to superinfection and the associated hyperinflamma-
tory response.
Discussion
Here, evidence is presented that lymphocytes play a pivotal role in
controlling the onset of innate immune-mediated inflammation by
regulating cytokine synthesis as well as host susceptibility to
secondary infection. Analysis of lymphocyte subsets in the naive
peritoneal cavity of mice revealed that B cells constitute about 70%
to 80% of the total lymphocyte population, of which the majority
have a B1 phenotype, with the remainder being B2 cells. CD3
cells as well as NK and / cells make up the remaining 20% of
lymphocytes. This profile differs to that found at resolution, which
comprises more innate-type lymphocytes and B1 cells expressing
MAC-1. Although we did not discern which lymphocyte or
combination of lymphocytes bestowed protection at onset or at
resolution, in a separate study, peritoneal CD3 T cells and in
particular B220 B cells were found to elaborate high levels of
IL-10 in a DP1-dependent manner,11 most likely explaining the
reduction in IL-10 in lymphocyte-deficient RAG1/ mice and
subsequent increase in PMN influx in these animals. Thus, given
the relative proportion of T cells versus B1 cells in the inflamed
cavity and the ability of B cells to synthesis comparatively high
levels of IL-10, we suspect that B lymphocytes may one of the
predominant cell types modulating acute inflammatory responses
to nonspecific stimuli.
As PMNs begin to accumulate in response to zymosan, B cells
disappeared in a PGD2-dependent manner, as there was equivalent
numbers of B cells in the inflamed cavity of hPGD2S/ at 6 hours
as there was in the naive cavity of wild-type mice. This accumula-
tion of B cells in hPGD2S knockout mice was reversed by
BW245C, a DP1 receptor agonist, with DP2(CRTH2) playing no
role in this setting. While the mechanism of PGD2-dependent
B-cell clearance is unknown, a Toll-like receptor (TLR)–mediated
transient down-regulation of integrins and CD9 on B1 cells was
shown to be required for detachment of these cells from the local
peritoneal matrix and their subsequent efflux from the inflamed
cavity.28 Whether BW245C alters CD9 expression needs further
investigation, but given that B cells disappear concomitantly with
PGD2 synthesis, it is possible that DP1 activation may play a role in
regulating this pathway of B1 cell detachment and efflux. The fate
of CD3 cells, on the other hand, is less clear. While their attachment
to the peritoneal lining can certainly be excluded, there is the
Figure 4. Absence of repopulating lymphocytes during nonresolving inflamma-
tion. (A) Zymosan was injected into the peritoneal cavity of pg91phox knockout mice,
which, when compared with controls, showed a more aggressive inflammatory
response that failed to resolve. (B) FACS analysis of cell types present during
resolution revealed a progressive repopulation of lymphocytes during resolution that
was lower in pg91phox knockout mice. (C) Lymphocytes obtained from the resolution
phase (72 hours) of normal strain-matched wild-type controls and comprising B1
cells, NK cells, and / T cells, as well as CD4/CD25 cells, were transferred back
into the peritoneal cavity of gp91phox knockout mice (72 hours) and subsequently
challenged, intraperitoneally, with LPS. Inflammation was reduced in gp91phox
knockout mice that received resolution-phase lymphocytes compared with gp91phox
mice alone. *P  .05; **P  .01 as determined by ANOVA, followed by Bonferroni
t test, with data expressed as means plus or minus SEM.
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possibility that these cells may die locally by programmed cell
death in response to 15d-PGJ2, which is synthesized concomitant
with their disappearance,11 and in our experience, a potent inducer
of lymphocyte apoptosis. However, future detailed work is required
to definitively identify whether they die locally or clear via draining
lymphatics. Thus, PGD2 exerts a dual role on resident B cells at
least—regulating their inflammatory cytokine release as well as
their efflux from the inflamed peritoneal cavity.
The mechanism by which lymphocytes exert their protective
effects in these experiments is unclear at this stage. Certainly, there
is a cytokine imbalance favoring proinflammatory TNF but
reduced IL-10 in the inflamed peritoneum of RAG mice, thereby
potentially explaining the enhanced influx of PMNs in these mice
compared with wild-type. Indeed, we have shown that both T and
B lymphocytes are capable of elaborating inflammatory cytokines,
which, on balance, in the inflamed peritoneum at least, serve to
limit PMN influx.11 However, in addition to cytokines/chemokines,
cell adhesion molecules are also central to facilitating PMN
adhesion and accumulation at sites of inflammation and, contrary to
data presented here, there is evidence showing that lymphocytes
trigger cell adhesion molecule expression. For instance, intracellu-
lar adhesion molecule 1 expression in Plasmodium-infected mice is
reduced in the brain but not the lung of RAG1/ mice, while
P-selectin expression is attenuated in both organs in these ani-
mals.29 Equally, T cells were shown to enhance the expression of
TNF-triggered endothelial cell adhesion molecule expression,
with these effects varying between vascular beds.30 On this basis, it
is difficult to reconcile the role circulating lymphocytes play in
up-regulating cell adhesion molecule expression on the leukocyte/
endothelial cell interface to that of the resident peritoneal T/B cells
other than to highlight the different profile of lymphocytes present
in the peritoneum (B1, B2, and small numbers of CD4/CD25 cells)
that exert a predominantly protective effect in both the naive and
postresolution state.
The trigger for lymphocyte repopulation is unclear, but critical
determinants of resolution such as PMN apoptosis or signals
released by macrophages during phagocytosis of apoptotic leuko-
cytes may play a central role. However, we have shown previously
that inducible cyclo-oxygenase is expressed during and is essential
for the resolution of acute inflammation,6,31,32 while others have
reported that lipoxygenase-lipoxygenase interaction products of
arachidonic as well as eicosapentaenoic and docosahexanoic acids
dampen the severity of inflammatory onset and trigger resolu-
tion.33-35 Taking a closer look at whether cyclo-oxygenase or
lipoxygenase play a role in lymphocyte repopulation, we found that
not only is COX-2 expressed during the resolution phase of
zymosan-induced peritonitis, but that its inhibition with either
NS-398 or the nonselective COX inhibitor indomethacin impairs
lymphocyte repopulation, in particular CD3 cells. However,
inhibition of lipoxygenase isoforms with baicalein was without
effect. These data implicate a COX-2 metabolite in the recruitment
of postresolution lymphocytes and therefore protection against host
susceptibility to superinfection (J. Newsom, M. Stables, P.C.-N.,
G.B., and D.W.G., manuscript in preparation).
Comparing repopulating lymphocytes with those in the naive
cavity revealed more NK cells, / T cells, and CD4/CD25 cells,
in addition to B1 cells with higher Mac-1 labeling than that found at
onset. The functional relevance of increased MAC-1 expression on
resolving B1 cells is not apparent at this stage, but may reflect a
state of differentiation/activation or a specific requirement for
migration back to the resolved peritoneum. However, repopulating
lymphocytes have no role in actively bringing about resolution, but
Figure 5. A summary of the scheme of events that
occurs in acute inflammation with reference to
lymphocyte trafficking. As inflammation ensues resi-
dent lymphocytes begin to disappear, with B1 cells
clearing via draining lymphatics and the fate of CD3
cells remaining unclear at this stage. Once inflamma-
tion begins to resolve, lymphocytes repopulate the site
of injury in a profile different to that in the naive state.
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protect against superinfection. In these experiments, GBS was
given into the resolving peritoneal cavities of wild-type as well as
RAG1/ mice. Interestingly, the degree of inflammation in
wild-type mice that received zymosan followed by GBS was not
significantly greater than the level of inflammation in resolving
wild-type mice not given GBS. In contrast, inflammation in
RAG1/ mice that received zymosan followed by GBS was
almost twice that of inoculated wild-type mice. This suggests that
resolution-phase lymphocytes confer protection against secondary
infection. This was certainly confirmed by injecting live bacteria to
RAG/ mice undergoing resolution, which subsequently died
substantially faster than wild-type mice treated in the same manner
(Figure 2F). It is unknown why the proportion and profile of
repopulating lymphocytes is different to that at onset. Perhaps as
resolving tissues are physiologically altered as a consequence of
the inflammatory event they underwent, host defense mechanisms
need to be fundamentally different to guard against superinfection
by recruiting more protective lymphocytes. On this theme, it is not
really understood when acutely inflamed tissues revert back to their
original state. Certainly, a population of macrophages (about
1  106) were found to linger for at least 3 weeks after a zymosan
peritonitis apparently resolved, supporting the idea that although
the original response was acute and transitory in terms of PMN
influx and efflux, its effects may be longer-lasting than originally
believed, thereby requiring a different profile and greater propor-
tion of lymphocytes to modulate future inflammatory events. This
may explain why inflammation in the resolving phase conferred
greater protection against GBS lethality than uninflamed or naive
mice (Figure 2D,F).
Taking these findings to a more clinically relevant setting, it
became clear that unlike wild-type mice, there was a deficit of
repopulating lymphocytes in nonresolving gp91phox knockout mice
bearing zymosan-induced peritonitis. Replenishing gp91phox knock-
out mice with resolution-phase lymphocytes taken from strain-
matched controls and then challenging animals with LPS conferred
protection compared with sham-operated gp91phox knockout mice.
Data from this study confirm that not only does lymphocyte
repopulation fail to occur in nonresolving inflammation, but that
resolving-phase lymphocytes protect against exaggerated inflamma-
tory responses to superinfection (Figures 2D,4C). On this note,
defects in innate lymphocyte functioning have been suggested to
lead to secondary infections associated with burn injury,36 while
increased lymphocyte apoptosis contributes to the pathogenesis of
sepsis,4,5 underlining the crucial role lymphocytes play in host
defense against nonspecific injury. Moreover, as NK cells were
originally described for their ability to lyse tumor cells,37 and
/ T cells have well-known tumor surveillance properties,38,39
their absence from sites of nonresolving inflammation may
be one of the predisposing factors to the development of
inflammation-related cancer.40 Thus, one of the hazards
of ongoing acute inflammation and consequently failed lympho-
cyte repopulation may be increased susceptibility to superinfec-
tion and even cancer as a result of lymphocyte apoptosis,
lymphocyte immunoparalysis, or, as presented here, a failure of
protective lymphocytes to repopulate after resolution.
In summary, we report a biphasic role for lymphocytes during
innate immune-mediated inflammation, summarized in Figure 5.
The first phase controls PMN trafficking with lymphocytes then
vacating the peritoneal cavity in response to PGD2 activating its
DP1 receptor. The second phase is characterized by lymphocyte
repopulation occurring after inflammation begins to resolve in a
different proportion and profile to that of the naive state. Impor-
tantly, repopulating lymphocytes have no role in bringing about
resolution, but protect against secondary infection.
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Abstract
In chronic granulomatous disease (CGD) there is failure to generate reactive oxygen metabolites
resulting in recurrent infections and persistent inflammatory events. As responses to sterile stimuli
in murine models of CGD also result in non-resolving inflammation, we investigated whether defects
in endogenous counter-regulatory mechanisms and/or pro-resolution pathways contribute to the
aetiology of CGD. To this end we carried out a series of experiments finding, in the first instance
that adenosine and cAMP, which dampen innate immune-mediated responses, show a biphasic
profile in resolving peritonitis; peaking at onset, waning as inflammation progresses and rising again
at resolution. We also found elevations in adenosine and cAMP in resolving human peritonitis. In
gp91phox-/- mice, an experimental model of CGD, levels of adenosine and cAMP were significantly
lower at onset and again at resolution. Corroborating the finding of others, we show that adenosine,
signalling through its A2A receptor and therefore elevating cAMP is not only anti-inflammatory but,
importantly, it does not impair pro-resolution pathways, properties typical of nonsteroidal anti-
inflammatory drugs. Conversely, antagonising the A2A receptor worsens acute inflammation and
prolongs resolution. Taking this further, activating the A2A receptor in gp91phox-/- mice was
dramatically anti-inflammatory regardless of the phase of the inflammatory response A2A agonists
were administered i.e. onset or resolution demonstrating wide and robust pharmacological flexibility
that is unlikely to subvert pro-resolution pathways. Therefore, we describe the biphasic profile of
adenosine and cAMP throughout the time course of acute inflammation that is dysregulated in CGD.
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INTRODUCTION
In response to injury/infection there is the sequential release of pro-inflammatory mediators
including complement(1), histamine(2,3), bradykinin(4) and 5-hydroxytryptamine(5) along
with cytokines and chemokines(6) that cause cell and edema accumulation. Concomitantly,
there are braking signals that temper the severity of this early onset phase including adrenaline
(7), adenosine(8-10), steroid hormones(11), cAMP(12) and counter-regulatory cytokines
including IL-10(13). In attempts to enhance our understanding of acute inflammation, we are
beginning to realise that, in addition to endogenous checkpoints that temper PMN trafficking
there are also signals that control the transition of PMNs to phagocytosing macrophages
(prostaglandin [PG]E2(14), IL6/IL6ra complex(15)), scavenge cytokine/chemokine from the
inflammatory environment (D6 scavenger receptor(16), lipoxins(17)) as well as clear
macrophages to the draining lymph nodes (PGD2(18) and resolvins(19)) leading to
inflammatory resolution. Advancing this paradigm even more, our group recently identified
the post-resolution influx of innate-type lymphocytes to sites of inflammation with a role in
controlling host responses to secondary inflammation and superinfection(20). Indeed, we
propose, for the first time, that one of the cardinal signs of resolution is the recruitment of
innate-type lymphocytes to sites of tissue injury concomitant with inflammation switching off.
It is argued that while inflammation has apparently resolved, classically defined by the
clearance of inflammatory leukocytes, there are events occurring locally involving innate-type
lymphocytes that have an impact on organ and host health long after inflammation has abated.
Thus, innate immune responses are designed to combat infection and repair injured tissues in
a timely manner. However, there are instances when the endogenous factors that control
immune severity become dysregulated, resulting in progression to chronic inflammation and
tissue injury. To combat this, anti-inflammatory agents were designed based on their inhibition
of signals that propagate inflammation(21) with little consideration for any adverse impact on
pro-resolution pathways, as has been demonstrated with non-steroidal anti-inflammatory drugs
(NSAIDs)(22). Consequently, when treating inflammation we must also aim to trigger its
resolution or, at least, not impair endogenous pathways that lead to tissue homeostasis(23),
with one of the hallmarks for this, in the peritoneum at least, being innate-type lymphocyte
repopulation(20).
There are many clinical examples where chronic inflammation could be hypothesised to be
potentially derived from dysregulated resolution pathways. Thus, a human disease that fails to
resolve and for which there is an experimental animal model amenable to scientific
interrogation, would aid enormously in elucidating the aetiology of chronic inflammation. To
this end, we turned to chronic granulomatous disease (CGD), which is an inherited
immunodeficiency syndrome caused by a defect in the oxygen metabolic-burst machinery
resulting in the inability to neutralise infection leading to persistent and recurrent inflammatory
responses and granulomatous tissue formation(24). Activity of NADPH oxidase system
(gp91phox, p22phox, p47phox and p67phox) is either absent or dysregulated in these patients
with the most common being X-linked CGD (∼65%) with defects in the gene encoding
gp91phox. Fortunately, for the purpose of understanding the aetiology of CGD, gp91phox
deficient mice display all the hallmarks of the human condition in response to infection(25).
Interestingly, there are reports showing that inflammation in CGD mice is also prolonged and
dysregulated in response to sterile stimuli(26,27), suggesting potential irregularities in
endogenous anti-inflammatory and/or pro-resolution pathways. We carried out a series of
studies in gp91phox-/- mice and found that of the factors known to control resolution, few
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appeared to be consistently dysregulated with the exception of adenosine and cAMP, levels of
which are significantly lower in experimental CGD compared to wild types.
Under physiological conditions, adenosine is continuously formed intracelluarly and
extracellularly. The intracellular production is mediated either by an intracellular 5′-
nucleotidase, which dephosphorylates AMP or by hydrolysis of S-adenosyl-homocysteine
(28). Adenosine generated within cells is transported into the extracellular space via bi-
directional transporters through facilitated diffusion that efficiently equilibrates intracellular
and extracellular levels of adenosine. Following trauma, there is a decrease of intracellular
ATP, accompanied by an accumulation of 5′-AMP and subsequently adenosine by the above
pathways, which may be sequentially metabolized to inosine, hypoxanthine and xanthine.
Expressed on cells of the hematopoietic system, adenosine receptors (A1, A2A, A2B, A3) belong
to the family of G-protein-coupled heptahelical transmembrane receptors, which either
stimulate (Gs) or inhibit (Gi) adenylyl cyclase, the enzyme that catalyzes the formation of
cAMP(28). Adenosine A1 and A3 receptors are high and low affinity receptors for adenosine,
respectively, with both being inhibitors of adenylyl cyclase. High-affinity A2A and low-affinity
A2B receptors, on the other hand, activate adenylyl cyclase, thereby increasing intracellular
levels of cAMP, resulting in potent immune-suppression and regulation of inflammatory
leukocyte trafficking. Besides controlling adenylyl cyclase, adenosine receptors are also
coupled by distinct G-proteins to several other effector systems, including calcium and
potassium channels, phospholipase C, D, A2, cGMP, phosphodiesterases, and mitogen-
activated protein kinases that modulate different cell functions. Thus, adenosine, released after
tissue injury or low oxygen tension associated with inflammation, has been regarded by some
to act as a first line sensor of immune damage where it prevents further damage by inhibiting
activated immune cells with its immune-suppression mediated by A2A receptor elevation of
cAMP(10,29).
In this study we report the biphasic synthesis of both adenosine and cAMP, first at the traditional
early onset phase of acute inflammation and again during resolution, with synthesis of these
immunosuppressive agents being significantly lower in CGD (gp91phox-/-) mice associated
with a severe and prolonged innate immune response to a sterile stimuli. We also show that
hyper-inflammation in gp91phox-/- mice can be rescued by A2A receptor activation as defined
by reduction in inflammatory leukocytes. Importantly, A2A receptor activation in
gp91phox-/- mice did not bring about resolution as this drug strategy was not associated with
innate-type lymphocyte repopulation that is typical of events that occur during normal
resolution in wild type leading to tissue homeostasis.
MATERIALS AND METHODS
Animal maintenance, induction of inflammation and human peritonitis sampling
gp91phox-/- mice (Jackson Laboratories, Maine, USA),along with wild type mice, were bred
under standard conditions and maintained in a 12h/12h light/dark cycle at 22 ± 1°C and given
food and tap water ad libitum in accordance with United Kingdom Home Office regulations.
The murine 7-day air pouch was elicited by the injection of 3ml of sterile air followed 7 days
later with the intra-pouch injection of 0.5ml 1% carrageenin. Peritonitis was induced by the
intraperitoneal injection of 1mg type A zymosan (Sigma) and cells enumerated by
haemocytometer at time points stated in results section by sterile PBS washout. Ethical
approval (P/03/136A) for collection of human peritonitis samples was obtained from St.
Bartholomew’s & the Royal London Hospitals from end stage renal failure patients undergoing
peritoneal dialysis.
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Macrophage isolation, culture and stimulation
Peripheral venous blood samples were collected from subjects into heparinised syringes (5U/
ml). Mononuclear cells were isolated by differential centrifugation (2000rpm, 30 mins, 20°C)
over Lymphoprep® (Axis-Shield, Oslo, Norway) and washed twice with sterile phosphate-
buffered saline (PBS) (GIBCO, Paisley, UK) at 1200rpm (5 mins, 20°C). Cells were re-
suspended in 10mls RPMI-1640 medium (Invitrogen, Paisley, UK) supplemented with 100U/
ml of penicillin (GIBCO) and 100μg/ml streptomycin (GIBCO) and 20mM Hepes buffer
(Sigma) (RPMI), and plated at a density of approximately 5×106 cells/ml in 8cm2 Nunclon™
Surface tissue culture dishes (Nunc, Roskilde, Denmark). After an initial culture period of 2
hours at 37°C, 5% CO2, the non-adherent cells were discarded and 10mls of fresh RPMI
supplemented with 10% foetal bovine serum (Sigma) (10% FBS/RPMI) added to each tissue
culture dish. Cells were then cultured for 5 days at 37°C, 5% CO2, with the addition of a further
10mls fresh 10% FBS/RPMI after 24 hours. Adherent cells were scraped on day 5 and re-plated
in 96-well culture plates at equal densities (105/well) in X-Vivo-15 medium (Cambrex,
Walkersville, MD, USA). These primary monocyte-derived macrophages were incubated
overnight at 37°C, 5% CO2 to adhere, and then stimulated for 24 hours with 200ng/ml
lipopolysaccharide (LPS) (Alexis, San Diego, CA, USA). These studies were approved by the
Joint UCL/UCLH Committees on the Ethics of Human Research (02/0324). Written informed
consent was obtained from all volunteers. No patient was studied more than once in each of
the different sets of experiments.
Pharmacological rescue experiments
gp91phox-/--/- and wild type mice were pre-treated (30mins) with the A2A receptor agonist
CGS 21680 (2mg/kg) with/without ZM241385 (2mg/kg, A2A receptor antagonist) followed
by zymosan intraperitoneally. Rolipram was dosed at 30mg/kg. The peritoneal cavity was
lavaged at 4 hours and cell number counted using a haemocytometer. For experiments in the
resolution phase, inflammation was firstly induced with zymosan followed by CGS 21680 or
vehicle (DMSO) at 24 and 36 hours. The peritoneal cavity was lavaged at 48 hours following
zymosan. Caffeine as well as its stable analogue, 8-(3-chlorostyryl)-caffeine (CSC) were dosed
at 3mg/kg.
Eicosanoid analysis
Samples stored at -20°C were thawed at room temperature and acidified to pH 3. Samples were
extracted using C18 columns (Waters). For PGD2, samples were then treated with
methoxylamine hydrochloride (MOX HCL) and the resulting stable PGD2-MOX measured by
EIA (Cayman Chemicals, USA). PGE2 was measured by EIA (Cayman Chemicals, USA)
while lipoxin A4 was quantified by ELISA (Neogen, USA).
Purine and cAMP measurements
Proteins in exudates were removed by ultrafiltration (30,000 Dalton cut-off). Purine
concentrations in samples were measured by high pressure liquid chromatography as
previously described(30).
FACS analysis and cytokine/chemokine analysis
Cytokines were measured by ELISA according to manufacturer’s instructions (eBiosciences).
FACS was carried out on Becton Dickinson Facscalibur with data analysed by Cellquest.
Leukocytes were incubated with antibodies for 30mins to either CD3/CD19 (Serotec, UK), B
cells (Ly220, Serotec), GR1 (BD Pharmingen, UK) or F4/80 (Caltag laboratories, CA, USA)
using respective isotype antibodies as controls (Serotec, UK) and compensated as appropriate
for dual labelling. For apoptosis, cells were incubated with annexin V/propidium iodide
Rajakariar et al. Page 4
J Immunol. Author manuscript; available in PMC 2010 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
(Becton Dickinson) and analysed on Becton Dickinson Facscalibur with data analysed by
Cellquest.
RESULTS
Inflammation is more severe and fails to resolve in gp91phox-/- mice
In the first set of experiments we characterised the profile of inflammation in wild types versus
gp91phox-/- mice. Zymosan injection into the mouse peritoneal cavity resulted in an
exaggerated influx of PMNs (Figure 1A, Ly6G positive cells) in knockouts during the early
onset phase with numbers declining up to 96h. F4/80 positive macrophage numbers were
similarly increased at onset in knockouts with levels remaining elevated throughout the entire
response, Figure 1B, underlining the non-resolving nature of inflammation that is characteristic
of CGD. As there was little difference in leukocyte apoptotic rates as determined by annexin
V/propidium iodide labelling between both animals, Figure 1C, failure of resolution in CGD
mice most likely resulted from continual influx and/or failed clearance of inflammatory
leukocytes.
Reduced synthesis of purines and cAMP in gp91phox-/- mice
The classic view as to why inflammation is more severe in CGD is explained by defects in
phagocytic oxidase resulting in impaired bacterial killing and consequently delayed removal
of the injurious agent. That notwithstanding, injection of sterile inflammatory stimuli also
results in an exaggerated inflammatory event that fails to resolve(26,27). Certainly, while this
may arise from a defect in phagocytosis(31), we questioned whether it may also point to a
possible defect in endogenous braking systems that counter-regulate acute inflammation(23,
32,33). To this end we screened for alterations in levels of anti-inflammatory and pro-resolution
mediators finding no consistent trend in arachidonic acid metabolism between CGD and wild
type mice bearing a zymosan-triggered peritonitis. For instance, PGD2(18,22,34), the lipoxins
(35) and PGE2(14) have all been shown to trigger inflammatory resolution, yet, with the
exception of PGE2 there was little evidence for defects in arachidonic acid metabolism being
involved in aetiology of CGD, Figures 2A-C. However, we noted a clear and robust reduction
in levels of cAMP in CGD mice compared to wild type animals, Figure 2D. Specifically,
intracellular cAMP was elevated during the early onset phase of zymosan-induced peritonitis
in wild type controls (4-6h), waning as inflammation progressed and became elevated again
post-resolution, Figure 2D. In gp91phox-/- mice bearing a zymosan-triggered peritonitis,
cAMP was significantly lower than wild types at onset and failed to show the post-resolution
elevation seen in wild types, Figure 2D. The functional relevance of raised cAMP post
resolution is being answered in another body of work (paper enclosed), which shows that cAMP
controls the phenotype of resolution-phase macrophages imparting upon them an
immunosuppressive state. We next examined why cAMP levels are lower in gp91phox-/- mice.
Certainly, PGs are well known elevators of cAMP (via EP2, EP4, DP1)(36) and are also present
and functional during the early as well as later stages of acute inflammation(22). Nonetheless,
there was no substantial difference in cyclooxygenase activity between wild types and
gp91phox-/- mice. In fact, there was an elevation of PGE2 (Figure 2A) in gp91phox knockouts
indicating possible signalling of this PG through its EP1 (increased Ca2+) and/or EP3 (IP3/
DAG) receptors in CGD mice. However, there was a biphasic profile of adenosine synthesis
mirroring that of cAMP - raised at onset and then again at resolution, Figure 2E. Adenosine
showed lower levels in gp91phox-/- mice than wild types and is a well described immuno-
modulator of acute inflammation serving to dampen PMN function and prevent chemical-
induced collateral liver injury(37). With its molecular actions exerted through four receptors
A1, A2 (A2A and A2B) as well as A3, signalling through A2A has received most attention as a
trigger for immuno-suppressive cAMP. Thus, from these studies we report the biphasic
synthesis of adenosine and cAMP in resolving models of acute inflammation, with their levels
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diminished in inflammation associated with CGD. It could be argued that it is the absence of
these endogenous anti-inflammatories in CGD that is responsible for its hyper-inflammatory,
non-resolving nature. Alternatively, persistence of the inflammatory stimulus would certainly
prevent resolution and consequently deactivate or override endogenous pro-resolution
pathways. The latter may indeed be the case as levels of cAMP released from monocyte-derived
macrophages obtained from CGD patients released similar quantities of cAMP per equivalent
cell numbers to those from healthy volunteers when stimulated with LPS, Figure 2F.
Adenosine and cAMP profiles in human resolving peritonitis
As an alternative to dialysis, patients on end-stage renal failure may undergo chronic
ambulatory peritoneal dialysis (CAPD) where a catheter is inserted to fill/drain the peritoneal
cavity with a high glucose solution with the peritoneal lining acting as a dialysing membrane.
Occasionally, patients experience bacterial infection (commonly S. aureus or S. epidermidis)
resulting in acute resolving peritonitis from which both effluent and cells can be analysed for
markers of inflammation and resolution(38). We measured levels of cAMP (Figure 3A) as well
as adenosine, (Figure 3B) in these samples and found that when overlaid on the inflammatory
leukocyte profile (Figure 3C), which peaked 24h after infection, cAMP as well as adenosine
was elevated as inflammation resolved. While these results corroborates that found in mice,
we have no data on the very early onset (∼ 6h) phase in humans to assess the very early release
of adenosine and cAMP in human inflammation. Thus, as in rodents, levels of cAMP and
adenosine were elevated as inflammation resolved.
Adenosine, via A2A is anti-inflammatory and not resolution-toxic
As with the plethora of effects NSAIDs exert on acute inflammation, it is well established that
by signalling through its A2A receptor, adenosine exerts protective effects during acute
inflammation at multiple levels. However, while NSAIDs dampen the early onset phase of
acute inflammation, they also obstruct pro-resolution processes(22). Therefore, we next
determined whether A2A signalling interferes with inflammatory resolution. In the first
instance, rats bearing a carrageenin-induced pleurisy were administered rolipram, a PDE4
inhibitor and therefore elevator of cAMP as well as CGS 21680, a specific A2A receptor agonist
30mins prior to carrageenin injection. Both drugs dampened leukocyte trafficking to the
inflamed cavity at onset i.e. 4h (Figure 4A), being associated with an expected rise in cAMP,
Figure 4B. In a mouse zymosan-induced peritonitis at 4h, CGS 21680 also dampened
inflammation in an A2A receptor dependent manner using ZM 241385 (A2A receptor
antagonist) (Figure 4C) associated with a significant increase in anti-inflammatory IL-10,
Figure 4D. Other drugs, including theophylline as well as beverages are known to alter cAMP
signalling and therefore may unwittingly affect inflammation. A single cup of coffee, for
instance, contains about 100mg of caffeine implying that an average person drinking one cup
of coffee per day will ingest caffeine at 1.5mg/kg. To investigate whether caffeine, a
methylxanthine with antagonistic effects on the A2A receptor(39) affects acute inflammation,
we administered caffeine as well as its stable analogue, 8-(3-chlorostyryl)-caffeine (CSC) at
3mg/kg 30mins before i.p. zymosan injection and found that both worsened inflammation
possibly by decreasing protective IL-10 levels, Figures 4E and F. Using a continual
pharmacological dosing regimen, mice were administered not only 30mins before zymosan
injection but were also given caffeine and CSC again at 12h and 18h after zymosan and their
effects assessed at 24h. The idea being that as inflammation resolves by 24h, any resolution-
toxic effects of these drugs would be detected, an important consideration with anti-
inflammatories that must be highlighted. CGS 21680 maintained a dampening of acute
inflammation without interfering with resolution, Figure 4G. On the other hand, caffeine at
doses representative of reasonable caffeine daily intake as well as its analogue, CSC,
maintained their pro-inflammatory effects, Figures 4G. Taking the doses of caffeine up to 10
and 30mg/kg, equivalent to 6-20 cups of coffee, resulted in a loss of pro-inflammatory effects.
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Therefore, from these experiments, A2A agonists exert anti-inflammatory effects not only
during the early onset phase of acute inflammation, the phase traditionally tested
experimentally for novel anti-inflammatories, but, importantly do not interfere with pro-
resolution pathways. An interesting observation was the corollorary to these experiments,
which revealed that caffeine has antagonistic effects on endogenous protective pathways and
is not only pro-inflammatory but potentially anti-resolution.
Adenosine via A2A is anti-inflammatory but not pro-resolving in gp91phox-/- mice
Being anti-inflammatory is not the same as possessing pro-resolution properties(23).
Therefore, in these final experiments, we determined whether drugs that signal through A2A
and raise cAMP rescued the hyper-inflammatory phenotype typical of gp91phox-/- mice and
importantly, whether they bring about resolution of inflammation in these animals. Thus, CGS
21680 was dosed orally 30mins before zymosan to gp91phox-/- and wild types with
inflammation assessed 4h later. Data revealed that leukocyte influx was greater in knockouts
than wild types and that A2A receptor activation in knockouts reversed inflammation back to
levels seen in drug-treated wild types (Figure 5A), with the principle effect being on PMN
numbers, Figure 5B. We then investigated whether CGS 21680, given therapeutically during
the equivalent of resolution in wild types, could alter the progression of inflammation in
gp91phox-/- mice. In wild types, CGS 21680, given at 24h and again at 36h after established
inflammation, had surprisingly no effect on leukocyte numbers at 48h i.e. CGS 21680 was
neither anti-inflammatory nor resolution-toxic in normal animals, Figure 5C. Interestingly, an
identical dosing regime in knockouts revealed that CGS 21680 was not only anti-inflammatory
in these animals but that it lowered inflammation below that of controls (Figure 5C)
concomitant with an elevation of cAMP, Figure 5D. To determine whether this was an anti-
inflammatory or a pro-resolution effect, we next quantified the number of lymphocytes in CGS
21680-treated gp91phox-/- mice. The rationale for using these criteria for resolution stemmed
from our recent findings, which revealed that as inflammation resolves, lymphocyte repopulate
the peritoneal cavity(20). Lymphocyte repopulation is not required to bring about resolution,
but is critical in restoring tissue homeostasis and conferring protection against superinfection.
In CGS 21680-treated gp91phox-/- mice, while there was a classic anti-inflammatory effect,
reducing predominantly PMN numbers, we argue that this is not a resolution effect as
repopulation lymphocytes were not seen, data not included.
DISCUSSION
Here we report an immediate increase in adenosine and cAMP at the early onset phase of acute
inflammation that wanes as the response progresses only to increase again as inflammation
resolves with levels being significantly lower in experimental CGD (gp91phox-/- mice).
Whether this is a direct result of an interaction between NADPH oxidase systems and adenosine
synthesis is unlikely as levels of cAMP in isolated cells from CDG patients produce similar
levels, on a cell-for-cell basis, to normal healthy volunteers. Therefore, does the persistent
nature of CGD arise from an inherent defect in counter-regulatory/pro-resolution pathways or
a much simpler explanation of CGD patients being incapable of clearing inflammatory stimuli
resulting in a persistent, almost frustrated innate immune response that consequently nullifies
endogenous protective pathways? As emphasised previously one of the most critical
determinants for resolution of inflammation is clearance of the inflammatory stimulus(23,
32). CGD is an example of where defects in clearance may be one of the primary causes of
exacerbated and prolonged responses. Certainly, PMNs from CGD patients have impaired
phagocytosis of immune-complexes while CGD macrophages are equally defective in their
clearance of apoptotic PMNs(31). Equally, the formation of granulomatous synovitis in
response to intra-articular zymosan injection in NADPH oxidase-deficient mice was suggested
to result from incomplete zymosan clearance from the joint due to impaired phagocytosis
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(26). This, therefore, suggests that dysregulation in cAMP and adenosine is secondary to that
of an overwhelming inflammatory event, whose pro-inflammatory signals deactivates or
overrides endogenous anti-inflammatory and/or pro-resolution pathways.
From the above argument it should not be assumed that all endogenous protective pathways
are depressed during CGD. Among some of the signals that counter-balance inflammatory
onset and/or trigger resolution, neither PGD2 nor native lipoxin A4 levels were statistically
different in gp91phox-/- mice compared to wild types at onset with the exception of PGD2,
which showed a trend towards a reduction in knockouts as inflammation resolved. That
notwithstanding, data presented here shows a more consistent dysregulation in the synthesis
of adenosine/cAMP in gp91phox-/- mice in response to sterile zymosan. We went on to
investigate and show that A2A receptor activation rescues the hyper-inflammatory response in
gp91phox-/- mice without subverting resolution in wild type animals. This latter point is
important as existing anti-inflammatories, NSAIDS for instance, while being protective by
virtue of their ability to dampen the early onset phase of acute inflammation, pirate resolution
and prolong inflammation(22). A2A receptor activation, on the other hand, is anti-inflammatory
without being resolution-toxic thereby displaying broader pharmacological flexibility and
potentially fewer side effects in terms of prolonging inflammation. However, these data are
counter-intuitive based on current understanding of cAMP in inflammatory leukocyte
longevity and clearance as derived from in vitro studies. For instance, elevating cAMP in PMNs
delays their apoptosis(40) while raising cAMP in monocyte-derived macrophages impairs their
phagocytic capacity(41) suggesting that activating A2A during inflammation and consequently
elevating cAMP would lengthen the life span of PMN, impair their clearance and prolong
inflammation. Despite these data from isolated cell systems, in vivo-derived data from Figures
4 and 5 clearly show that A2A receptor activation is anti-inflammatory without being resolution-
toxic and that activation of this receptor at any phase of CGD, dampens inflammation. This
implies that CGD is in a constant state of perpetual acute inflammation and that A2A receptors
inhibit PMN influx. The current treatment regime for CGD patients is antibacterial and
antifungal prophylaxis(42), but for exacerbations of inflammatory events, perhaps concomitant
A2A receptor activation would dampen associated inflammatory responses without subverting
pro-resolution pathways. At the very least, such patients should avoid caffeine (and perhaps
other dietary methylxanthines such as theobromine) as it may nullify whatever protection
residual adenosine may confer in CGD during inflammatory events.
As mentioned previously, being anti-inflammatory in pharmacological terms, is distinct from
being pro-resolution(23). We make this assertion based on ongoing work from our laboratory
where we have shown in the resolving peritoneum not only a disappearance of PMN via
apoptosis and macrophages via lymphatic drainage, but the influx of innate-type lymphocytes
as inflammation resolves(20). These repopulating lymphocytes do not switch off inflammation
but modulate post-inflammatory responses to bacteria in the context of secondary infection. In
fact, when the cellular composition of the naïve peritoneal cavity is examined, innate type
lymphocytes are a predominant cell type along with resident macrophages. These lymphocytes
disappear in response to inflammatory stimulus not before secreting cytokines that modulate
the severity of the inflammatory response such that in RAG1-/- mice, for instance, inflammation
is more exaggerated in terms of PMN trafficking. Therefore, as inflammation resolves, we
suspect that repopulating lymphocytes simply reflect the inflamed tissue reverting to its prior
physiological state under the control of as yet un-indentified endogenous factors. Interestingly,
we found no repopulating lymphocytes in the peritoneal cavity of gp91phox-/- mice at the
equivalent time points of resolution in wild types. Moreover, while activation of A2A was
certainly anti-inflammatory in gp91phox-/- mice by virtue of it inhibition of PMN numbers
when administered therapeutically at the equivalent phase of resolution in wild types, it did
not bring about resolution in gp91phox-/- as defined by its inability to trigger lymphocyte
repopulation. Along these lines, activating A2A with CGS 21680 at earlier time point, which
Rajakariar et al. Page 8
J Immunol. Author manuscript; available in PMC 2010 March 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
exerted classic anti-inflammatory effects as defined by reduced PMN numbers (Figure 4C and
5A-B) was also without effect on lymphocyte numbers. This suggests that other factors, besides
that which signal cAMP are responsible for lymphocyte repopulation and reversion to
homeostasis.
Our finding of adenosine being secreted and cAMP expressed during the early onset phase of
the zymosan-induce peritonitis was not surprising given the established role these factors play
in counter-regulating innate-immune mediated tissue damage(9,10). The re-appearance of
cAMP and adenosine again at resolution, however, is a reflection of our growing understanding
of resolution being an active, immuno-suppressive event controlled by endogenous counter-
regulatory stop signals. The point however, is that adenosine/cAMP appears after the bulk of
the inflammatory cells, including PMNs and monocyte-derived macrophages have disappeared
either by apoptosis or lymphatic drainage. In another report (paper enclosed) we have identified
the presence of a population of resolution-phase macrophages (rM) that have not vacated the
peritoneum and are derived from a common Ly6C-positive monocyte precursor and which
possess a unique phenotype. These rM cells express all the typical markers of alternatively-
activated M2 cells along with iNOS and COX 2. It transpires that this phenotype is controlled
by cAMP, which if inhibited or elevated transforms the phenotype of resolution-phase
macrophage to that of M1 cells and vice versa, respectively. Thus, the post-resolution
expression of cAMP is not required to switch off inflammation per se but is most likely the
next step in post-inflammation tissue restitution and attempts to restore homeostasis.
From data presented in this study, A2A is shown to be anti-inflammatory whilst not affecting
pro-resolution pathways. However, it is well known that caffeine is a non-specific A2A receptor
antagonist as it can antagonise A1 as well as A2A but possesses a lower affinity for the A3
receptor(39). Resulting from its non-specific inhibition of A2A, caffeine may therefore worsen
inflammation and negatively affect pro-resolution pathways. Indeed, dosing animals with 2mg/
kg caffeine or its stable analogue just before zymosan injection exaggerated the inflammatory
response 4h later and also impaired resolution. This is important as the amount of caffeine
administered to mice is equivalent to a realistic 1-2 cups of coffee. Increasing doses of caffeine
to unrealistic 10-30 mg/kg, as also done in this current study, caused a loss of caffeine’s pro-
inflammatory impact as at these levels and higher (100mg/kg) caffeine may become a PDE4
inhibitor resulting in cAMP elevation, as shown in vivo recently(43). Given the wide
consumption of caffeine in the form of coffee and tea at least, we need to be aware of the data
presented in this paper and that presented by others(43), which emphasises that interfering with
endogenous protective pathways, adenosine in this case, at realistic levels of socially-consumed
beverages will hamper innate immune responses, thus impairing the ability to combat
infections concomitant with prolonging resolution. However, any attempts to increase caffeine
intake in the hope of inhibiting PDE4 in order to dampen inflammation via cAMP elevation
would require prohibitively high quantities of the drug. Thus, the most likely result of social
caffeine consumption would be pro-inflammatory and resolution toxicity.
In conclusion, we show that of the endogenous anti-inflammatory pathways examined in CGD,
both adenosine and its intracellular signalling molecule, cAMP, show dysregulation in their
synthesis at onset and resolution suggesting that CGD is in a constant state of pro-inflammation
and PMN trafficking with no apparent attempts at resolution due to the persistence of the
inflammatory stimulus. Rescuing this hyper-inflammatory state with A2A agonists shows
powerful anti-inflammation that does not bring about resolution as it inhibits PMN trafficking
but does not initiate lymphocyte repopulation and reversal to homeostasis. Nonetheless it does
suggest a potential treatment regime to dampen the hyper-innate immune component of CGD-
associated infections.
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Figure 1.
Inflammation is more severe and fails to resolve in gp91phox-/- mice. Intraperitoneal zymosan
injection resulted in a more exaggerated influx of (A) Ly6G-positive PMNs in gp91phox-/-
mice along with (B) F4/80-positive monocyte-derived macrophages that persisted in these
animals past the equivalent time point of resolution in wild types with the persistence of this
response not due to (C) reduced apoptosis in gp91phox-/- mice. n = 8-10 animals per group
with data expressed as mean ± SEM.
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Figure 2.
Adenosine and cAMP synthesis is abrogated in gp91phox-/- mice. In an attempt to identify
potential dysregulations in the synthesis of endogenous anti-inflammatory/pro-resolution
factors in gp91phox-/- mice, arachidonic acid metabolism, as determined by (A) PGD2, (B)
lipoxin A4 as well as (C) PGE2 were determined and found not to show a consistent reduction
in gp91phox-/- mice compared to wild types. However, (D) cAMP was elevated at the early
onset phase of a murine peritonitis and then again at resolution in wild type animals, but was
significantly lower in gp91phox-/- mice at both phases. (E) Adenosine, which signals through
A2a receptors to elevate cAMP, was also measured in these peritonitis samples peaking at
onset and again at resolution with levels being reduced in gp91phox-/- mice (filled columns)
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compared to wild types (empty columns). While this would suggest dysregulated cAMP
signalling in CGD, (F) release of cAMP from LPS-stimulated monocyte-derived macrophages
obtained from healthy human volunteers was equivalent to that from CGD patients. This
indicates that there is no direct interaction between NADPH oxidase and adenosine/cAMP,
with the latter most likely being diminished or over ridden by suppressive factors released
during severe inflammation typical of CGD. n = 6-10 animals per group with data expressed
as mean ± SEM.
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Figure 3.
Expression of adenosine and cAMP concomitant with resolution of human peritonitis.
Peritonitis samples were obtained from patients undergoing chronic ambulatory peritoneal
dialysis and who experience transient infection that usually resolves with a few days. Analysis
of cell-free exudates revealed a peak in (A) cAMP and (B) adenosine as (C) inflammation
resolved. n = 6-8 patients with data expressed as mean ± SEM.
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Figure 4.
Adenosine, via A2A is anti-inflammatory and not resolution-toxic. The selective A2A agonist
CGS 21680 as well as the PDE4 inhibitor rolipram, which increases cAMP were dosed at 10
and 30 mg/kg respectively, to rats bearing a carrageenin-induced pleurisy. In (A) rolipram and
CGS 21680 were dosed 30 mins prior to pleurisy induction and their effects assessed 4h later
with A2A receptor activation exerting an anti-inflammatory effect concomitant with an increase
in (B) cAMP in this model. A2A receptor activation was also examined in a zymosan-induced
peritonitis dosed 30mins prior to zymosan injection and the effects of CGS 21680 with or
without ZM241385 (A2A receptor antagonist) determined 4h later revealing, again, that (C)
CGS 21680 is anti-inflammatory in this model concomitant with an elevation in (D) anti-
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inflammatory IL-10. Conversely, the A2A receptor antagonist (E) caffeine and its (F) stable
analogue, CSC worsened inflammation and depressed IL-10, respectively, when administered
in a similar manner to receptor agonists. In the final set of experiments we demonstrated that
A2A receptor activation maintained its anti-inflammatory effects and did not interfere with
resolution pathways as injection of (G) CGS 21680, given 30mins before zymosan and again
12h and 18h later continued to dampen inflammation while caffeine and its analogue worsened
the response as determined at 24h. n = 8 animals per group; *, P≤ 0.05; **, P≤0.01, as
determined by ANOVA, followed by Bonferroni t test, with data expressed as mean ± SEM.
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Figure 5.
Adenosine, via A2A is anti-inflammatory but not pro-resolution in gp91phox-/- mice. Wild type
and gp91phox-/- mice were injected with zymosan i.p. and the A2A agonist CGS 21680 given
either (A-B) 30mins before stimulus injection to both wild types and knockouts and its effects
determined 4h later or (C) administered to both animal types therapeutically i.e. 24h and 36h
after zymosan and its effects on resolution and (D) cAMP determined at 48h. n = 6 animals
per group; *, P≤ 0.05; **, P≤0.01, as determined by ANOVA, followed by Bonferroni t test,
with data expressed as mean ± SEM.
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